

Exhibit A

Source: Pomerantz LLP

May 06, 2022 20:00 ET

Pomerantz Law Firm Announces the Filing of a Class Action Against Amazon.com, Inc. and Certain Officers – AMZN

NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amazon.com, Inc. ("Amazon" or the "Company") (NASDAQ: AMZN) and certain of its officers. The class action, filed in the United States District Court for the Western District of Washington, Seattle Division, and docketed under 22-cv-00617, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired

If you are a shareholder who purchased or otherwise acquired Amazon securities during the Class Period, you have until July 5, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Amazon is a multinational technology company that engages primarily in the businesses of e-commerce, cloud computing, digital streaming, and artificial intelligence.

On the Company's Amazon.com e-commerce platform, Amazon sells both third-party merchandise and Amazon's own private-label products. As the owner and operator of the Amazon.com e-commerce platform, Amazon has access to certain non-public data of the third-party sellers that use the Amazon.com platform.

On or around June 3, 2019, the U.S. House Committee on the Judiciary initiated a bipartisan investigation into the state of competition online. The investigation, led by the Subcommittee on Antitrust, Commercial and Administrative Law (the "Subcommittee"), examined the business practices and market dominance of Facebook, Google, Apple, and, of particular relevance, Amazon (the "Subcommittee Investigation").

In the course of the Subcommittee Investigation, the Subcommittee held several oversight hearings in which various officers of the above referenced companies, including their respective Chief Executive Officers, offered witness testimony on topics such as the effect of market power on the press, innovation, and privacy, and the market dominance of the firms under investigation. After each of the hearings, members of the Subcommittee submitted questions for the record to the witnesses.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the Defendants' public statements throughout the Class Period were materially false and/or misleading.

On March 9, 2022, media outlets reported that the House Judiciary Committee had requested that the U.S. Department of Justice open a criminal investigation into Amazon and certain of its executives for allegedly lying to Congress about its business practices during the course of the Subcommittee Investigation.

In response, Amazon asserted that there was “no factual basis” for the House Judiciary Committee’s allegations.

Then, on April 6, 2022, *The Wall Street Journal* published an article entitled “SEC Is Investigating How Amazon Disclosed Business Practices.” The article reported, *inter alia*, that the SEC’s probe has been underway for more than a year and focuses on Amazon’s disclosures regarding its use of third-party seller data for its own private-label business.

On this news, Amazon’s stock price fell \$105.98 per share, or 3.2%, to close at \$3,175.12 per share on April 6, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

Exhibit B

**PLAINTIFF'S CERTIFICATION
PURSUANT TO FEDERAL SECURITIES LAWS**


The undersigned, Titus Noltenius and Andreas Holzapfel, on behalf of Universal-Investment-Gesellschaft mbH (“Universal”), on account of its funds listed in Schedule A (the “Funds”), declare the following as to the claims asserted, or to be asserted, under the federal securities laws:

1. We have reviewed a complaint against Amazon.com, Inc. (“Amazon”).
2. We are duly authorized to institute legal action on behalf of Universal and the Funds, including litigation against Amazon and any other defendants.
3. Universal and the Funds did not purchase or sell the security that is the subject of this litigation at the direction of plaintiff’s counsel or in order to participate in any private action under the federal securities laws.
4. Universal is willing to serve as lead plaintiff and understands that a lead plaintiff is a representative party who acts on behalf of other class members in directing the action, and whose duties may include testifying at deposition and trial. Universal also understands that it is subject to the jurisdiction of the Court and will be bound by all rulings of the Court, including rulings regarding any judgments.
5. Universal will not accept any payment for serving as a representative party beyond the Funds’ *pro rata* share of any recovery, except reasonable costs and expenses, such as lost wages and travel expenses, directly related to the class representation, as ordered or approved by the Court.
6. Universal has not sought to serve as a lead plaintiff or representative party on behalf of a class in any action under the federal securities laws filed during the three-year period preceding the date of this Certification.
7. Universal understands that this is not a claim form, and that the Funds’ ability to share in any recovery as a member of the class is unaffected by Universal’s decision to serve as a representative party.
8. Attached hereto as Schedule A is a complete listing of all transactions the Funds made during the Class Period in the security that is the subject of this litigation. Universal will provide records of those transactions upon request.
9. Universal is also represented and counseled in this matter by its attorney, Deborah M. Sturman of Sturman LLC.


We declare under penalty of perjury, under the laws of the United States of America, that the foregoing is true and correct to the best of our knowledge, information and belief.

Executed this 4th day of July, 2022.

For Universal-Investment-Gesellschaft-mbH:



Titus Noltenius
Director



Andreas Holzapfel
Director

Schedule A
Universal-Investment-Gesellschaft mbH
Amazon Inc. (AMZN)

Class Period: 02/01/2019 - 04/28/2022

	Date	Shares	Price
012300-012301			
Purchases:			
	3/19/2019	60.00	1,776.47
	3/21/2019	30.00	1,799.00
	5/6/2019	20.00	1,925.34
	7/10/2019	60.00	1,995.40
	2/5/2020	40.00	2,070.00
	2/10/2020	35.00	2,124.88
	3/19/2020	40.00	1,875.00
	3/20/2020	20.00	1,942.59
	4/14/2020	20.00	2,200.47
	5/4/2020	20.00	2,317.14
	6/10/2020	20.00	2,644.88
	9/1/2020	30.00	3,494.79
	10/12/2020	40.00	3,348.50
	10/16/2020	20.00	3,370.69
	12/17/2020	15.00	3,250.00
	12/29/2020	20.00	3,311.00
	2/2/2021	35.00	3,389.90
	2/3/2021	15.00	3,425.26
	4/8/2021	35.00	3,312.97
	4/12/2021	25.00	3,373.82
	4/27/2021	15.00	3,434.65
	6/17/2021	40.00	3,404.06
	6/23/2021	20.00	3,505.00
	7/6/2021	20.00	3,582.07
	11/4/2021	40.00	3,454.92
	11/9/2021	20.00	3,562.83
	11/19/2021	20.00	3,712.69
	3/28/2022	35.00	3,333.30
	4/1/2022	15.00	3,310.64
Sales:	6/4/2019	-30.00	1,684.29
	6/6/2019	-80.00	1,731.45
	9/30/2019	-60.00	1,722.95

Date	Shares	Price
3/6/2020	-75.00	1,894.70
4/23/2020	-20.00	2,410.43
5/29/2020	-20.00	2,415.94
7/6/2020	-40.00	2,939.39
7/6/2020	-40.00	3,010.89
9/15/2020	-30.00	3,166.67
12/10/2020	-25.00	3,120.32
1/12/2021	-30.00	3,109.21
1/13/2021	-40.00	3,161.07
2/22/2021	-50.00	3,222.19
5/4/2021	-15.00	3,305.05
5/10/2021	-60.00	3,226.12
8/2/2021	-20.00	3,324.14
8/13/2021	-60.00	3,293.14
1/5/2022	-30.00	3,332.32
1/13/2022	-50.00	3,276.00

017200-017204

Purchases:	2/1/2019	210.00	1,647.97
	9/30/2020	130.00	3,141.14
	6/14/2021	175.00	3,359.93
Sales:	4/28/2020	-245.00	2,313.81

017200-017206

Purchases:	5/20/2021	66.00	3,245.29
------------	-----------	-------	----------

133400-133401

Purchases:	9/18/2019	300.00	1,817.35
	3/3/2020	75.00	1,979.85
	6/17/2021	150.00	3,465.92
	7/9/2021	50.00	3,721.20
	8/12/2021	50.00	3,289.42
Sales:	4/27/2020	-175.00	2,434.16
	4/28/2020	-200.00	2,350.16

135600-135601

Purchases:	11/23/2021	200.00	3,611.36
------------	------------	--------	----------

136800-136801

	Date	Shares	Price
Purchases:	3/18/2022	350.00	3,159.34
	3/22/2022	250.00	3,236.11

141D00-141D01

Purchases:	7/19/2021	130.00	3,532.58
	10/12/2021	70.00	3,257.00
	1/26/2022	80.00	2,811.07

141H00-141H01

Purchases:	11/17/2020	120.00	3,172.81
	12/16/2020	80.00	3,197.71

141N00-141N04

Purchases:	3/25/2021	43,000.00	3,046.26
------------	-----------	-----------	----------

141N00-141N05

Purchases:	3/4/2020	450.00	1,946.57
	9/15/2020	180.00	3,151.29
	9/28/2020	150.00	3,146.57
	10/27/2020	190.00	3,259.73
	10/29/2020	160.00	3,206.45
	11/20/2020	120.00	3,117.02
	10/14/2021	175.00	3,303.33
	11/10/2021	2,526.00	3,482.05
Sales:	11/26/2021	-326.00	3,530.92

142F00-142F01

Purchases:	12/18/2020	281.00	3,249.42
	8/19/2021	91.00	3,197.89
	1/20/2022	72.00	3,156.68

221800-221801

Purchases:	1/29/2021	20.00	3,231.34
	2/1/2021	25.00	3,280.69
	2/2/2021	25.00	3,389.99
	2/3/2021	20.00	3,369.00
	2/5/2021	10.00	3,327.21
	2/23/2021	10.00	3,164.39
	3/1/2021	10.00	3,127.59

	Date	Shares	Price
	4/29/2021	25.00	3,466.06
	6/7/2021	10.00	3,199.99
	8/25/2021	15.00	3,296.43
	10/7/2021	5.00	3,312.28
	12/1/2021	15.00	3,526.17
	12/28/2021	10.00	3,398.00
Sales:	12/14/2021	-5.00	3,360.20
	12/15/2021	-5.00	3,340.00
	12/16/2021	-10.00	3,447.00

222100-222101

Purchases:	2/4/2020	50.00	2,031.10
	3/17/2020	340.00	1,805.96
	3/20/2020	90.00	1,928.13
	4/8/2020	90.00	2,019.22
	1/25/2021	90.00	3,328.77
	2/25/2021	70.00	3,144.69
	3/5/2021	15.00	2,976.60
	3/9/2021	65.00	3,054.90
	4/29/2021	100.00	3,481.66
	8/13/2021	65.00	3,290.37
	8/19/2021	65.00	3,226.80
	9/7/2021	150.00	3,519.74
	10/29/2021	55.00	3,311.21
	11/18/2021	70.00	3,679.99
	11/24/2021	50.00	3,580.64
	12/1/2021	100.00	3,538.06
	1/26/2022	70.00	2,861.14
	1/27/2022	100.00	2,836.26
	2/17/2022	130.00	3,157.26
	2/24/2022	94.00	2,837.93
Sales:	6/15/2020	-45.00	2,525.78
	6/24/2020	-155.00	2,780.00
	6/25/2020	-15.00	2,736.47
	7/15/2020	-50.00	3,051.63
	10/11/2021	-110.00	3,277.38
	2/3/2022	-294.00	2,796.39

222200-222201

	Date	Shares	Price
Purchases:	7/6/2021	500.00	3,639.72
	8/26/2021	250.00	3,309.55
	1/26/2022	150.00	2,895.69

22B200-22B201

Purchases:	1/20/2022	273.00	3,135.32
	1/25/2022	23.00	2,844.85
	2/1/2022	40.00	3,003.00
	2/15/2022	48.00	3,150.92
	2/22/2022	27.00	3,009.57
	3/1/2022	41.00	3,054.65
	3/8/2022	33.00	2,733.67
	3/15/2022	30.00	2,857.00
	4/5/2022	7.00	3,354.83
	4/12/2022	38.00	3,073.85

22B300-22B301

Purchases:	2/4/2022	138.00	3,103.30
	2/9/2022	32.00	3,241.37
	2/11/2022	160.00	3,144.00
	2/14/2022	25.00	3,092.29
	2/25/2022	10.00	3,007.81
	3/23/2022	28.00	3,307.28
	4/1/2022	18.00	3,282.92

242B00-242B01

Purchases:	12/3/2019	320.00	1,760.00
	12/5/2019	20.00	1,744.12
	1/23/2020	30.00	1,885.09
	1/27/2020	1,980.00	1,828.34
	3/5/2020	130.00	1,924.03
	4/7/2020	210.00	2,011.60
	5/8/2020	40.00	2,379.61
	6/9/2020	200.00	2,529.74
	7/6/2020	180.00	3,057.04
	8/5/2020	90.00	3,205.03
	9/3/2020	90.00	3,368.00
	10/5/2020	130.00	3,199.20
	11/5/2020	100.00	3,322.00

	Date	Shares	Price
	12/3/2020	220.00	3,186.73
	1/6/2021	200.00	3,138.38
	2/3/2021	70.00	3,312.53
	3/3/2021	80.00	3,005.00
	3/12/2021	70.00	3,089.49
	4/8/2021	50.00	3,310.90
	5/5/2021	130.00	3,270.54
	6/7/2021	180.00	3,196.68
	7/2/2021	600.00	3,510.98
	8/4/2021	430.00	3,354.72
	8/23/2021	200.00	3,265.87
	9/3/2021	650.00	3,478.05
	10/5/2021	460.00	3,221.00
	11/3/2021	468.00	3,384.00
	12/3/2021	560.00	3,389.79
	1/5/2022	200.00	3,287.14
	1/7/2022	242.00	3,251.08
	2/3/2022	390.00	2,776.91
	3/3/2022	530.00	2,957.97
	4/5/2022	490.00	3,281.10
Sales:	12/22/2021	-180.00	3,420.74

242U00-242U01

Purchases:	5/4/2021	120.00	3,322.39
	5/7/2021	32.00	3,305.47
	5/12/2021	17.00	3,205.67
	5/28/2021	13.00	3,239.19
	6/7/2021	28.00	3,204.51
	6/17/2021	31.00	3,433.09
	7/6/2021	27.00	3,609.97
	7/21/2021	45.00	3,577.62
	8/16/2021	45.00	3,245.98
	8/24/2021	31.00	3,304.05
	10/20/2021	38.00	3,452.15
	12/13/2021	20.00	3,437.95
	1/6/2022	93.00	3,269.02
	2/18/2022	26.00	3,084.73
	3/9/2022	51.00	2,765.32
Sales:	1/25/2022	-35.00	2,844.85

	Date	Shares	Price
	2/3/2022	-150.00	2,834.75
266400-266401			
Purchases:	5/19/2021	100.00	3,216.80
302900-302901			
Purchases:	2/1/2021	350.00	3,244.17
	2/4/2021	250.00	3,328.35
	2/9/2021	250.00	3,312.49
	3/11/2021	90.00	3,104.26
Sales:	10/8/2021	-115.00	3,318.74
	3/18/2022	-310.00	3,141.38
332000-332001			
Purchases:	11/20/2019	30.00	1,754.08
	1/16/2020	20.00	1,868.46
	6/12/2020	16.00	2,621.46
	6/17/2020	27.00	2,643.28
	6/18/2020	15.00	2,651.75
	6/24/2020	49.00	2,757.40
	6/26/2020	25.00	2,774.81
	7/15/2020	32.00	3,080.00
	10/16/2020	39.00	3,370.69
	10/23/2020	49.00	3,168.80
	1/29/2021	37.00	3,231.59
	3/2/2021	31.00	3,143.47
	4/14/2021	70.00	3,379.98
	4/16/2021	104.00	3,374.19
	4/26/2021	48.00	3,350.00
	5/10/2021	45.00	3,282.32
	8/5/2021	60.00	3,356.22
	8/19/2021	105.00	3,214.60
	11/18/2021	85.00	3,572.04
	12/21/2021	40.00	3,328.27
Sales:	3/21/2019	-20.00	1,803.70
	6/18/2019	-25.00	1,920.21
	2/13/2020	-18.00	2,156.03
	6/2/2020	-24.00	2,465.35
	10/14/2020	-45.00	3,447.00

Date	Shares	Price
10/20/2021	-85.00	3,448.80
12/16/2021	-120.00	3,465.27

332200-332201

Purchases:	11/21/2019	50.00	1,742.49
	9/8/2020	45.00	3,224.97
	12/4/2020	30.00	3,174.08
	1/29/2021	55.00	3,230.58
	2/19/2021	21.00	3,328.23
	3/9/2021	31.00	3,017.99
	4/15/2021	40.00	3,371.41
	8/19/2021	53.00	3,215.87
	8/24/2021	50.00	3,290.79
	1/25/2022	30.00	2,843.51
Sales:	6/11/2019	-50.00	1,884.35
	6/2/2020	-40.00	2,450.28
	7/7/2021	-30.00	3,716.68
	10/20/2021	-70.00	3,450.84
	12/16/2021	-95.00	3,466.30

332700-332701

Purchases:	3/19/2020	110.00	1,905.27
	3/27/2020	55.00	1,918.90
	5/20/2020	105.00	2,477.87
	8/4/2020	100.00	3,148.00
	12/22/2020	150.00	3,201.35
	2/26/2021	120.00	3,072.56
	4/15/2021	160.00	3,371.11
	7/8/2021	50.00	3,643.66
	8/5/2021	60.00	3,356.22
	8/19/2021	100.00	3,212.99
	9/8/2021	240.00	3,526.86
	12/21/2021	300.00	3,335.26
	12/28/2021	50.00	3,403.65
	3/14/2022	40.00	2,930.30
Sales:	10/20/2021	-150.00	3,444.88

375200-375203

Purchases:	7/26/2021	679.00	3,697.96
------------	-----------	--------	----------

Date	Shares	Price
7/27/2021	1,186.00	3,626.79
7/28/2021	69.00	3,625.53
7/29/2021	38.00	3,350.00
7/29/2021	124.00	3,482.72
7/30/2021	76.00	3,337.50
8/3/2021	7.00	3,300.00
8/11/2021	29.00	3,300.86
8/12/2021	38.00	3,274.75
8/16/2021	76.00	3,236.97
8/19/2021	37.00	3,199.95
9/1/2021	121.00	3,517.37
9/3/2021	43.00	3,449.71
9/9/2021	76.00	3,527.04
9/9/2021	82.00	3,527.04
10/19/2021	4.00	3,449.19
10/29/2021	103.00	3,294.08
12/13/2021	67.00	3,396.87
12/15/2021	51.00	3,337.41
12/16/2021	16.00	3,392.23
1/10/2022	132.00	3,150.09
1/21/2022	75.00	2,994.91
3/8/2022	30.00	2,698.44

379400-379404

Purchases:	3/29/2021	4,604.00	3,054.17
	4/21/2021	39.00	3,316.00
	6/8/2021	265.00	3,222.42
	2/1/2022	316.00	3,003.00
	4/27/2022	228.00	2,803.83
Sales:	3/21/2022	-368.00	3,200.45

431000-431001

Purchases:	1/5/2021	80.00	3,193.75
	2/19/2021	40.00	3,317.66
	7/22/2021	30.00	3,586.42
	1/4/2022	20.00	3,336.78

431A00-431A01

Purchases:	2/1/2021	30.00	3,309.73
------------	----------	-------	----------

	Date	Shares	Price
	2/19/2021	20.00	3,328.23
	3/3/2021	50.00	3,040.22
	4/23/2021	110.00	3,317.05
	6/11/2021	90.00	3,345.47
	8/12/2021	100.00	3,304.60

431D00-431D01

Purchases:	11/24/2020	30.00	3,106.81
	12/2/2020	20.00	3,220.33
	1/12/2022	10.00	3,322.47

431J00-431J01

Purchases:	7/23/2021	30.00	3,647.60
------------	-----------	-------	----------

432C00-432C01

Purchases:	6/28/2021	20.00	3,430.58
------------	-----------	-------	----------

432L00-432L01

Purchases:	7/23/2021	47.00	3,640.00
	8/5/2021	5.00	3,356.22
	8/20/2021	11.00	3,199.11
	9/14/2021	7.00	3,465.22
	10/4/2021	10.00	3,200.00
	10/22/2021	8.00	3,419.80
	12/22/2021	16.00	3,383.00
	12/29/2021	14.00	3,416.80
	4/7/2022	10.00	3,157.52
Sales:	1/19/2022	-16.00	3,174.85
	2/9/2022	-50.00	3,239.40

432P00-432P01

Purchases:	8/11/2021	20.00	3,330.75
	9/3/2021	4.00	3,453.94
	11/8/2021	7.00	3,523.24
	1/19/2022	7.00	3,174.85
	1/21/2022	26.00	2,975.00
	2/3/2022	9.00	2,834.75
	2/24/2022	8.00	2,793.59

	Date	Shares	Price
433800-433801			
Purchases:	6/7/2021	25.00	3,196.68
437200-437201			
Purchases:	5/3/2019	40.00	1,959.85
	5/23/2019	10.00	1,836.59
	7/23/2019	8.00	1,984.38
	12/23/2019	22.00	1,788.10
	3/5/2020	12.00	1,947.10
	6/10/2020	26.00	2,663.43
	9/16/2020	18.00	3,142.44
	11/9/2020	14.00	3,228.87
	11/9/2020	14.00	3,257.79
	11/19/2020	17.00	3,108.41
	11/30/2020	18.00	3,151.59
	4/29/2021	32.00	3,506.80
	11/17/2021	16.00	3,562.34
Sales:	11/10/2020	-14.00	3,069.20
437400-437401			
Purchases:	3/16/2020	650.00	1,703.05
	3/26/2020	500.00	1,900.21
	2/9/2021	600.00	3,315.68
	2/10/2021	600.00	3,267.50
	2/23/2021	118.00	3,124.57
	3/4/2021	620.00	3,014.00
	3/8/2021	735.00	3,014.38
	4/6/2021	176.00	3,239.26
	6/8/2021	503.00	3,222.61
	8/2/2021	558.00	3,330.64
	8/20/2021	110.00	3,202.58
	10/11/2021	100.00	3,275.00
	12/6/2021	180.00	3,411.62
	12/6/2021	651.00	3,411.62
	12/27/2021	116.00	3,413.69
	12/28/2021	123.00	3,405.54
	12/30/2021	120.00	3,392.95
	1/10/2022	140.00	3,149.82
	1/11/2022	130.00	3,254.20

	Date	Shares	Price
	1/14/2022	110.00	3,203.00
	1/18/2022	129.00	3,175.95
	1/19/2022	100.00	3,168.79
	1/21/2022	133.00	2,905.24
	1/21/2022	130.00	2,938.29
	1/24/2022	320.00	2,780.00
	1/25/2022	150.00	2,798.40
	3/4/2022	150.00	2,891.47
	3/7/2022	100.00	2,808.81
	3/8/2022	120.00	2,700.00
	4/25/2022	175.00	2,868.79
	4/28/2022	150.00	2,838.82
Sales:	8/4/2020	-50.00	3,110.82
	6/18/2021	-250.00	3,479.99
	6/21/2021	-130.00	3,476.42
	6/23/2021	-102.00	3,505.00
	7/7/2021	-100.00	3,725.52
	7/12/2021	-96.00	3,744.24
	7/13/2021	-64.00	3,757.16
	8/31/2021	-146.00	3,424.80
	8/31/2021	-52.00	3,431.63
	9/2/2021	-68.00	3,494.76
	9/9/2021	-100.00	3,525.50
	11/8/2021	-120.00	3,518.71
	11/19/2021	-150.00	3,736.16
	2/1/2022	-125.00	2,983.34
	2/4/2022	-100.00	3,079.54
	2/4/2022	-600.00	3,112.13
	2/10/2022	-150.00	3,167.00
	3/10/2022	-130.00	2,913.70
	3/10/2022	-125.00	2,938.46
	3/21/2022	-150.00	3,219.00
	3/28/2022	-125.00	3,340.74
	3/29/2022	-130.00	3,407.68
	4/5/2022	-225.00	3,354.83

437900-437901

Purchases:	11/3/2020	260.00	3,014.71
	11/9/2020	40.00	3,241.97

	Date	Shares	Price
	4/28/2021	260.00	3,460.01
	7/29/2021	160.00	3,633.26
	10/29/2021	200.00	3,324.68
	2/2/2022	200.00	3,048.43
Sales:	3/5/2021	-60.00	2,969.05
	5/3/2021	-260.00	3,447.12
	8/18/2021	-100.00	3,223.89
	8/23/2021	-300.00	3,246.72
	2/4/2022	-100.00	3,018.05
	3/8/2022	-100.00	2,754.05

439000-439001

Purchases:	1/4/2021	61.00	3,270.00
	10/20/2021	10.00	3,452.15
	2/4/2022	4.00	3,112.13
Sales:	1/3/2022	-15.00	3,352.77
	1/25/2022	-5.00	2,844.85

439600-439601

Purchases:	11/10/2020	15.00	3,095.02
	5/26/2021	15.00	3,269.84

439900-439901

Purchases:	3/16/2021	40.00	3,119.51
	8/6/2021	60.00	3,348.77

443800-443801

Purchases:	1/19/2021	37.00	3,117.43
	1/20/2021	27.00	3,215.83
	1/26/2021	20.00	3,312.93
Sales:	9/27/2021	-6.00	3,351.27
	12/8/2021	-11.00	3,503.70

451900-451901

Purchases:	9/3/2019	490.00	1,792.28
	10/23/2019	60.00	1,753.86
	11/27/2019	50.00	1,804.75
	3/17/2020	150.00	1,717.99
	4/2/2020	150.00	1,914.62

	Date	Shares	Price
	4/8/2020	1,100.00	2,013.04
	4/17/2020	1,500.00	2,377.24
	4/21/2020	500.00	2,297.18
	5/6/2020	3,000.00	2,352.33
	5/11/2020	1,500.00	2,400.52
	6/9/2020	500.00	2,544.69
	8/11/2020	300.00	3,111.86
	9/9/2020	700.00	3,213.55
	9/17/2020	500.00	3,000.82
	11/6/2020	1,000.00	3,250.28
	12/3/2020	1,000.00	3,214.07
	12/21/2020	200.00	3,220.23
	1/14/2021	200.00	3,154.04
	1/5/2022	400.00	3,322.63
	1/10/2022	300.00	3,158.23
	2/8/2022	1,000.00	3,129.67
	3/11/2022	1,100.00	2,927.04
	3/16/2022	2,000.00	2,975.27
	3/18/2022	1,000.00	3,216.46
Sales:	8/10/2021	-400.00	3,353.78
	10/11/2021	-700.00	3,285.15

572Q00-572Q01

Purchases:	9/13/2021	2,230.00	3,457.17
	9/16/2021	7.00	3,488.24
	9/20/2021	29.00	3,355.73
	9/24/2021	2,002.00	3,425.52
	9/27/2021	30.00	3,405.80
	10/5/2021	25.00	3,221.00
	10/8/2021	53.00	3,288.62
	10/14/2021	18.00	3,299.86
	10/18/2021	32.00	3,446.74
	10/22/2021	36.00	3,335.55
	10/29/2021	13.00	3,372.43
	11/5/2021	32.00	3,518.99
	11/10/2021	1.00	3,482.05
	11/19/2021	50.00	3,676.57
	12/16/2021	71.00	3,377.42
	12/23/2021	57.00	3,421.37

	Date	Shares	Price
	1/10/2022	49.00	3,229.72
	1/28/2022	71.00	2,879.56
	2/9/2022	50.00	3,223.79
	3/4/2022	41.00	2,912.82
	3/14/2022	44.00	2,837.06
	3/25/2022	52.00	3,295.47
	4/4/2022	61.00	3,366.93
	4/8/2022	122.00	3,089.21
	4/13/2022	2.00	3,110.82
	4/21/2022	56.00	2,965.92
Sales:	9/22/2021	-47.00	3,380.05
	12/8/2021	-3.00	3,523.16
	12/9/2021	-103.00	3,483.42
	12/13/2021	-93.00	3,391.35
	1/12/2022	-1.00	3,304.14
	3/9/2022	-16.00	2,785.58
	3/11/2022	-11.00	2,910.49

574900-574901

Purchases:	11/16/2021	100.00	3,542.82
Sales:	12/29/2021	-20.00	3,388.67

576700-576701

Purchases:	3/26/2019	170.00	1,793.00
	4/9/2019	120.00	1,835.84
	5/10/2019	150.00	1,889.98
	6/5/2019	260.00	1,738.50
	7/17/2019	120.00	1,992.03
	8/5/2019	520.00	1,765.13
	8/12/2019	130.00	1,784.92
	9/3/2019	280.00	1,771.02
	10/4/2019	200.00	1,739.65
	10/18/2019	260.00	1,757.51
	1/7/2020	160.00	1,904.50
	2/18/2020	50.00	2,155.67
	3/2/2020	260.00	1,953.95
	3/10/2020	250.00	1,891.82
	3/19/2020	100.00	1,880.93
	3/24/2020	360.00	1,940.10

Date	Shares	Price
4/2/2020	60.00	1,918.83
4/8/2020	120.00	2,043.00
4/21/2020	90.00	2,328.12
5/4/2020	130.00	2,315.99
6/12/2020	209.00	2,545.02
8/10/2020	20.00	3,148.16
8/17/2020	200.00	3,182.41
8/28/2020	200.00	3,401.80
12/2/2020	100.00	3,203.53
1/7/2021	120.00	3,162.16
1/27/2021	270.00	3,232.58
2/19/2021	540.00	3,249.90
3/10/2021	250.00	3,057.64
3/26/2021	250.00	3,052.03
4/26/2021	440.00	3,409.00
5/21/2021	450.00	3,250.00
6/22/2021	440.00	3,505.44
7/13/2021	710.00	3,677.36
8/23/2021	1,376.00	3,265.87
9/24/2021	722.00	3,425.52
10/22/2021	700.00	3,335.55
11/24/2021	920.00	3,580.41
12/15/2021	190.00	3,466.30
1/21/2022	350.00	2,852.86
2/22/2022	318.00	3,003.95
3/10/2022	330.00	2,936.35
4/6/2022	400.00	3,175.12

579000-579002

Purchases:	7/22/2021	160.00	3,613.77
	3/14/2022	150.00	2,917.90

**PLAINTIFF'S CERTIFICATION
PURSUANT TO FEDERAL SECURITIES LAWS**

The undersigned, Matthias Müller and Martin Groos, on behalf of Universal-Investment-Luxembourg S.A. (“Universal”), on account of its funds listed in Schedule A (the “Funds”), declare the following as to the claims asserted, or to be asserted, under the federal securities laws:

1. We have reviewed a complaint against Amazon.com, Inc. (“Amazon”).
2. We are duly authorized to institute legal action on behalf of Universal and the Funds, including litigation against Amazon and any other defendants.
3. Universal and the Funds did not purchase or sell the security that is the subject of this litigation at the direction of plaintiff’s counsel or in order to participate in any private action under the federal securities laws.
4. Universal is willing to serve as lead plaintiff and understands that a lead plaintiff is a representative party who acts on behalf of other class members in directing the action, and whose duties may include testifying at deposition and trial. Universal also understands that it is subject to the jurisdiction of the Court and will be bound by all rulings of the Court, including rulings regarding any judgments.
5. Universal will not accept any payment for serving as a representative party beyond the Funds’ *pro rata* share of any recovery, except reasonable costs and expenses, such as lost wages and travel expenses, directly related to the class representation, as ordered or approved by the Court.
6. Universal has not sought to serve as a lead plaintiff or representative party on behalf of a class in any action under the federal securities laws filed during the three-year period preceding the date of this Certification.
7. Universal understands that this is not a claim form, and that the Funds’ ability to share in any recovery as a member of the class is unaffected by Universal’s decision to serve as a representative party.
8. Attached hereto as Schedule A is a complete listing of all transactions the Funds made during the Class Period in the security that is the subject of this litigation. Universal will provide records of those transactions upon request.
9. Universal is also represented and counseled in this matter by its attorney, Deborah M. Sturman of Sturman LLC.


We declare under penalty of perjury, under the laws of the United States of America, that the foregoing is true and correct to the best of our knowledge, information and belief.

Executed this 1 day of July, 2022.

For Universal-Investment-Luxembourg S.A.:



Matthias Müller
Managing Director



Martin Grobs
Managing Director

Schedule A
Universal-Investment-Luxembourg S.A.
Amazon Inc. (AMZN)

Class Period: 02/01/2019 - 04/28/2022

	Date	Shares	Price
707200-707203			
Purchases:	10/1/2020	30.00	3,208.40
	10/6/2020	40.00	3,165.92
	10/28/2020	20.00	3,203.84
	5/4/2021	30.00	3,350.00
Sales:	10/25/2021	-40.00	3,336.65
711000-711001			
Purchases:	7/16/2019	39.00	2,020.44
	10/24/2019	27.00	1,777.83
	1/17/2020	89.00	1,870.12
	3/17/2020	61.00	1,775.84
	3/19/2020	200.00	1,851.99
	7/28/2020	60.00	3,057.70
	8/12/2020	48.00	3,138.88
	9/1/2020	29.00	3,492.36
	9/29/2020	50.00	3,175.99
	10/27/2020	40.00	3,237.43
	10/29/2020	40.00	3,196.98
	10/30/2020	35.00	3,091.70
	11/19/2020	25.00	3,110.63
	12/21/2020	50.00	3,206.18
	1/14/2021	66.00	3,127.47
	1/20/2021	35.00	3,211.02
	1/22/2021	35.00	3,296.21
	1/29/2021	39.00	3,229.38
	4/1/2021	40.00	3,161.00
	4/29/2021	115.00	3,497.51
	4/30/2021	40.00	3,529.88
	6/9/2021	110.00	3,281.15
	6/25/2021	75.00	3,401.46
	7/9/2021	90.00	3,712.29
	7/30/2021	60.00	3,359.23

	Date	Shares	Price
	8/20/2021	50.00	3,196.31
	8/24/2021	35.00	3,286.17
	9/17/2021	25.00	3,486.50
	11/22/2021	40.00	3,683.82
	11/26/2021	65.00	3,604.00
	12/6/2021	40.00	3,399.25
	12/9/2021	60.00	3,483.42
	12/17/2021	60.00	3,317.19
	12/20/2021	100.00	3,337.00
	1/5/2022	35.00	3,317.59
	1/10/2022	50.00	3,229.72
	1/20/2022	30.00	3,147.93
Sales:	2/20/2020	-65.00	2,166.22
	4/8/2020	-48.00	2,013.43
	4/17/2020	-97.00	2,354.70
	4/21/2020	-45.00	2,386.50
	5/20/2020	-61.00	2,485.12
	6/3/2020	-117.00	2,470.21
	2/4/2022	-200.00	3,109.36
	2/4/2022	-220.00	3,112.13

769300-769301

Purchases:	7/22/2019	1,143.00	1,985.63
	3/12/2020	60.00	1,720.77
	4/27/2020	83.00	2,395.60
	7/9/2021	188.00	3,721.34
	11/10/2021	134.00	3,526.41
	2/1/2022	190.00	3,003.12
	4/20/2022	289.00	3,084.36
	4/21/2022	290.00	2,988.79

770000-770001

Purchases:	2/12/2021	1,395.00	3,245.52
	1/26/2022	70.00	2,826.98
Sales:	2/22/2021	-45.00	3,208.13
	4/1/2021	-60.00	3,119.15
	1/5/2022	-90.00	3,328.89
	1/19/2022	-100.00	3,174.85
	2/16/2022	-50.00	3,141.00

	Date	Shares	Price
	2/22/2022	-440.00	3,012.18

770100-770101

Purchases:	2/12/2021	130.00	3,245.48
Sales:	4/1/2021	-15.00	3,119.14
	10/18/2021	-10.00	3,408.81
	2/22/2022	-45.00	3,012.22

770200-770201

Purchases:	2/12/2021	280.00	3,245.50
Sales:	4/1/2021	-35.00	3,119.19
	1/24/2022	-25.00	2,780.00
	2/16/2022	-20.00	3,141.46
	2/22/2022	-70.00	3,012.16

770300-770301

Purchases:	2/12/2021	530.00	3,245.51
	4/8/2022	20.00	3,135.20
Sales:	3/26/2021	-20.00	3,044.06
	2/22/2022	-170.00	3,012.18
	4/6/2022	-30.00	3,234.74

770900-770901

Purchases:	3/17/2020	1,640.00	1,837.37
	3/19/2020	538.00	1,921.27
	3/20/2020	207.00	1,926.30
	3/27/2020	228.00	1,915.16
	4/6/2020	245.00	1,960.33
	12/2/2020	250.00	3,210.95
	1/20/2021	300.00	3,227.42
	1/25/2021	270.00	3,336.36
	2/1/2021	200.00	3,297.37
	3/31/2021	600.00	3,103.52
	4/29/2021	643.00	3,481.66
	8/20/2021	283.00	3,198.15
	8/23/2021	400.00	3,271.42
	8/23/2021	500.00	3,271.42
	11/18/2021	750.00	3,679.99
	11/24/2021	129.00	3,580.64

	Date	Shares	Price
	11/26/2021	854.00	3,607.45
	12/22/2021	140.00	3,433.94
	2/24/2022	590.00	3,000.61
Sales:	6/12/2020	-314.00	2,545.75
	6/24/2020	-174.00	2,780.00
	7/15/2020	-150.00	3,074.97
	7/15/2020	-100.00	3,080.07
	7/16/2020	-150.00	2,969.27
	3/10/2021	-204.00	3,054.91
	9/27/2021	-870.00	3,396.27
	10/11/2021	-776.00	3,275.76
	2/3/2022	-1,880.00	2,796.39
	4/5/2022	-477.00	3,302.09

771400-771401

Purchases:	10/28/2019	33.00	1,773.96
	3/26/2020	332.00	1,923.67
	6/3/2020	102.00	2,483.70
	5/4/2021	190.00	3,335.58
	5/11/2021	202.00	3,134.87
	8/24/2021	220.00	3,306.45
	10/11/2021	110.00	3,284.95
	12/15/2021	98.00	3,317.50
	3/4/2022	228.00	2,896.41
	4/22/2022	204.00	2,971.18
Sales:	11/6/2019	-285.00	1,796.12
	7/10/2020	-70.00	3,192.96
	2/9/2021	-164.00	3,308.32
	2/12/2021	-200.00	3,247.15
	8/12/2021	-170.00	3,295.66
	8/20/2021	-222.00	3,197.94
	3/16/2022	-247.00	2,963.00

772400-772401

Purchases:	3/25/2020	63.00	1,909.65
	10/7/2020	26.00	3,162.35
	10/27/2020	17.00	3,225.00
	10/30/2020	10.00	3,157.75
	11/3/2020	18.00	3,048.41

	Date	Shares	Price
	11/4/2020	110.00	3,226.86
	1/5/2021	35.00	3,218.51
	7/6/2021	80.00	3,530.00
	8/26/2021	60.00	3,299.00
	9/14/2021	60.00	3,450.00
Sales:	9/22/2020	-8.00	3,034.90
	1/22/2021	-71.00	3,304.31
	2/23/2021	-60.00	3,144.35
	3/8/2021	-40.00	3,018.72
	12/9/2021	-25.00	3,483.42
	1/11/2022	-100.00	3,230.00

775400-775401

Purchases:	2/4/2020	88.00	2,049.67
	2/11/2020	92.00	2,150.80
	2/25/2020	23.00	1,983.00
	3/5/2020	25.00	1,924.03
	7/13/2020	25.00	3,104.00
	7/27/2020	29.00	3,055.21
	8/24/2020	14.00	3,311.07
	11/27/2020	95.00	3,199.30
	11/27/2020	74.00	3,209.87
	4/7/2021	41.00	3,279.39
	5/3/2021	39.00	3,484.73
	6/9/2021	28.00	3,286.79
	7/19/2021	62.00	3,523.46
	1/14/2022	49.00	3,203.00
	1/21/2022	25.00	2,970.36
	2/3/2022	25.00	2,818.00
Sales:	5/4/2020	-34.00	2,313.99
	5/28/2020	-86.00	2,410.29
	9/28/2021	-66.00	3,316.69
	11/1/2021	-47.00	3,321.39

780600-780601

Purchases:	2/2/2022	10.00	3,012.25
------------	----------	-------	----------

793400-793401

Purchases:	4/22/2022	198.00	2,887.00
------------	-----------	--------	----------

Date	Shares	Price
4/26/2022	15.00	2,816.33

Exhibit C

Amazon Inc. (AMZN)
Universal-Investment-Gesellschaft mbH

Class Period: 2/1/2019 - 4/28/2022

Hold Price: \$ 112.8616

012300-012301					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	3/19/2019	1,200	\$ 88.8235	(\$ 106,588.20)	
Purchase	3/21/2019	600	\$ 89.9500	(\$ 53,970.00)	
Purchase	5/6/2019	400	\$ 96.2670	(\$ 38,506.80)	
Sale	6/4/2019	(600)	\$ 84.2145	\$ 50,528.70	
Sale	6/6/2019	(1,600)	\$ 86.5725	\$ 138,516.00	
Purchase	7/10/2019	1,200	\$ 99.7700	(\$ 119,724.00)	
Sale	9/30/2019	(1,200)	\$ 86.1475	\$ 103,376.99	
Purchase	2/5/2020	800	\$ 103.5000	(\$ 82,800.00)	
Purchase	2/10/2020	700	\$ 106.2440	(\$ 74,370.80)	
Sale	3/6/2020	(1,500)	\$ 94.7350	\$ 142,102.50	
Purchase	3/19/2020	800	\$ 93.7499	(\$ 74,999.91)	
Purchase	3/20/2020	400	\$ 97.1295	(\$ 38,851.80)	
Purchase	4/14/2020	400	\$ 110.0235	(\$ 44,009.40)	
Sale	4/23/2020	(400)	\$ 120.5215	\$ 48,208.60	
Purchase	5/4/2020	400	\$ 115.8572	(\$ 46,342.88)	
Sale	5/29/2020	(400)	\$ 120.7970	\$ 48,318.80	
Purchase	6/10/2020	400	\$ 132.2440	(\$ 52,897.60)	
Sale	7/6/2020	(800)	\$ 146.9695	\$ 117,575.59	
Sale	7/6/2020	(800)	\$ 150.5446	\$ 120,435.70	
Purchase	9/1/2020	600	\$ 174.7395	(\$ 104,843.70)	
Sale	9/15/2020	(600)	\$ 158.3335	\$ 95,000.10	
Purchase	10/12/2020	800	\$ 167.4250	(\$ 133,940.00)	
Purchase	10/16/2020	400	\$ 168.5345	(\$ 67,413.80)	
Sale	12/10/2020	(500)	\$ 156.0162	\$ 78,008.08	
Purchase	12/17/2020	300	\$ 162.5000	(\$ 48,750.00)	
Purchase	12/29/2020	400	\$ 165.5500	(\$ 66,220.00)	
Sale	1/12/2021	(600)	\$ 155.4605	\$ 93,276.30	
Sale	1/13/2021	(800)	\$ 158.0535	\$ 126,442.80	

Purchase	2/2/2021	700	\$ 169.4950	(\$ 118,646.50)
Purchase	2/3/2021	300	\$ 171.2630	(\$ 51,378.90)
Sale	2/22/2021	(1,000)	\$ 161.1095	\$ 161,109.52
Purchase	4/8/2021	700	\$ 165.6485	(\$ 115,953.94)
Purchase	4/12/2021	500	\$ 168.6910	(\$ 84,345.52)
Purchase	4/27/2021	300	\$ 171.7323	(\$ 51,519.68)
Sale	5/4/2021	(300)	\$ 165.2525	\$ 49,575.75
Sale	5/10/2021	(1,200)	\$ 161.3060	\$ 193,567.20
Purchase	6/17/2021	800	\$ 170.2028	(\$ 136,162.20)
Purchase	6/23/2021	400	\$ 175.2500	(\$ 70,100.00)
Purchase	7/6/2021	400	\$ 179.1035	(\$ 71,641.41)
Sale	8/2/2021	(400)	\$ 166.2070	\$ 66,482.80
Sale	8/13/2021	(1,200)	\$ 164.6570	\$ 197,588.40
Purchase	11/4/2021	800	\$ 172.7458	(\$ 138,196.64)
Purchase	11/9/2021	400	\$ 178.1413	(\$ 71,256.50)
Purchase	11/19/2021	400	\$ 185.6345	(\$ 74,253.80)
Sale	1/5/2022	(600)	\$ 166.6159	\$ 99,969.56
Sale	1/13/2022	(1,000)	\$ 163.7999	\$ 163,799.86
Purchase	3/28/2022	700	\$ 166.6650	(\$ 116,665.50)
Purchase	4/1/2022	300	\$ 165.5321	(\$ 49,659.62)
<i>Purchase in Lookback Period</i>	5/11/2022	500	\$ 108.1705	(\$ 54,085.25)
<i>Sale of Shares Purchased in Lookback Period</i>	5/17/2022	(500)	\$ 111.6788	\$ 55,839.38
Net Proceeds of Transactions				(\$ 210,125.85)
Value of 1,000 retained shares @ \$ 112.8616 per share				\$ 112,861.59
(Loss)/Gain for 012300-012301^b				(\$ 97,264.26)

017200-017204

Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		8,400		
Purchase	2/1/2019	4,200	\$ 82.3986	(\$ 346,074.00)
Sale	4/28/2020	(4,200)	\$ 115.6903	\$ 485,899.44
Sale of Pre-Class Shares	4/28/2020	(700)	\$ 115.6903	\$ 80,983.24
Purchase	9/30/2020	2,600	\$ 157.0570	(\$ 408,348.20)

Purchase	6/14/2021	3,500	\$ 167.9965	(\$ 587,987.73)
Net Proceeds of Transactions				(\$ 856,510.49)
Value of 6,100 retained shares @ \$ 112.8616 per share				\$ 688,455.70
(Loss)/Gain for 017200-017204^b				(\$ 168,054.79)

017200-017206				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	5/20/2021	1,320	\$ 162.2645	(\$ 214,189.14)
Net Proceeds of Transactions				(\$ 214,189.14)
Value of 1,320 retained shares @ \$ 112.8616 per share				\$ 148,977.30
(Loss)/Gain for 017200-017206^b				(\$ 65,211.84)

133400-133401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	9/18/2019	6,000	\$ 90.8674	(\$ 545,204.64)
Purchase	3/3/2020	1,500	\$ 98.9927	(\$ 148,489.12)
Sale	4/27/2020	(3,500)	\$ 121.7081	\$ 425,978.50
Sale	4/28/2020	(4,000)	\$ 117.5082	\$ 470,032.90
Purchase	6/17/2021	3,000	\$ 173.2960	(\$ 519,888.00)
Purchase	7/9/2021	1,000	\$ 186.0600	(\$ 186,060.00)
Purchase	8/12/2021	1,000	\$ 164.4710	(\$ 164,471.00)
<i>Purchase in Lookback Period</i>	6/7/2022	1,000	\$ 122.0000	(\$ 122,000.00)
Net Proceeds of Transactions				(\$ 668,101.36)
Value of 5,000 retained shares @ \$ 112.8616 per share				\$ 564,307.95
(Loss)/Gain for 133400-133401^b				(\$ 103,793.41)

135600-135601				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	11/23/2021	4,000	\$ 180.5678	(\$ 722,271.00)
Net Proceeds of Transactions				(\$ 722,271.00)
Value of 4,000 retained shares @ \$ 112.8616 per share				\$ 451,446.36
(Loss)/Gain for 135600-135601^b				(\$ 270,824.64)

136800-136801
Page 3

Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/18/2022	7,000	\$ 157.9670	(\$ 1,105,769.00)
Purchase	3/22/2022	5,000	\$ 161.8055	(\$ 809,027.50)
<i>Purchase in Lookback Period</i>	<i>5/16/2022</i>	<i>2,500</i>	<i>\$ 110.7306</i>	<i>(\$ 276,826.60)</i>
Net Proceeds of Transactions				(\$ 1,914,796.50)
Value of 12,000 retained shares @ \$ 112.8616 per share				\$ 1,354,339.09
(Loss)/Gain for 136800-136801^b				(\$ 560,457.41)

141D00-141D01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/19/2021	2,600	\$ 176.6290	(\$ 459,235.40)	
Purchase	10/12/2021	1,400	\$ 162.8500	(\$ 227,990.00)	
Purchase	1/26/2022	1,600	\$ 140.5533	(\$ 224,885.20)	
Net Proceeds of Transactions				(\$ 912,110.60)	
Value of 5,600 retained shares @ \$ 112.8616 per share				\$ 632,024.91	
(Loss)/Gain for 141D00-141D01^b				(\$ 280,085.69)	

141H00-141H01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/17/2020	2,400	\$ 158.6403	(\$ 380,736.60)	
Purchase	12/16/2020	1,600	\$ 159.8855	(\$ 255,816.80)	
Net Proceeds of Transactions				(\$ 636,553.40)	
Value of 4,000 retained shares @ \$ 112.8616 per share				\$ 451,446.36	
(Loss)/Gain for 141H00-141H01^b				(\$ 185,107.04)	

141N00-141N04					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	3/25/2021	860,000	\$ 152.3130	(\$ 130,989,180.00)	
Net Proceeds of Transactions				(\$ 130,989,180.00)	
Value of 860,000 retained shares @ \$ 112.8616 per share				\$ 97,060,968.18	
(Loss)/Gain for 141N00-141N04^b				(\$ 33,928,211.82)	

141N00-141N05					
Transaction Type	Date	Quantity	Price ^a	Amount	

Purchase	3/4/2020	9,000	\$ 97.3285	(\$ 875,956.50)
Purchase	9/15/2020	3,600	\$ 157.5647	(\$ 567,233.06)
Purchase	9/28/2020	3,000	\$ 157.3285	(\$ 471,985.40)
Purchase	10/27/2020	3,800	\$ 162.9865	(\$ 619,348.70)
Purchase	10/29/2020	3,200	\$ 160.3225	(\$ 513,031.90)
Purchase	11/20/2020	2,400	\$ 155.8510	(\$ 374,042.40)
Purchase	10/14/2021	3,500	\$ 165.1666	(\$ 578,083.22)
Purchase	11/10/2021	50,520	\$ 174.1025	(\$ 8,795,658.30)
Sale	11/26/2021	(6,520)	\$ 176.5459	\$ 1,151,079.24
Net Proceeds of Transactions				(\$ 11,644,260.25)
Value of 72,500 retained shares @ \$ 112.8616 per share				\$ 8,182,465.34
(Loss)/Gain for 141N00-141N05^b				(\$ 3,461,794.91)

142F00-142F01					
	Transaction Type	Date	Quantity	Price ^a	Amount
Purchase		12/18/2020	5,620	\$ 162.4710	(\$ 913,087.02)
Purchase		8/19/2021	1,820	\$ 159.8945	(\$ 291,007.99)
Purchase		1/20/2022	1,440	\$ 157.8340	(\$ 227,280.96)
Net Proceeds of Transactions					(\$ 1,431,375.97)
Value of 8,880 retained shares @ \$ 112.8616 per share					\$ 1,002,210.93
(Loss)/Gain for 142F00-142F01^b					(\$ 429,165.04)

221800-221801					
	Transaction Type	Date	Quantity	Price ^a	Amount
Purchase		1/29/2021	400	\$ 161.5670	(\$ 64,626.80)
Purchase		2/1/2021	500	\$ 164.0343	(\$ 82,017.13)
Purchase		2/2/2021	500	\$ 169.4995	(\$ 84,749.75)
Purchase		2/3/2021	400	\$ 168.4500	(\$ 67,380.00)
Purchase		2/5/2021	200	\$ 166.3603	(\$ 33,272.05)
Purchase		2/23/2021	200	\$ 158.2195	(\$ 31,643.90)
Purchase		3/1/2021	200	\$ 156.3795	(\$ 31,275.90)
Purchase		4/29/2021	500	\$ 173.3028	(\$ 86,651.38)
Purchase		6/7/2021	200	\$ 159.9995	(\$ 31,999.90)
Purchase		8/25/2021	300	\$ 164.8213	(\$ 49,446.38)

Purchase	10/7/2021	100	\$ 165.6140	(\$ 16,561.40)
Purchase	12/1/2021	300	\$ 176.3085	(\$ 52,892.55)
Sale	12/14/2021	(100)	\$ 168.0100	\$ 16,801.00
Sale	12/15/2021	(100)	\$ 167.0000	\$ 16,700.00
Sale	12/16/2021	(200)	\$ 172.3498	\$ 34,469.95
Purchase	12/28/2021	200	\$ 169.9000	(\$ 33,980.00)
<i>Sale of Class Shares in Lookback Period</i>	<i>5/6/2022</i>	<i>(1,600)</i>	<i>\$ 121.6900</i>	<i>\$ 194,704.00</i>
Net Proceeds of Transactions				(\$ 403,822.18)
Value of 2,000 retained shares @ \$ 112.8616 per share				\$ 225,723.18
(Loss)/Gain for 221800-221801^b				(\$ 178,099.00)

222100-222101				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		16,000		
Purchase	2/4/2020	1,000	\$ 101.5548	(\$ 101,554.80)
Purchase	3/17/2020	6,800	\$ 90.2978	(\$ 614,025.21)
Purchase	3/20/2020	1,800	\$ 96.4065	(\$ 173,531.70)
Purchase	4/8/2020	1,800	\$ 100.9610	(\$ 181,729.80)
Sale	6/15/2020	(900)	\$ 126.2892	\$ 113,660.30
Sale	6/24/2020	(3,100)	\$ 139.0000	\$ 430,900.00
Sale	6/25/2020	(300)	\$ 136.8237	\$ 41,047.11
Sale	7/15/2020	(1,000)	\$ 152.5813	\$ 152,581.25
Purchase	1/25/2021	1,800	\$ 166.4385	(\$ 299,589.29)
Purchase	2/25/2021	1,400	\$ 157.2345	(\$ 220,128.25)
Purchase	3/5/2021	300	\$ 148.8300	(\$ 44,649.00)
Purchase	3/9/2021	1,300	\$ 152.7448	(\$ 198,568.18)
Purchase	4/29/2021	2,000	\$ 174.0831	(\$ 348,166.11)
Purchase	8/13/2021	1,300	\$ 164.5183	(\$ 213,873.75)
Purchase	8/19/2021	1,300	\$ 161.3399	(\$ 209,741.88)
Purchase	9/7/2021	3,000	\$ 175.9870	(\$ 527,961.14)
Sale	10/11/2021	(2,200)	\$ 163.8692	\$ 360,512.24
Purchase	10/29/2021	1,100	\$ 165.5604	(\$ 182,116.42)
Purchase	11/18/2021	1,400	\$ 183.9995	(\$ 257,599.29)

Purchase	11/24/2021	1,000	\$ 179.0321	(\$ 179,032.10)
Purchase	12/1/2021	2,000	\$ 176.9030	(\$ 353,805.94)
Purchase	1/26/2022	1,400	\$ 143.0571	(\$ 200,280.00)
Purchase	1/27/2022	2,000	\$ 141.8130	(\$ 283,626.00)
Sale	2/3/2022	(5,880)	\$ 139.8196	\$ 822,138.98
Purchase	2/17/2022	2,600	\$ 157.8631	(\$ 410,444.00)
Purchase	2/24/2022	1,880	\$ 141.8967	(\$ 266,765.81)
<i>Purchase in Lookback Period</i>	5/13/2022	5,000	\$ 111.4753	(\$ 557,376.38)
Net Proceeds of Transactions				(\$ 3,346,348.79)
Value of 23,800 retained shares @ \$ 112.8616 per share				\$ 2,686,105.86
(Loss)/Gain for 222100-222101^b				(\$ 660,242.93)

222200-222201					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/6/2021	10,000	\$ 181.9859	(\$ 1,819,859.30)	
Purchase	8/26/2021	5,000	\$ 165.4774	(\$ 827,387.18)	
Purchase	1/26/2022	3,000	\$ 144.7845	(\$ 434,353.50)	
Net Proceeds of Transactions				(\$ 3,081,599.98)	
Value of 18,000 retained shares @ \$ 112.8616 per share				\$ 2,031,508.64	
(Loss)/Gain for 222200-222201^b				(\$ 1,050,091.34)	

22B200-22B201					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	1/20/2022	5,460	\$ 156.7660	(\$ 855,942.36)	
Purchase	1/25/2022	460	\$ 142.2425	(\$ 65,431.55)	
Purchase	2/1/2022	800	\$ 150.1500	(\$ 120,120.00)	
Purchase	2/15/2022	960	\$ 157.5460	(\$ 151,244.16)	
Purchase	2/22/2022	540	\$ 150.4785	(\$ 81,258.39)	
Purchase	3/1/2022	820	\$ 152.7325	(\$ 125,240.65)	
Purchase	3/8/2022	660	\$ 136.6835	(\$ 90,211.11)	
Purchase	3/15/2022	600	\$ 142.8500	(\$ 85,710.00)	
Purchase	4/5/2022	140	\$ 167.7415	(\$ 23,483.81)	
Purchase	4/12/2022	760	\$ 153.6925	(\$ 116,806.30)	
<i>Purchase in Lookback Period</i>	5/4/2022	2,720	\$ 122.9991	(\$ 334,557.52)	

Purchase in Lookback Period	5/13/2022	1,880	\$ 110.2466	(\$ 207,263.56)
Sale of Shares Purchased in Lookback Period	5/20/2022	(1,000)	\$ 109.0107	\$ 109,010.72
Sale of Shares Purchased in Lookback Period	5/31/2022	(3,600)	\$ 116.1451	\$ 418,122.25
Sale of Class Shares in Lookback Period	5/31/2022	(11,200)	\$ 116.1451	\$ 1,300,824.78
(Loss)/Gain for 22B200-22B201^b				(\$ 414,623.55)

22B300-22B301					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	2/4/2022	2,760	\$ 155.1649	(\$ 428,255.15)	
Purchase	2/9/2022	640	\$ 162.0683	(\$ 103,723.68)	
Purchase	2/11/2022	3,200	\$ 157.2002	(\$ 503,040.53)	
Purchase	2/14/2022	500	\$ 154.6144	(\$ 77,307.18)	
Purchase	2/25/2022	200	\$ 150.3903	(\$ 30,078.06)	
Purchase	3/23/2022	560	\$ 165.3640	(\$ 92,603.86)	
Purchase	4/1/2022	360	\$ 164.1460	(\$ 59,092.56)	
<i>Sale of Class Shares in Lookback Period</i>	5/13/2022	(300)	\$ 115.7409	\$ 34,722.27	
<i>Sale of Class Shares in Lookback Period</i>	5/27/2022	(520)	\$ 114.0369	\$ 59,299.18	
<i>Purchase in Lookback Period</i>	6/3/2022	700	\$ 122.7795	(\$ 85,945.65)	
Net Proceeds of Transactions				(\$ 1,200,079.57)	
Value of 7,400 retained shares @ \$ 112.8616 per share				\$ 835,175.77	
(Loss)/Gain for 22B300-22B301^b				(\$ 364,903.79)	

242B00-242B01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	12/3/2019	6,400	\$ 88.0000	(\$ 563,200.00)	
Purchase	12/5/2019	400	\$ 87.2060	(\$ 34,882.40)	
Purchase	1/23/2020	600	\$ 94.2545	(\$ 56,552.70)	
Purchase	1/27/2020	39,600	\$ 91.4170	(\$ 3,620,113.20)	
Purchase	3/5/2020	2,600	\$ 96.2015	(\$ 250,123.90)	
Purchase	4/7/2020	4,200	\$ 100.5800	(\$ 422,436.00)	
Purchase	5/8/2020	800	\$ 118.9805	(\$ 95,184.40)	
Purchase	6/9/2020	4,000	\$ 126.4870	(\$ 505,948.00)	
Purchase	7/6/2020	3,600	\$ 152.8520	(\$ 550,267.20)	

Purchase	8/5/2020	1,800	\$ 160.2515	(\$ 288,452.70)
Purchase	9/3/2020	1,800	\$ 168.4000	(\$ 303,120.00)
Purchase	10/5/2020	2,600	\$ 159.9600	(\$ 415,896.00)
Purchase	11/5/2020	2,000	\$ 166.1000	(\$ 332,200.00)
Purchase	12/3/2020	4,400	\$ 159.3365	(\$ 701,080.60)
Purchase	1/6/2021	4,000	\$ 156.9190	(\$ 627,676.00)
Purchase	2/3/2021	1,400	\$ 165.6265	(\$ 231,877.10)
Purchase	3/3/2021	1,600	\$ 150.2500	(\$ 240,400.00)
Purchase	3/12/2021	1,400	\$ 154.4745	(\$ 216,264.30)
Purchase	4/8/2021	1,000	\$ 165.5450	(\$ 165,545.00)
Purchase	5/5/2021	2,600	\$ 163.5270	(\$ 425,170.20)
Purchase	6/7/2021	3,600	\$ 159.8340	(\$ 575,402.40)
Purchase	7/2/2021	12,000	\$ 175.5490	(\$ 2,106,588.00)
Purchase	8/4/2021	8,600	\$ 167.7360	(\$ 1,442,529.60)
Purchase	8/23/2021	4,000	\$ 163.2935	(\$ 653,174.00)
Purchase	9/3/2021	13,000	\$ 173.9025	(\$ 2,260,732.50)
Purchase	10/5/2021	9,200	\$ 161.0500	(\$ 1,481,660.00)
Purchase	11/3/2021	9,360	\$ 169.2000	(\$ 1,583,712.00)
Purchase	12/3/2021	11,200	\$ 169.4895	(\$ 1,898,282.40)
Sale	12/22/2021	(3,600)	\$ 171.0370	\$ 615,733.20
Purchase	1/5/2022	4,000	\$ 164.3570	(\$ 657,428.00)
Purchase	1/7/2022	4,840	\$ 162.5540	(\$ 786,761.36)
Purchase	2/3/2022	7,800	\$ 138.8455	(\$ 1,082,994.90)
Purchase	3/3/2022	10,600	\$ 147.8985	(\$ 1,567,724.10)
Purchase	4/5/2022	9,800	\$ 164.0550	(\$ 1,607,739.00)
<i>Purchase in Lookback Period</i>	5/4/2022	7,000	\$ 125.9285	(\$ 881,499.50)
<i>Purchase in Lookback Period</i>	6/3/2022	8,000	\$ 122.3500	(\$ 978,800.00)
<i>Purchase in Lookback Period</i>	6/14/2022	3,000	\$ 104.1600	(\$ 312,480.00)
Net Proceeds of Transactions				(\$ 27,135,384.76)
Value of 191,200 retained shares @ \$ 112.8616 per share				\$ 21,579,136.18
(Loss)/Gain for 242B00-242B01^b				(\$ 5,556,248.58)

242U00-242U01

Transaction Type	Date Page 9	Quantity	Amount
------------------	----------------	----------	--------

			Price ^a	
Purchase	5/4/2021	2,400	\$ 166.1195	(\$ 398,686.80)
Purchase	5/7/2021	640	\$ 165.2735	(\$ 105,775.03)
Purchase	5/12/2021	340	\$ 160.2837	(\$ 54,496.45)
Purchase	5/28/2021	260	\$ 161.9595	(\$ 42,109.47)
Purchase	6/7/2021	560	\$ 160.2255	(\$ 89,726.29)
Purchase	6/17/2021	620	\$ 171.6544	(\$ 106,425.70)
Purchase	7/6/2021	540	\$ 180.4986	(\$ 97,469.26)
Purchase	7/21/2021	900	\$ 178.8810	(\$ 160,992.86)
Purchase	8/16/2021	900	\$ 162.2988	(\$ 146,068.94)
Purchase	8/24/2021	620	\$ 165.2025	(\$ 102,425.55)
Purchase	10/20/2021	760	\$ 172.6075	(\$ 131,181.70)
Purchase	12/13/2021	400	\$ 171.8975	(\$ 68,759.00)
Purchase	1/6/2022	1,860	\$ 163.4510	(\$ 304,018.86)
Sale	1/25/2022	(700)	\$ 142.2425	\$ 99,569.75
Sale	2/3/2022	(3,000)	\$ 141.7375	\$ 425,212.50
Purchase	2/18/2022	520	\$ 154.2365	(\$ 80,203.00)
Purchase	3/9/2022	1,020	\$ 138.2661	(\$ 141,031.41)
<i>Sale of Class Shares in Lookback Period</i>	5/19/2022	(8,640)	\$ 114.2507	\$ 987,125.76
(Loss)/Gain for 242U00-242U01^b				(\$ 517,462.31)

266400-266401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	5/19/2021	2,000	\$ 160.8400	(\$ 321,680.06)
Net Proceeds of Transactions				(\$ 321,680.06)
Value of 2,000 retained shares @ \$ 112.8616 per share				\$ 225,723.18
(Loss)/Gain for 266400-266401^b				(\$ 95,956.88)

302900-302901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/1/2021	7,000	\$ 162.2085	(\$ 1,135,459.50)
Purchase	2/4/2021	5,000	\$ 166.4175	(\$ 832,087.50)
Purchase	2/9/2021	5,000	\$ 165.6245	(\$ 828,122.50)
Purchase	3/11/2021	1,800	\$ 155.2130	(\$ 279,383.40)

Sale	10/8/2021	(2,300)	\$ 165.9370	\$ 381,655.04
Sale	3/18/2022	(6,200)	\$ 157.0690	\$ 973,827.80
Net Proceeds of Transactions				(\$ 1,719,570.06)
Value of 10,300 retained shares @ \$ 112.8616 per share				\$ 1,162,474.39
(Loss)/Gain for 302900-302901^b				(\$ 557,095.67)

332000-332001				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		3,000		
Sale of Pre-Class Shares	3/21/2019	(400)	\$ 90.1852	\$ 36,074.06
Sale of Pre-Class Shares	6/18/2019	(500)	\$ 96.0107	\$ 48,005.33
Purchase	11/20/2019	600	\$ 87.7040	(\$ 52,622.40)
Purchase	1/16/2020	400	\$ 93.4231	(\$ 37,369.22)
Sale	2/13/2020	(360)	\$ 107.8015	\$ 38,808.54
Sale	6/2/2020	(480)	\$ 123.2675	\$ 59,168.40
Purchase	6/12/2020	320	\$ 131.0730	(\$ 41,943.36)
Purchase	6/17/2020	540	\$ 132.1639	(\$ 71,368.49)
Purchase	6/18/2020	300	\$ 132.5875	(\$ 39,776.25)
Purchase	6/24/2020	980	\$ 137.8700	(\$ 135,112.60)
Purchase	6/26/2020	500	\$ 138.7404	(\$ 69,370.18)
Purchase	7/15/2020	640	\$ 154.0000	(\$ 98,560.00)
Sale	10/14/2020	(900)	\$ 172.3500	\$ 155,115.00
Purchase	10/16/2020	780	\$ 168.5345	(\$ 131,456.91)
Purchase	10/23/2020	980	\$ 158.4401	(\$ 155,271.27)
Purchase	1/29/2021	740	\$ 161.5796	(\$ 119,568.88)
Purchase	3/2/2021	620	\$ 157.1735	(\$ 97,447.57)
Purchase	4/14/2021	1,400	\$ 168.9992	(\$ 236,598.91)
Purchase	4/16/2021	2,080	\$ 168.7094	(\$ 350,915.51)
Purchase	4/26/2021	960	\$ 167.5000	(\$ 160,800.00)
Purchase	5/10/2021	900	\$ 164.1160	(\$ 147,704.40)
Purchase	8/5/2021	1,200	\$ 167.8110	(\$ 201,373.20)
Purchase	8/19/2021	2,100	\$ 160.7298	(\$ 337,532.65)
Sale	10/20/2021	(1,700)	\$ 172.4398	\$ 293,147.62

Purchase	11/18/2021	1,700	\$ 178.6021	(\$ 303,623.52)
Sale	12/16/2021	(2,400)	\$ 173.2634	\$ 415,832.11
Purchase	12/21/2021	800	\$ 166.4133	(\$ 133,130.60)
Net Proceeds of Transactions				(\$ 1,959,474.25)
Value of 12,700 retained shares @ \$ 112.8616 per share				\$ 1,433,342.20
(Loss)/Gain for 332000-332001^b				(\$ 526,132.04)

332200-332201				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		4,500		
Sale of Pre-Class Shares	6/11/2019	(1,000)	\$ 94.2175	\$ 94,217.50
Purchase	11/21/2019	1,000	\$ 87.1245	(\$ 87,124.50)
Sale	6/2/2020	(800)	\$ 122.5140	\$ 98,011.20
Purchase	9/8/2020	900	\$ 161.2485	(\$ 145,123.65)
Purchase	12/4/2020	600	\$ 158.7042	(\$ 95,222.50)
Purchase	1/29/2021	1,100	\$ 161.5290	(\$ 177,681.94)
Purchase	2/19/2021	420	\$ 166.4115	(\$ 69,892.83)
Purchase	3/9/2021	620	\$ 150.8995	(\$ 93,557.69)
Purchase	4/15/2021	800	\$ 168.5705	(\$ 134,856.40)
Sale	7/7/2021	(600)	\$ 185.8340	\$ 111,500.40
Purchase	8/19/2021	1,060	\$ 160.7936	(\$ 170,441.17)
Purchase	8/24/2021	1,000	\$ 164.5394	(\$ 164,539.42)
Sale	10/20/2021	(1,400)	\$ 172.5420	\$ 241,558.80
Sale	12/16/2021	(1,900)	\$ 173.3150	\$ 329,298.50
Purchase	1/25/2022	600	\$ 142.1753	(\$ 85,305.18)
Net Proceeds of Transactions				(\$ 443,376.37)
Value of 3,400 retained shares @ \$ 112.8616 per share				\$ 383,729.41
(Loss)/Gain for 332200-332201^b				(\$ 59,646.96)

332700-332701				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/19/2020	2,200	\$ 95.2634	(\$ 209,579.45)
Purchase	3/27/2020	1,100	\$ 95.9448	(\$ 105,539.30)
Purchase	5/20/2020	2,100	\$ 123.8935	(\$ 260,176.35)

Purchase	8/4/2020	2,000	\$ 157.3999	(\$ 314,799.81)
Purchase	12/22/2020	3,000	\$ 160.0675	(\$ 480,202.50)
Purchase	2/26/2021	2,400	\$ 153.6282	(\$ 368,707.71)
Purchase	4/15/2021	3,200	\$ 168.5556	(\$ 539,377.80)
Purchase	7/8/2021	1,000	\$ 182.1831	(\$ 182,183.05)
Purchase	8/5/2021	1,200	\$ 167.8110	(\$ 201,373.20)
Purchase	8/19/2021	2,000	\$ 160.6493	(\$ 321,298.59)
Purchase	9/8/2021	4,800	\$ 176.3430	(\$ 846,446.59)
Sale	10/20/2021	(3,000)	\$ 172.2440	\$ 516,732.14
Purchase	12/21/2021	6,000	\$ 166.7632	(\$ 1,000,578.98)
Purchase	12/28/2021	1,000	\$ 170.1825	(\$ 170,182.50)
Purchase	3/14/2022	800	\$ 146.5149	(\$ 117,211.91)
<i>Purchase in Lookback Period</i>	5/10/2022	1,400	\$ 111.3119	(\$ 155,836.69)
Net Proceeds of Transactions				(\$ 4,600,925.60)
Value of 29,800 retained shares @ \$ 112.8616 per share				\$ 3,363,275.41
(Loss)/Gain for 332700-332701^b				(\$ 1,237,650.19)

375200-375203				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	7/26/2021	13,580	\$ 184.8978	(\$ 2,510,912.26)
Purchase	7/27/2021	23,720	\$ 181.3396	(\$ 4,301,374.72)
Purchase	7/28/2021	1,380	\$ 181.2765	(\$ 250,161.58)
Purchase	7/29/2021	2,480	\$ 174.1360	(\$ 431,857.35)
Purchase	7/29/2021	760	\$ 167.5000	(\$ 127,300.00)
Purchase	7/30/2021	1,520	\$ 166.8750	(\$ 253,650.00)
Purchase	8/3/2021	140	\$ 165.0000	(\$ 23,100.00)
Purchase	8/11/2021	580	\$ 165.0431	(\$ 95,724.97)
Purchase	8/12/2021	760	\$ 163.7377	(\$ 124,440.68)
Purchase	8/16/2021	1,520	\$ 161.8487	(\$ 246,009.99)
Purchase	8/19/2021	740	\$ 159.9976	(\$ 118,398.19)
Purchase	9/1/2021	2,420	\$ 175.8685	(\$ 425,601.88)
Purchase	9/3/2021	860	\$ 172.4856	(\$ 148,337.58)
Purchase	9/9/2021	1,640	\$ 176.3519	(\$ 289,217.08)

Purchase	9/9/2021	1,520	\$ 176.3519	(\$ 268,054.85)
Purchase	10/19/2021	80	\$ 172.4595	(\$ 13,796.76)
Purchase	10/29/2021	2,060	\$ 164.7039	(\$ 339,289.94)
Purchase	12/13/2021	1,340	\$ 169.8437	(\$ 227,590.52)
Purchase	12/15/2021	1,020	\$ 166.8705	(\$ 170,207.90)
Purchase	12/16/2021	320	\$ 169.6116	(\$ 54,275.72)
Purchase	1/10/2022	2,640	\$ 157.5044	(\$ 415,811.62)
Purchase	1/21/2022	1,500	\$ 149.7456	(\$ 224,618.36)
Purchase	3/8/2022	600	\$ 134.9219	(\$ 80,953.14)
<i>Purchase in Lookback Period</i>	4/29/2022	4,340	\$ 127.2505	(\$ 552,267.06)
<i>Purchase in Lookback Period</i>	5/2/2022	1,380	\$ 119.9974	(\$ 165,596.42)
<i>Purchase in Lookback Period</i>	5/5/2022	1,340	\$ 115.3995	(\$ 154,635.28)
<i>Purchase in Lookback Period</i>	5/6/2022	1,340	\$ 114.5023	(\$ 153,433.06)
<i>Purchase in Lookback Period</i>	5/9/2022	1,300	\$ 109.9799	(\$ 142,973.93)
<i>Purchase in Lookback Period</i>	5/11/2022	1,660	\$ 105.2584	(\$ 174,728.93)
Net Proceeds of Transactions				(\$ 11,140,685.09)
Value of 63,180 retained shares @ \$ 112.8616 per share				\$ 7,130,595.31
(Loss)/Gain for 375200-375203^b				(\$ 4,010,089.78)

379400-379404				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/29/2021	92,080	\$ 152.7085	(\$ 14,061,398.68)
Purchase	4/21/2021	780	\$ 165.8000	(\$ 129,324.00)
Purchase	6/8/2021	5,300	\$ 161.1212	(\$ 853,942.17)
Purchase	2/1/2022	6,320	\$ 150.1500	(\$ 948,948.00)
Sale	3/21/2022	(7,360)	\$ 160.0225	\$ 1,177,765.45
Purchase	4/27/2022	4,560	\$ 140.1915	(\$ 639,273.24)
Net Proceeds of Transactions				(\$ 15,455,120.64)
Value of 101,680 retained shares @ \$ 112.8616 per share				\$ 11,475,766.56
(Loss)/Gain for 379400-379404^b				(\$ 3,979,354.08)

431000-431001				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	1/5/2021	1,600	\$ 159.6875	(\$ 255,500.00)

Purchase	2/19/2021	800	\$ 165.8828	(\$ 132,706.20)
Purchase	7/22/2021	600	\$ 179.3210	(\$ 107,592.60)
Purchase	1/4/2022	400	\$ 166.8388	(\$ 66,735.52)
Net Proceeds of Transactions				(\$ 562,534.32)
Value of 3,400 retained shares @ \$ 112.8616 per share				\$ 383,729.41
(Loss)/Gain for 431000-431001^b				(\$ 178,804.91)

431A00-431A01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	2/1/2021	600	\$ 165.4864	(\$ 99,291.82)	
Purchase	2/19/2021	400	\$ 166.4115	(\$ 66,564.60)	
Purchase	3/3/2021	1,000	\$ 152.0111	(\$ 152,011.10)	
Purchase	4/23/2021	2,200	\$ 165.8524	(\$ 364,875.20)	
Purchase	6/11/2021	1,800	\$ 167.2735	(\$ 301,092.30)	
Purchase	8/12/2021	2,000	\$ 165.2300	(\$ 330,460.00)	
<i>Sale of Class Shares in Lookback Period</i>	5/2/2022	<i>(8,000)</i>	<i>\$ 124.3900</i>	<i>\$ 995,120.00</i>	
(Loss)/Gain for 431A00-431A01^b				(\$ 319,175.02)	

431D00-431D01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/24/2020	600	\$ 155.3406	(\$ 93,204.36)	
Purchase	12/2/2020	400	\$ 161.0165	(\$ 64,406.60)	
Purchase	1/12/2022	200	\$ 166.1235	(\$ 33,224.70)	
Net Proceeds of Transactions				(\$ 190,835.66)	
Value of 1,200 retained shares @ \$ 112.8616 per share				\$ 135,433.91	
(Loss)/Gain for 431D00-431D01^b				(\$ 55,401.75)	

431J00-431J01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/23/2021	600	\$ 182.3798	(\$ 109,427.88)	
<i>Sale of Class Shares in Lookback Period</i>	5/2/2022	<i>(600)</i>	<i>\$ 124.3900</i>	<i>\$ 74,634.00</i>	
(Loss)/Gain for 431J00-431J01^b				(\$ 34,793.88)	

Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	6/28/2021	400	\$ 171.5290	(\$ 68,611.59)
<i>Sale of Class Shares in Lookback Period</i>	5/3/2022	(400)	\$ 125.9277	\$ 50,371.07
(Loss)/Gain for 432C00-432C01^b				(\$ 18,240.52)

432L00-432L01				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	7/23/2021	940	\$ 182.0000	(\$ 171,080.00)
Purchase	8/5/2021	100	\$ 167.8110	(\$ 16,781.10)
Purchase	8/20/2021	220	\$ 159.9555	(\$ 35,190.21)
Purchase	9/14/2021	140	\$ 173.2610	(\$ 24,256.54)
Purchase	10/4/2021	200	\$ 160.0000	(\$ 32,000.00)
Purchase	10/22/2021	160	\$ 170.9900	(\$ 27,358.40)
Purchase	12/22/2021	320	\$ 169.1500	(\$ 54,128.00)
Purchase	12/29/2021	280	\$ 170.8400	(\$ 47,835.20)
Sale	1/19/2022	(320)	\$ 158.7425	\$ 50,797.60
Sale	2/9/2022	(1,000)	\$ 161.9700	\$ 161,970.00
Purchase	4/7/2022	200	\$ 157.8760	(\$ 31,575.20)
<i>Purchase in Lookback Period</i>	6/15/2022	300	\$ 103.8600	(\$ 31,158.00)
Net Proceeds of Transactions				(\$ 227,437.05)
Value of 1,240 retained shares @ \$ 112.8616 per share				\$ 139,948.37
(Loss)/Gain for 432L00-432L01^b				(\$ 87,488.68)

432P00-432P01				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	8/11/2021	400	\$ 166.5375	(\$ 66,615.00)
Purchase	9/3/2021	80	\$ 172.6970	(\$ 13,815.76)
Purchase	11/8/2021	140	\$ 176.1620	(\$ 24,662.68)
Purchase	1/19/2022	140	\$ 158.7425	(\$ 22,223.95)
Purchase	1/21/2022	520	\$ 148.7500	(\$ 77,350.00)
Purchase	2/3/2022	180	\$ 141.7375	(\$ 25,512.75)
Purchase	2/24/2022	160	\$ 139.6795	(\$ 22,348.72)
<i>Purchase in Lookback Period</i>	5/9/2022	800	\$ 110.2500	(\$ 88,200.00)

Purchase in Lookback Period	5/25/2022	300	\$ 103,8120	(\$ 31,143.60)
Net Proceeds of Transactions				(\$ 252,528.86)
Value of 1,620 retained shares @ \$ 112.8616 per share				\$ 182,835.78
(Loss)/Gain for 432P00-432P01 ^b				(\$ 69,693.08)

433800-433801				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		700		
Purchase	6/7/2021	500	\$ 159.8340	(\$ 79,917.00)
Net Proceeds of Transactions				(\$ 79,917.00)
Value of 500 retained shares @ \$ 112.8616 per share				\$ 56,430.80
(Loss)/Gain for 433800-433801 ^b				(\$ 23,486.20)

437200-437201				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	5/3/2019	800	\$ 97.9925	(\$ 78,394.00)
Purchase	5/23/2019	200	\$ 91.8295	(\$ 18,365.90)
Purchase	7/23/2019	160	\$ 99.2190	(\$ 15,875.04)
Purchase	12/23/2019	440	\$ 89.4050	(\$ 39,338.20)
Purchase	3/5/2020	240	\$ 97.3550	(\$ 23,365.20)
Purchase	6/10/2020	520	\$ 133.1715	(\$ 69,249.18)
Purchase	9/16/2020	360	\$ 157.1220	(\$ 56,563.91)
Purchase	11/9/2020	280	\$ 161.4435	(\$ 45,204.18)
Purchase	11/9/2020	280	\$ 162.8895	(\$ 45,609.06)
Sale	11/10/2020	(280)	\$ 153.4600	\$ 42,968.80
Purchase	11/19/2020	340	\$ 155.4203	(\$ 52,842.89)
Purchase	11/30/2020	360	\$ 157.5797	(\$ 56,728.70)
Purchase	4/29/2021	640	\$ 175.3400	(\$ 112,217.60)
Purchase	11/17/2021	320	\$ 178.1171	(\$ 56,997.46)
Net Proceeds of Transactions				(\$ 627,782.51)
Value of 4,660 retained shares @ \$ 112.8616 per share				\$ 525,935.01
(Loss)/Gain for 437200-437201 ^b				(\$ 101,847.50)

437400-437401
Page 17

Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/16/2020	13,000	\$ 85.1525	(\$ 1,106,982.50)
Purchase	3/26/2020	10,000	\$ 95.0105	(\$ 950,105.00)
Sale	8/4/2020	(1,000)	\$ 155.5409	\$ 155,540.90
Purchase	2/9/2021	12,000	\$ 165.7841	(\$ 1,989,409.00)
Purchase	2/10/2021	12,000	\$ 163.3750	(\$ 1,960,499.41)
Purchase	2/23/2021	2,360	\$ 156.2287	(\$ 368,699.69)
Purchase	3/4/2021	12,400	\$ 150.7000	(\$ 1,868,680.00)
Purchase	3/8/2021	14,700	\$ 150.7191	(\$ 2,215,570.50)
Purchase	4/6/2021	3,520	\$ 161.9630	(\$ 570,109.76)
Purchase	6/8/2021	10,060	\$ 161.1305	(\$ 1,620,972.83)
Sale	6/18/2021	(5,000)	\$ 173.9995	\$ 869,997.50
Sale	6/21/2021	(2,600)	\$ 173.8210	\$ 451,934.60
Sale	6/23/2021	(2,040)	\$ 175.2500	\$ 357,510.00
Sale	7/7/2021	(2,000)	\$ 186.2758	\$ 372,551.50
Sale	7/12/2021	(1,920)	\$ 187.2120	\$ 359,447.04
Sale	7/13/2021	(1,280)	\$ 187.8582	\$ 240,458.46
Purchase	8/2/2021	11,160	\$ 166.5320	(\$ 1,858,497.54)
Purchase	8/20/2021	2,200	\$ 160.1290	(\$ 352,283.80)
Sale	8/31/2021	(2,920)	\$ 171.2400	\$ 500,020.80
Sale	8/31/2021	(1,040)	\$ 171.5817	\$ 178,444.92
Sale	9/2/2021	(1,360)	\$ 174.7380	\$ 237,643.68
Sale	9/9/2021	(2,000)	\$ 176.2750	\$ 352,550.00
Purchase	10/11/2021	2,000	\$ 163.7500	(\$ 327,500.00)
Sale	11/8/2021	(2,400)	\$ 175.9353	\$ 422,244.64
Sale	11/19/2021	(3,000)	\$ 186.8081	\$ 560,424.30
Purchase	12/6/2021	13,020	\$ 170.5809	(\$ 2,220,963.32)
Purchase	12/6/2021	3,600	\$ 170.5809	(\$ 614,091.24)
Purchase	12/27/2021	2,320	\$ 170.6843	(\$ 395,987.48)
Purchase	12/28/2021	2,460	\$ 170.2770	(\$ 418,881.42)
Purchase	12/30/2021	2,400	\$ 169.6475	(\$ 407,154.00)
Purchase	1/10/2022	2,800	\$ 157.4911	(\$ 440,975.05)
Purchase	1/11/2022	2,600	\$ 162.7100	(\$ 423,046.00)

Purchase	1/14/2022	2,200	\$ 160.1500	(\$ 352,330.00)
Purchase	1/18/2022	2,580	\$ 158.7977	(\$ 409,698.14)
Purchase	1/19/2022	2,000	\$ 158.4394	(\$ 316,878.76)
Purchase	1/21/2022	2,660	\$ 145.2619	(\$ 386,396.66)
Purchase	1/21/2022	2,600	\$ 146.9147	(\$ 381,978.30)
Purchase	1/24/2022	6,400	\$ 139.0000	(\$ 889,600.00)
Purchase	1/25/2022	3,000	\$ 139.9201	(\$ 419,760.36)
Sale	2/1/2022	(2,500)	\$ 149.1670	\$ 372,917.50
Sale	2/4/2022	(12,000)	\$ 155.6065	\$ 1,867,278.00
Sale	2/4/2022	(2,000)	\$ 153.9770	\$ 307,954.06
Sale	2/10/2022	(3,000)	\$ 158.3500	\$ 475,050.00
Purchase	3/4/2022	3,000	\$ 144.5735	(\$ 433,720.50)
Purchase	3/7/2022	2,000	\$ 140.4403	(\$ 280,880.50)
Purchase	3/8/2022	2,400	\$ 135.0000	(\$ 324,000.00)
Sale	3/10/2022	(2,600)	\$ 145.6850	\$ 378,781.00
Sale	3/10/2022	(2,500)	\$ 146.9229	\$ 367,307.19
Sale	3/21/2022	(3,000)	\$ 160.9500	\$ 482,850.00
Sale	3/28/2022	(2,500)	\$ 167.0368	\$ 417,592.11
Sale	3/29/2022	(2,600)	\$ 170.3840	\$ 442,998.40
Sale	4/5/2022	(4,500)	\$ 167.7415	\$ 754,836.75
Purchase	4/25/2022	3,500	\$ 143.4393	(\$ 502,037.50)
Purchase	4/28/2022	3,000	\$ 141.9410	(\$ 425,823.00)
<i>Purchase in Lookback Period</i>	4/29/2022	2,600	\$ 127.2234	(\$ 330,780.96)
<i>Purchase in Lookback Period</i>	4/29/2022	1,600	\$ 126.7971	(\$ 202,875.30)
<i>Purchase in Lookback Period</i>	5/2/2022	4,400	\$ 122.4010	(\$ 538,564.40)
<i>Purchase in Lookback Period</i>	5/2/2022	3,000	\$ 122.4010	(\$ 367,203.00)
<i>Purchase in Lookback Period</i>	5/5/2022	2,960	\$ 123.0000	(\$ 364,080.00)
<i>Purchase in Lookback Period</i>	5/6/2022	3,100	\$ 115.0000	(\$ 356,500.00)
<i>Sale of Shares Purchased in Lookback Period</i>	5/23/2022	(17,660)	\$ 107.7040	\$ 1,902,052.64
<i>Sale of Class Shares in Lookback Period</i>	5/23/2022	(14,340)	\$ 113.4653	\$ 1,627,092.32
<i>Sale of Class Shares in Lookback Period</i>	6/1/2022	(3,800)	\$ 121.3879	\$ 461,274.10
<i>Sale of Class Shares in Lookback Period</i>	6/9/2022	(9,000)	\$ 120.9554	\$ 1,088,598.56
Net Proceeds of Transactions				(\$ 11,130,213.94)

Value of 77,040 retained shares @ \$ 112.8616 per share	\$ 8,694,856.96
(Loss)/Gain for 437400-437401 ^b	(\$ 2,435,356.97)

437900-437901					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/3/2020	5,200	\$ 150.7355	(\$ 783,824.60)	
Purchase	11/9/2020	800	\$ 162.0987	(\$ 129,678.92)	
Sale	3/5/2021	(1,200)	\$ 148.4524	\$ 178,142.82	
Purchase	4/28/2021	5,200	\$ 173.0003	(\$ 899,601.38)	
Sale	5/3/2021	(5,200)	\$ 172.3560	\$ 896,251.36	
Purchase	7/29/2021	3,200	\$ 181.6630	(\$ 581,321.60)	
Sale	8/18/2021	(2,000)	\$ 161.1945	\$ 322,389.00	
Sale	8/23/2021	(6,000)	\$ 162.3360	\$ 974,016.00	
Purchase	10/29/2021	4,000	\$ 166.2339	(\$ 664,935.56)	
Purchase	2/2/2022	4,000	\$ 152.4215	(\$ 609,686.03)	
Sale	2/4/2022	(2,000)	\$ 150.9025	\$ 301,805.00	
Sale	3/8/2022	(2,000)	\$ 137.7027	\$ 275,405.45	
<i>Sale of Class Shares in Lookback Period</i>	<i>5/6/2022</i>	<i>(4,000)</i>	<i>\$ 121.6900</i>	<i>\$ 486,760.00</i>	
(Loss)/Gain for 437900-437901 ^b					(\$ 234,278.46)

439000-439001					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	1/4/2021	1,220	\$ 163.5000	(\$ 199,470.00)	
Purchase	10/20/2021	200	\$ 172.6075	(\$ 34,521.50)	
Sale	1/3/2022	(300)	\$ 167.6385	\$ 50,291.55	
Sale	1/25/2022	(100)	\$ 142.2425	\$ 14,224.25	
Purchase	2/4/2022	80	\$ 155.6065	(\$ 12,448.52)	
Net Proceeds of Transactions					(\$ 181,924.22)
Value of 1,100 retained shares @ \$ 112.8616 per share					\$ 124,147.75
(Loss)/Gain for 439000-439001 ^b					(\$ 57,776.47)

439600-439601					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/10/2020	300	\$ 154.7510	(\$ 46,425.30)	

Purchase	5/26/2021	300	\$ 163.4920	(\$ 49,047.60)
Net Proceeds of Transactions				(\$ 95,472.90)
Value of 600 retained shares @ \$ 112.8616 per share				\$ 67,716.95
(Loss)/Gain for 439600-439601^b				(\$ 27,755.95)

439900-439901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/16/2021	800	\$ 155.9756	(\$ 124,780.50)
Purchase	8/6/2021	1,200	\$ 167.4383	(\$ 200,925.90)
Net Proceeds of Transactions				(\$ 325,706.40)
Value of 2,000 retained shares @ \$ 112.8616 per share				\$ 225,723.18
(Loss)/Gain for 439900-439901^b				(\$ 99,983.22)

443800-443801				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	1/19/2021	740	\$ 155.8715	(\$ 115,344.91)
Purchase	1/20/2021	540	\$ 160.7914	(\$ 86,827.36)
Purchase	1/26/2021	400	\$ 165.6463	(\$ 66,258.51)
Sale	9/27/2021	(120)	\$ 167.5635	\$ 20,107.62
Sale	12/8/2021	(220)	\$ 175.1850	\$ 38,540.70
Net Proceeds of Transactions				(\$ 209,782.45)
Value of 1,340 retained shares @ \$ 112.8616 per share				\$ 151,234.53
(Loss)/Gain for 443800-443801^b				(\$ 58,547.92)

451900-451901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	9/3/2019	9,800	\$ 89.6141	(\$ 878,217.89)
Purchase	10/23/2019	1,200	\$ 87.6928	(\$ 105,231.36)
Purchase	11/27/2019	1,000	\$ 90.2375	(\$ 90,237.50)
Purchase	3/17/2020	3,000	\$ 85.8997	(\$ 257,699.24)
Purchase	4/2/2020	3,000	\$ 95.7308	(\$ 287,192.50)
Purchase	4/8/2020	22,000	\$ 100.6519	(\$ 2,214,341.00)
Purchase	4/17/2020	30,000	\$ 118.8620	(\$ 3,565,860.96)
Purchase	4/21/2020	10,000	\$ 114.8588	(\$ 1,148,588.00)

Purchase	5/6/2020	60,000	\$ 117.6164	(\$ 7,056,983.70)
Purchase	5/11/2020	30,000	\$ 120.0262	(\$ 3,600,785.70)
Purchase	6/9/2020	10,000	\$ 127.2345	(\$ 1,272,345.25)
Purchase	8/11/2020	6,000	\$ 155.5930	(\$ 933,557.94)
Purchase	9/9/2020	14,000	\$ 160.6774	(\$ 2,249,484.23)
Purchase	9/17/2020	10,000	\$ 150.0410	(\$ 1,500,410.00)
Purchase	11/6/2020	20,000	\$ 162.5141	(\$ 3,250,282.50)
Purchase	12/3/2020	20,000	\$ 160.7036	(\$ 3,214,071.10)
Purchase	12/21/2020	4,000	\$ 161.0117	(\$ 644,046.90)
Purchase	1/14/2021	4,000	\$ 157.7018	(\$ 630,807.22)
Sale	8/10/2021	(8,000)	\$ 167.6891	\$ 1,341,512.64
Sale	10/11/2021	(14,000)	\$ 164.2574	\$ 2,299,603.67
Purchase	1/5/2022	8,000	\$ 166.1314	(\$ 1,329,050.84)
Purchase	1/10/2022	6,000	\$ 157.9114	(\$ 947,468.34)
Purchase	2/8/2022	20,000	\$ 156.4833	(\$ 3,129,665.80)
Purchase	3/11/2022	22,000	\$ 146.3519	(\$ 3,219,741.36)
Purchase	3/16/2022	40,000	\$ 148.7636	(\$ 5,950,542.60)
Purchase	3/18/2022	20,000	\$ 160.8231	(\$ 3,216,461.60)
<i>Purchase in Lookback Period</i>	5/11/2022	92,000	\$ 108.9369	(\$ 10,022,198.94)
<i>Purchase in Lookback Period</i>	5/20/2022	36,000	\$ 109.3907	(\$ 3,938,064.48)
<i>Purchase in Lookback Period</i>	6/14/2022	30,000	\$ 102.8818	(\$ 3,086,454.00)
Net Proceeds of Transactions				(\$ 47,051,957.22)
Value of 352,000 retained shares @ \$ 112.8616 per share				\$ 39,727,280.00
(Loss)/Gain for 451900-451901^b				(\$ 7,324,677.22)

572Q00-572Q01				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	9/13/2021	44,600	\$ 172.8585	(\$ 7,709,489.10)
Purchase	9/16/2021	140	\$ 174.4120	(\$ 24,417.68)
Purchase	9/20/2021	580	\$ 167.7865	(\$ 97,316.17)
Sale	9/22/2021	(940)	\$ 169.0025	\$ 158,862.35
Purchase	9/24/2021	40,040	\$ 171.2760	(\$ 6,857,891.04)
Purchase	9/27/2021	600	\$ 170.2900	(\$ 102,174.00)

Purchase	10/5/2021	500	\$ 161.0500	(\$ 80,525.00)
Purchase	10/8/2021	1,060	\$ 164.4310	(\$ 174,296.86)
Purchase	10/14/2021	360	\$ 164.9930	(\$ 59,397.48)
Purchase	10/18/2021	640	\$ 172.3370	(\$ 110,295.68)
Purchase	10/22/2021	720	\$ 166.7775	(\$ 120,079.80)
Purchase	10/29/2021	260	\$ 168.6215	(\$ 43,841.59)
Purchase	11/5/2021	640	\$ 175.9495	(\$ 112,607.68)
Purchase	11/10/2021	20	\$ 174.1025	(\$ 3,482.05)
Purchase	11/19/2021	1,000	\$ 183.8285	(\$ 183,828.50)
Sale	12/8/2021	(60)	\$ 176.1580	\$ 10,569.48
Sale	12/9/2021	(2,060)	\$ 174.1710	\$ 358,792.26
Sale	12/13/2021	(1,860)	\$ 169.5675	\$ 315,395.55
Purchase	12/16/2021	1,420	\$ 168.8710	(\$ 239,796.82)
Purchase	12/23/2021	1,140	\$ 171.0685	(\$ 195,018.09)
Purchase	1/10/2022	980	\$ 161.4860	(\$ 158,256.28)
Sale	1/12/2022	(20)	\$ 165.2070	\$ 3,304.14
Purchase	1/28/2022	1,420	\$ 143.9780	(\$ 204,448.76)
Purchase	2/9/2022	1,000	\$ 161.1895	(\$ 161,189.50)
Purchase	3/4/2022	820	\$ 145.6410	(\$ 119,425.62)
Sale	3/9/2022	(320)	\$ 139.2790	\$ 44,569.28
Sale	3/11/2022	(220)	\$ 145.5245	\$ 32,015.39
Purchase	3/14/2022	880	\$ 141.8530	(\$ 124,830.64)
Purchase	3/25/2022	1,040	\$ 164.7735	(\$ 171,364.44)
Purchase	4/4/2022	1,220	\$ 168.3465	(\$ 205,382.73)
Purchase	4/8/2022	2,440	\$ 154.4605	(\$ 376,883.62)
Purchase	4/13/2022	40	\$ 155.5410	(\$ 6,221.64)
Purchase	4/21/2022	1,120	\$ 148.2960	(\$ 166,091.52)
<i>Purchase in Lookback Period</i>	5/11/2022	2,520	\$ 105.3720	(\$ 265,537.44)
<i>Purchase in Lookback Period</i>	5/31/2022	1,200	\$ 120.2095	(\$ 144,251.40)
<i>Sale of Shares Purchased in Lookback Period</i>	6/2/2022	(600)	\$ 122.2020	\$ 73,321.20
<i>Purchase in Lookback Period</i>	6/8/2022	2,740	\$ 121.1800	(\$ 332,033.20)
<i>Sale of Shares Purchased in Lookback Period</i>	6/9/2022	(360)	\$ 116.1500	\$ 41,814.00
Net Proceeds of Transactions				(\$ 16,885,043.84)

Value of 99,200 retained shares @ \$ 112.8616 per share	\$ 11,195,869.82
(Loss)/Gain for 572Q00-572Q01 ^b	(\$ 5,689,174.02)

574900-574901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	11/16/2021	2,000	\$ 177.1408	(\$ 354,281.50)
Sale	12/29/2021	(400)	\$ 169.4335	\$ 67,773.39
Net Proceeds of Transactions				(\$ 286,508.11)
Value of 1,600 retained shares @ \$ 112.8616 per share				\$ 180,578.55
(Loss)/Gain for 574900-574901 ^b				(\$ 105,929.56)

576700-576701				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		30,700		
Purchase	3/26/2019	3,400	\$ 89.6500	(\$ 304,810.00)
Purchase	4/9/2019	2,400	\$ 91.7920	(\$ 220,300.80)
Purchase	5/10/2019	3,000	\$ 94.4990	(\$ 283,497.00)
Purchase	6/5/2019	5,200	\$ 86.9250	(\$ 452,010.00)
Purchase	7/17/2019	2,400	\$ 99.6015	(\$ 239,043.60)
Purchase	8/5/2019	10,400	\$ 88.2565	(\$ 917,867.60)
Purchase	8/12/2019	2,600	\$ 89.2460	(\$ 232,039.60)
Purchase	9/3/2019	5,600	\$ 88.5510	(\$ 495,885.60)
Purchase	10/4/2019	4,000	\$ 86.9825	(\$ 347,930.00)
Purchase	10/18/2019	5,200	\$ 87.8755	(\$ 456,952.60)
Purchase	1/7/2020	3,200	\$ 95.2250	(\$ 304,720.00)
Purchase	2/18/2020	1,000	\$ 107.7835	(\$ 107,783.50)
Purchase	3/2/2020	5,200	\$ 97.6975	(\$ 508,027.00)
Purchase	3/10/2020	5,000	\$ 94.5910	(\$ 472,955.00)
Purchase	3/19/2020	2,000	\$ 94.0465	(\$ 188,093.00)
Purchase	3/24/2020	7,200	\$ 97.0050	(\$ 698,436.00)
Purchase	4/2/2020	1,200	\$ 95.9415	(\$ 115,129.80)
Purchase	4/8/2020	2,400	\$ 102.1500	(\$ 245,160.00)
Purchase	4/21/2020	1,800	\$ 116.4060	(\$ 209,530.80)
Purchase	5/4/2020	2,600	\$ 115.7995	(\$ 301,078.70)

Purchase	6/12/2020	4,180	\$ 127.2510	(\$ 531,909.18)
Purchase	8/10/2020	400	\$ 157.4080	(\$ 62,963.20)
Purchase	8/17/2020	4,000	\$ 159.1205	(\$ 636,482.00)
Purchase	8/28/2020	4,000	\$ 170.0900	(\$ 680,360.00)
Purchase	12/2/2020	2,000	\$ 160.1765	(\$ 320,353.00)
Purchase	1/7/2021	2,400	\$ 158.1080	(\$ 379,459.20)
Purchase	1/27/2021	5,400	\$ 161.6290	(\$ 872,796.60)
Purchase	2/19/2021	10,800	\$ 162.4950	(\$ 1,754,946.00)
Purchase	3/10/2021	5,000	\$ 152.8820	(\$ 764,410.00)
Purchase	3/26/2021	5,000	\$ 152.6015	(\$ 763,007.50)
Purchase	4/26/2021	8,800	\$ 170.4500	(\$ 1,499,960.00)
Purchase	5/21/2021	9,000	\$ 162.5000	(\$ 1,462,500.00)
Purchase	6/22/2021	8,800	\$ 175.2720	(\$ 1,542,393.60)
Purchase	7/13/2021	14,200	\$ 183.8680	(\$ 2,610,925.60)
Purchase	8/23/2021	27,520	\$ 163.2935	(\$ 4,493,837.12)
Purchase	9/24/2021	14,440	\$ 171.2760	(\$ 2,473,225.44)
Purchase	10/22/2021	14,000	\$ 166.7775	(\$ 2,334,885.00)
Purchase	11/24/2021	18,400	\$ 179.0205	(\$ 3,293,977.20)
Purchase	12/15/2021	3,800	\$ 173.3150	(\$ 658,597.00)
Purchase	1/21/2022	7,000	\$ 142.6430	(\$ 998,501.00)
Purchase	2/22/2022	6,360	\$ 150.1975	(\$ 955,256.10)
Purchase	3/10/2022	6,600	\$ 146.8175	(\$ 968,995.50)
Purchase	4/6/2022	8,000	\$ 158.7560	(\$ 1,270,048.00)
Net Proceeds of Transactions				(\$ 38,431,038.84)
Value of 265,900 retained shares @ \$ 112.8616 per share				\$ 30,009,897.02
(Loss)/Gain for 576700-576701^b				(\$ 8,421,141.82)

579000-579002					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/22/2021	3,200	\$ 180.6885	(\$ 578,203.04)	
Purchase	3/14/2022	3,000	\$ 145.8952	(\$ 437,685.71)	
Net Proceeds of Transactions					(\$ 1,015,888.75)
Value of 6,200 retained shares @ \$ 112.8616 per share					\$ 699,741.86

(Loss)/Gain for 579000-579002^b**(\$ 316,146.88)****Grand Total for 45 Funds****(Loss)/Gain^b****(\$ 84,417,267.97)**

^a Any shares sold within 90 days after the end of the class period have been valued at the higher price between the actual sale price and the average closing price from the end of the class period to the date of the sale.

^b Losses calculated on a last-in first-out (LIFO) basis.

Amazon Inc. (AMZN)
Universal-Investment-Luxembourg S.A.

Class Period: 2/1/2019 - 4/28/2022

Hold Price: \$ 112.8616

707200-707203					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	10/1/2020	600	\$ 160.4200	(\$ 96,252.00)	
Purchase	10/6/2020	800	\$ 158.2961	(\$ 126,636.89)	
Purchase	10/28/2020	400	\$ 160.1919	(\$ 64,076.74)	
Purchase	5/4/2021	600	\$ 167.5000	(\$ 100,500.00)	
Sale	10/25/2021	(800)	\$ 166.8325	\$ 133,465.96	
<i>Purchase in Lookback Period</i>	5/23/2022	300	\$ 108.4610	(\$ 32,538.30)	
Net Proceeds of Transactions					(\$ 253,999.67)
Value of 1,600 retained shares @ \$ 112.8616 per share					\$ 180,578.55
(Loss)/Gain for 707200-707203^b					(\$ 73,421.12)

711000-711001					
Transaction Type	Date	Quantity	Price ^a	Amount	
Pre-Class Shares		4,680			
Purchase	7/16/2019	780	\$ 101.0222	(\$ 78,797.34)	
Purchase	10/24/2019	540	\$ 88.8915	(\$ 48,001.41)	
Purchase	1/17/2020	1,780	\$ 93.5060	(\$ 166,440.68)	
Sale	2/20/2020	(1,300)	\$ 108.3110	\$ 140,804.30	
Purchase	3/17/2020	1,220	\$ 88.7918	(\$ 108,325.94)	
Purchase	3/19/2020	4,000	\$ 92.5995	(\$ 370,398.00)	
Sale	4/8/2020	(960)	\$ 100.6715	\$ 96,644.64	
Sale	4/17/2020	(1,940)	\$ 117.7350	\$ 228,405.90	
Sale	4/21/2020	(900)	\$ 119.3250	\$ 107,392.50	
Sale	5/20/2020	(1,220)	\$ 124.2558	\$ 151,592.02	
Sale	6/3/2020	(2,000)	\$ 123.5107	\$ 247,021.43	
Sale of Pre-Class Shares	6/3/2020	(340)	\$ 123.5107	\$ 41,993.64	
Purchase	7/28/2020	1,200	\$ 152.8850	(\$ 183,462.00)	
Purchase	8/12/2020	960	\$ 156.9441	(\$ 150,666.30)	
Purchase	9/1/2020	580	\$ 174.6180	(\$ 101,278.44)	

Purchase	9/29/2020	1,000	\$ 158.7995	(\$ 158,799.50)
Purchase	10/27/2020	800	\$ 161.8715	(\$ 129,497.20)
Purchase	10/29/2020	800	\$ 159.8490	(\$ 127,879.20)
Purchase	10/30/2020	700	\$ 154.5848	(\$ 108,209.37)
Purchase	11/19/2020	500	\$ 155.5315	(\$ 77,765.75)
Purchase	12/21/2020	1,000	\$ 160.3090	(\$ 160,309.00)
Purchase	1/14/2021	1,320	\$ 156.3735	(\$ 206,413.02)
Purchase	1/20/2021	700	\$ 160.5510	(\$ 112,385.70)
Purchase	1/22/2021	700	\$ 164.8103	(\$ 115,367.18)
Purchase	1/29/2021	780	\$ 161.4690	(\$ 125,945.82)
Purchase	4/1/2021	800	\$ 158.0500	(\$ 126,440.00)
Purchase	4/29/2021	2,300	\$ 174.8755	(\$ 402,213.71)
Purchase	4/30/2021	800	\$ 176.4938	(\$ 141,195.00)
Purchase	6/9/2021	2,200	\$ 164.0575	(\$ 360,926.50)
Purchase	6/25/2021	1,500	\$ 170.0730	(\$ 255,109.50)
Purchase	7/9/2021	1,800	\$ 185.6143	(\$ 334,105.71)
Purchase	7/30/2021	1,200	\$ 167.9615	(\$ 201,553.80)
Purchase	8/20/2021	1,000	\$ 159.8153	(\$ 159,815.25)
Purchase	8/24/2021	700	\$ 164.3083	(\$ 115,015.78)
Purchase	9/17/2021	500	\$ 174.3248	(\$ 87,162.39)
Purchase	11/22/2021	800	\$ 184.1911	(\$ 147,352.90)
Purchase	11/26/2021	1,300	\$ 180.2000	(\$ 234,260.00)
Purchase	12/6/2021	800	\$ 169.9625	(\$ 135,970.00)
Purchase	12/9/2021	1,200	\$ 174.1710	(\$ 209,005.20)
Purchase	12/17/2021	1,200	\$ 165.8594	(\$ 199,031.30)
Purchase	12/20/2021	2,000	\$ 166.8500	(\$ 333,700.00)
Purchase	1/5/2022	700	\$ 165.8794	(\$ 116,115.55)
Purchase	1/10/2022	1,000	\$ 161.4860	(\$ 161,486.00)
Purchase	1/20/2022	600	\$ 157.3966	(\$ 94,437.94)
Sale	2/4/2022	(4,400)	\$ 155.6065	\$ 684,668.60
Sale	2/4/2022	(4,000)	\$ 155.4679	\$ 621,871.72
<i>Sale of Class Shares in Lookback Period</i>		5/23/2022	(10,100)	\$ 113.4653 \$ 1,145,999.47
Net Proceeds of Transactions				(\$ 2,920,437.79)

Value of 14,940 retained shares @ \$ 112.8616 per share	\$ 1,686,152.17
(Loss)/Gain for 711000-711001 ^b	(\$ 1,234,285.62)

769300-769301					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/22/2019	22,860	\$ 99.2815	(\$ 2,269,575.09)	
Purchase	3/12/2020	1,200	\$ 86.0385	(\$ 103,246.20)	
Purchase	4/27/2020	1,660	\$ 119.7798	(\$ 198,834.40)	
Purchase	7/9/2021	3,760	\$ 186.0670	(\$ 699,611.90)	
Purchase	11/10/2021	2,680	\$ 176.3203	(\$ 472,538.34)	
Purchase	2/1/2022	3,800	\$ 150.1562	(\$ 570,593.50)	
Purchase	4/20/2022	5,780	\$ 154.2181	(\$ 891,380.36)	
Purchase	4/21/2022	5,800	\$ 149.4394	(\$ 866,748.23)	
Net Proceeds of Transactions				(\$ 6,072,528.02)	
Value of 47,540 retained shares @ \$ 112.8616 per share				\$ 5,365,440.03	
(Loss)/Gain for 769300-769301 ^b				(\$ 707,087.99)	

770000-770001					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	2/12/2021	27,900	\$ 162.2761	(\$ 4,527,502.67)	
Sale	2/22/2021	(900)	\$ 160.4065	\$ 144,365.85	
Sale	4/1/2021	(1,200)	\$ 155.9577	\$ 187,149.28	
Sale	1/5/2022	(1,800)	\$ 166.4447	\$ 299,600.40	
Sale	1/19/2022	(2,000)	\$ 158.7425	\$ 317,485.00	
Purchase	1/26/2022	1,400	\$ 141.3489	(\$ 197,888.52)	
Sale	2/16/2022	(1,000)	\$ 157.0500	\$ 157,050.01	
Sale	2/22/2022	(8,800)	\$ 150.6090	\$ 1,325,359.19	
Net Proceeds of Transactions				(\$ 2,294,381.46)	
Value of 13,600 retained shares @ \$ 112.8616 per share				\$ 1,534,917.64	
(Loss)/Gain for 770000-770001 ^b				(\$ 759,463.83)	

770100-770101					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	2/12/2021	2,600	\$ 162.2742	(\$ 421,912.90)	

Sale	4/1/2021	(300)	\$ 155.9568	\$ 46,787.05
Sale	10/18/2021	(200)	\$ 170.4404	\$ 34,088.08
Sale	2/22/2022	(900)	\$ 150.6110	\$ 135,549.88
Net Proceeds of Transactions				(\$ 205,487.89)
Value of 1,200 retained shares @ \$ 112.8616 per share				\$ 135,433.91
(Loss)/Gain for 770100-770101^b				(\$ 70,053.98)

770200-770201				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/12/2021	5,600	\$ 162.2750	(\$ 908,740.18)
Sale	4/1/2021	(700)	\$ 155.9593	\$ 109,171.54
Sale	1/24/2022	(500)	\$ 139.0000	\$ 69,500.00
Sale	2/16/2022	(400)	\$ 157.0730	\$ 62,829.20
Sale	2/22/2022	(1,400)	\$ 150.6081	\$ 210,851.31
Net Proceeds of Transactions				(\$ 456,388.13)
Value of 2,600 retained shares @ \$ 112.8616 per share				\$ 293,440.14
(Loss)/Gain for 770200-770201^b				(\$ 162,947.99)

770300-770301				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/12/2021	10,600	\$ 162.2757	(\$ 1,720,122.51)
Sale	3/26/2021	(400)	\$ 152.2030	\$ 60,881.20
Sale	2/22/2022	(3,400)	\$ 150.6092	\$ 512,071.25
Sale	4/6/2022	(600)	\$ 161.7369	\$ 97,042.11
Purchase	4/8/2022	400	\$ 156.7600	(\$ 62,704.00)
Net Proceeds of Transactions				(\$ 1,112,831.95)
Value of 6,600 retained shares @ \$ 112.8616 per share				\$ 744,886.50
(Loss)/Gain for 770300-770301^b				(\$ 367,945.45)

770900-770901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/17/2020	32,800	\$ 91.8687	(\$ 3,013,292.54)
Purchase	3/19/2020	10,760	\$ 96.0633	(\$ 1,033,640.62)
Purchase	3/20/2020	4,140	\$ 96.3150	(\$ 398,744.10)

Purchase	3/27/2020	4,560	\$ 95.7582	(\$ 436,657.48)
Purchase	4/6/2020	4,900	\$ 98.0165	(\$ 480,280.61)
Sale	6/12/2020	(6,280)	\$ 127.2877	\$ 799,366.91
Sale	6/24/2020	(3,480)	\$ 139.0000	\$ 483,720.00
Sale	7/15/2020	(2,000)	\$ 154.0034	\$ 308,006.81
Sale	7/15/2020	(3,000)	\$ 153.7485	\$ 461,245.50
Sale	7/16/2020	(3,000)	\$ 148.4637	\$ 445,391.00
Purchase	12/2/2020	5,000	\$ 160.5473	(\$ 802,736.50)
Purchase	1/20/2021	6,000	\$ 161.3711	(\$ 968,226.33)
Purchase	1/25/2021	5,400	\$ 166.8178	(\$ 900,816.26)
Purchase	2/1/2021	4,000	\$ 164.8684	(\$ 659,473.48)
Sale	3/10/2021	(4,080)	\$ 152.7455	\$ 623,201.82
Purchase	3/31/2021	12,000	\$ 155.1762	(\$ 1,862,114.16)
Purchase	4/29/2021	12,860	\$ 174.0831	(\$ 2,238,708.09)
Purchase	8/20/2021	5,660	\$ 159.9073	(\$ 905,075.49)
Purchase	8/23/2021	8,000	\$ 163.5708	(\$ 1,308,566.04)
Purchase	8/23/2021	10,000	\$ 163.5708	(\$ 1,635,707.55)
Sale	9/27/2021	(17,400)	\$ 169.8137	\$ 2,954,758.64
Sale	10/11/2021	(15,520)	\$ 163.7882	\$ 2,541,992.77
Purchase	11/18/2021	15,000	\$ 183.9995	(\$ 2,759,992.43)
Purchase	11/24/2021	2,580	\$ 179.0321	(\$ 461,902.82)
Purchase	11/26/2021	17,080	\$ 180.3723	(\$ 3,080,758.12)
Purchase	12/22/2021	2,800	\$ 171.6968	(\$ 480,751.10)
Sale	2/3/2022	(37,600)	\$ 139.8196	\$ 5,257,215.27
Purchase	2/24/2022	11,800	\$ 150.0306	(\$ 1,770,361.43)
Sale	4/5/2022	(9,540)	\$ 165.1045	\$ 1,575,096.83
<i>Purchase in Lookback Period</i>	5/13/2022	1,520	\$ 111.4753	(\$ 169,442.42)
<i>Sale of Shares Purchased in Lookback Period</i>	5/23/2022	(1,520)	\$ 106.6360	\$ 162,086.72
<i>Sale of Class Shares in Lookback Period</i>	5/23/2022	(1,580)	\$ 113.4653	\$ 179,275.16
<i>Sale of Class Shares in Lookback Period</i>	5/31/2022	(1,500)	\$ 118.5690	\$ 177,853.50
<i>Sale of Class Shares in Lookback Period</i>	6/1/2022	(2,600)	\$ 122.0705	\$ 317,383.30
<i>Sale of Class Shares in Lookback Period</i>	6/3/2022	(1,900)	\$ 124.2500	\$ 236,075.00
<i>Sale of Class Shares in Lookback Period</i>	6/3/2022	(1,180)	\$ 121.7645	\$ 143,682.11

Net Proceeds of Transactions	(\$ 8,693,540.51)
Value of 64,680 retained shares @ \$ 112.8616 per share	\$ 7,299,887.70
(Loss)/Gain for 770900-770901 ^b	(\$ 1,393,652.81)

771400-771401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	10/28/2019	660	\$ 88.6982	(\$ 58,540.78)
Sale	11/6/2019	(660)	\$ 89.8058	\$ 59,271.82
Sale of Pre-Class Shares	11/6/2019	(5,040)	\$ 89.8058	\$ 452,621.15
Purchase	3/26/2020	6,640	\$ 96.1833	(\$ 638,656.98)
Purchase	6/3/2020	2,040	\$ 124.1852	(\$ 253,337.84)
Sale	7/10/2020	(1,400)	\$ 159.6480	\$ 223,507.20
Sale	2/9/2021	(3,280)	\$ 165.4158	\$ 542,563.78
Sale	2/12/2021	(4,000)	\$ 162.3577	\$ 649,430.61
Purchase	5/4/2021	3,800	\$ 166.7788	(\$ 633,759.25)
Purchase	5/11/2021	4,040	\$ 156.7437	(\$ 633,244.45)
Sale	8/12/2021	(3,400)	\$ 164.7830	\$ 560,262.10
Sale	8/20/2021	(4,440)	\$ 159.8969	\$ 709,942.10
Purchase	8/24/2021	4,400	\$ 165.3225	(\$ 727,418.80)
Purchase	10/11/2021	2,200	\$ 164.2475	(\$ 361,344.50)
Purchase	12/15/2021	1,960	\$ 165.8752	(\$ 325,115.39)
Purchase	3/4/2022	4,560	\$ 144.8203	(\$ 660,380.75)
Sale	3/16/2022	(4,940)	\$ 148.1501	\$ 731,861.72
Purchase	4/22/2022	4,080	\$ 148.5588	(\$ 606,119.92)
Net Proceeds of Transactions				(\$ 1,421,079.33)
Value of 12,260 retained shares @ \$ 112.8616 per share				\$ 1,383,683.10
(Loss)/Gain for 771400-771401 ^b				(\$ 37,396.23)

772400-772401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/25/2020	1,260	\$ 95.4823	(\$ 120,307.73)
Sale	9/22/2020	(160)	\$ 151.7450	\$ 24,279.20
Purchase	10/7/2020	520	\$ 158.1173	(\$ 82,220.98)
Purchase	10/27/2020	340	\$ 161.2500	(\$ 54,825.00)

Purchase	10/30/2020	200	\$ 157.8875	(\$ 31,577.50)
Purchase	11/3/2020	360	\$ 152.4205	(\$ 54,871.38)
Purchase	11/4/2020	2,200	\$ 161.3431	(\$ 354,954.72)
Purchase	1/5/2021	700	\$ 160.9255	(\$ 112,647.85)
Sale	1/22/2021	(1,420)	\$ 165.2155	\$ 234,606.01
Sale	2/23/2021	(1,200)	\$ 157.2173	\$ 188,660.76
Sale	3/8/2021	(800)	\$ 150.9358	\$ 120,748.65
Purchase	7/6/2021	1,600	\$ 176.5000	(\$ 282,400.00)
Purchase	8/26/2021	1,200	\$ 164.9500	(\$ 197,940.00)
Purchase	9/14/2021	1,200	\$ 172.5000	(\$ 207,000.00)
Sale	12/9/2021	(500)	\$ 174.1710	\$ 87,085.50
Sale	1/11/2022	(2,000)	\$ 161.5000	\$ 323,000.00
<i>Sale of Class Shares in Lookback Period</i>	5/20/2022	(440)	\$ 113.8344	\$ 50,087.13
Net Proceeds of Transactions				(\$ 470,277.91)
Value of 3,060 retained shares @ \$ 112.8616 per share				\$ 345,356.47
(Loss)/Gain for 772400-772401^b				(\$ 124,921.45)

775400-775401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/4/2020	1,760	\$ 102.4835	(\$ 180,370.96)
Purchase	2/11/2020	1,840	\$ 107.5400	(\$ 197,873.60)
Purchase	2/25/2020	460	\$ 99.1500	(\$ 45,609.00)
Purchase	3/5/2020	500	\$ 96.2015	(\$ 48,100.75)
Sale	5/4/2020	(680)	\$ 115.6995	\$ 78,675.66
Sale	5/28/2020	(1,720)	\$ 120.5143	\$ 207,284.52
Purchase	7/13/2020	500	\$ 155.2000	(\$ 77,600.00)
Purchase	7/27/2020	580	\$ 152.7605	(\$ 88,601.09)
Purchase	8/24/2020	280	\$ 165.5535	(\$ 46,354.98)
Purchase	11/27/2020	1,900	\$ 159.9648	(\$ 303,933.20)
Purchase	11/27/2020	1,480	\$ 160.4935	(\$ 237,530.38)
Purchase	4/7/2021	820	\$ 163.9695	(\$ 134,454.99)
Purchase	5/3/2021	780	\$ 174.2365	(\$ 135,904.47)
Purchase	6/9/2021	560	\$ 164.3395	(\$ 92,030.10)

Purchase	7/19/2021	1,240	\$ 176.1729	(\$ 218,454.38)
Sale	9/28/2021	(1,320)	\$ 165.8346	\$ 218,901.63
Sale	11/1/2021	(940)	\$ 166.0697	\$ 156,105.49
Purchase	1/14/2022	980	\$ 160.1500	(\$ 156,947.00)
Purchase	1/21/2022	500	\$ 148.5180	(\$ 74,259.00)
Purchase	2/3/2022	500	\$ 140.9001	(\$ 70,450.03)
<i>Sale of Class Shares in Lookback Period</i>	4/29/2022	(3,380)	\$ 125.6059	\$ 424,547.91
<i>Sale of Class Shares in Lookback Period</i>	5/2/2022	(6,640)	\$ 124.3900	\$ 825,949.60
(Loss)/Gain for 775400-775401^b				(\$ 197,009.13)

780600-780601				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/2/2022	200	\$ 150.6125	(\$ 30,122.50)
<i>Sale of Class Shares in Lookback Period</i>	5/31/2022	(200)	\$ 120.2095	\$ 24,041.90
(Loss)/Gain for 780600-780601^b				(\$ 6,080.60)

793400-793401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	4/22/2022	3,960	\$ 144.3500	(\$ 571,626.00)
Purchase	4/26/2022	300	\$ 140.8167	(\$ 42,245.00)
<i>Purchase in Lookback Period</i>	5/9/2022	7,760	\$ 111.4394	(\$ 864,769.67)
<i>Purchase in Lookback Period</i>	5/26/2022	760	\$ 110.6730	(\$ 84,111.48)
<i>Purchase in Lookback Period</i>	6/3/2022	420	\$ 122.3500	(\$ 51,387.00)
Net Proceeds of Transactions				(\$ 613,871.00)
Value of 4,260 retained shares @ \$ 112.8616 per share				\$ 480,790.38
(Loss)/Gain for 793400-793401^b				(\$ 133,080.62)

Grand Total for 13 Funds	
(Loss)/Gain^b	(\$ 5,267,346.81)

^a Any shares sold within 90 days after the end of the class period have been valued at the higher price between the actual sale price and the average closing price from the end of the class period to the date of the sale.

^b Losses calculated on a last-in first-out (LIFO) basis.

Amazon Inc. (AMZN)
Universal-Investment-Gesellschaft mbH

Class Period: 2/1/2019 - 4/5/2022

Hold Price: \$ 122.8643

012300-012301					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	3/19/2019	1,200	\$ 88.8235	(\$ 106,588.20)	
Purchase	3/21/2019	600	\$ 89.9500	(\$ 53,970.00)	
Purchase	5/6/2019	400	\$ 96.2670	(\$ 38,506.80)	
Sale	6/4/2019	(600)	\$ 84.2145	\$ 50,528.70	
Sale	6/6/2019	(1,600)	\$ 86.5725	\$ 138,516.00	
Purchase	7/10/2019	1,200	\$ 99.7700	(\$ 119,724.00)	
Sale	9/30/2019	(1,200)	\$ 86.1475	\$ 103,376.99	
Purchase	2/5/2020	800	\$ 103.5000	(\$ 82,800.00)	
Purchase	2/10/2020	700	\$ 106.2440	(\$ 74,370.80)	
Sale	3/6/2020	(1,500)	\$ 94.7350	\$ 142,102.50	
Purchase	3/19/2020	800	\$ 93.7499	(\$ 74,999.91)	
Purchase	3/20/2020	400	\$ 97.1295	(\$ 38,851.80)	
Purchase	4/14/2020	400	\$ 110.0235	(\$ 44,009.40)	
Sale	4/23/2020	(400)	\$ 120.5215	\$ 48,208.60	
Purchase	5/4/2020	400	\$ 115.8572	(\$ 46,342.88)	
Sale	5/29/2020	(400)	\$ 120.7970	\$ 48,318.80	
Purchase	6/10/2020	400	\$ 132.2440	(\$ 52,897.60)	
Sale	7/6/2020	(800)	\$ 146.9695	\$ 117,575.59	
Sale	7/6/2020	(800)	\$ 150.5446	\$ 120,435.70	
Purchase	9/1/2020	600	\$ 174.7395	(\$ 104,843.70)	
Sale	9/15/2020	(600)	\$ 158.3335	\$ 95,000.10	
Purchase	10/12/2020	800	\$ 167.4250	(\$ 133,940.00)	
Purchase	10/16/2020	400	\$ 168.5345	(\$ 67,413.80)	
Sale	12/10/2020	(500)	\$ 156.0162	\$ 78,008.08	
Purchase	12/17/2020	300	\$ 162.5000	(\$ 48,750.00)	
Purchase	12/29/2020	400	\$ 165.5500	(\$ 66,220.00)	
Sale	1/12/2021	(600)	\$ 155.4605	\$ 93,276.30	
Sale	1/13/2021	(800)	\$ 158.0535	\$ 126,442.80	

Purchase	2/2/2021	700	\$ 169.4950	(\$ 118,646.50)
Purchase	2/3/2021	300	\$ 171.2630	(\$ 51,378.90)
Sale	2/22/2021	(1,000)	\$ 161.1095	\$ 161,109.52
Purchase	4/8/2021	700	\$ 165.6485	(\$ 115,953.94)
Purchase	4/12/2021	500	\$ 168.6910	(\$ 84,345.52)
Purchase	4/27/2021	300	\$ 171.7323	(\$ 51,519.68)
Sale	5/4/2021	(300)	\$ 165.2525	\$ 49,575.75
Sale	5/10/2021	(1,200)	\$ 161.3060	\$ 193,567.20
Purchase	6/17/2021	800	\$ 170.2028	(\$ 136,162.20)
Purchase	6/23/2021	400	\$ 175.2500	(\$ 70,100.00)
Purchase	7/6/2021	400	\$ 179.1035	(\$ 71,641.41)
Sale	8/2/2021	(400)	\$ 166.2070	\$ 66,482.80
Sale	8/13/2021	(1,200)	\$ 164.6570	\$ 197,588.40
Purchase	11/4/2021	800	\$ 172.7458	(\$ 138,196.64)
Purchase	11/9/2021	400	\$ 178.1413	(\$ 71,256.50)
Purchase	11/19/2021	400	\$ 185.6345	(\$ 74,253.80)
Sale	1/5/2022	(600)	\$ 166.6159	\$ 99,969.56
Sale	1/13/2022	(1,000)	\$ 163.7999	\$ 163,799.86
Purchase	3/28/2022	700	\$ 166.6650	(\$ 116,665.50)
Purchase	4/1/2022	300	\$ 165.5321	(\$ 49,659.62)
<i>Purchase in Lookback Period</i>	5/11/2022	500	\$ 108.1705	(\$ 54,085.25)
<i>Sale of Shares Purchased in Lookback Period</i>	5/17/2022	(500)	\$ 111.6788	\$ 55,839.38
Net Proceeds of Transactions				(\$ 210,125.85)
Value of 1,000 retained shares @ \$ 122.8643 per share				\$ 122,864.33
(Loss)/Gain for 012300-012301^b				(\$ 87,261.52)

017200-017204

Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		8,400		
Purchase	2/1/2019	4,200	\$ 82.3986	(\$ 346,074.00)
Sale	4/28/2020	(4,200)	\$ 115.6903	\$ 485,899.44
Sale of Pre-Class Shares	4/28/2020	(700)	\$ 115.6903	\$ 80,983.24
Purchase	9/30/2020	2,600	\$ 157.0570	(\$ 408,348.20)

Purchase	6/14/2021	3,500	\$ 167.9965	(\$ 587,987.73)
Net Proceeds of Transactions				(\$ 856,510.49)
Value of 6,100 retained shares @ \$ 122.8643 per share				\$ 749,472.43
(Loss)/Gain for 017200-017204^b				(\$ 107,038.06)

017200-017206				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	5/20/2021	1,320	\$ 162.2645	(\$ 214,189.14)
Net Proceeds of Transactions				(\$ 214,189.14)
Value of 1,320 retained shares @ \$ 122.8643 per share				\$ 162,180.92
(Loss)/Gain for 017200-017206^b				(\$ 52,008.22)

133400-133401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	9/18/2019	6,000	\$ 90.8674	(\$ 545,204.64)
Purchase	3/3/2020	1,500	\$ 98.9927	(\$ 148,489.12)
Sale	4/27/2020	(3,500)	\$ 121.7081	\$ 425,978.50
Sale	4/28/2020	(4,000)	\$ 117.5082	\$ 470,032.90
Purchase	6/17/2021	3,000	\$ 173.2960	(\$ 519,888.00)
Purchase	7/9/2021	1,000	\$ 186.0600	(\$ 186,060.00)
Purchase	8/12/2021	1,000	\$ 164.4710	(\$ 164,471.00)
<i>Purchase in Lookback Period</i>	6/7/2022	1,000	\$ 122.0000	(\$ 122,000.00)
Net Proceeds of Transactions				(\$ 668,101.36)
Value of 5,000 retained shares @ \$ 122.8643 per share				\$ 614,321.67
(Loss)/Gain for 133400-133401^b				(\$ 53,779.69)

135600-135601				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	11/23/2021	4,000	\$ 180.5678	(\$ 722,271.00)
Net Proceeds of Transactions				(\$ 722,271.00)
Value of 4,000 retained shares @ \$ 122.8643 per share				\$ 491,457.33
(Loss)/Gain for 135600-135601^b				(\$ 230,813.67)

136800-136801
Page 37

Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/18/2022	7,000	\$ 157.9670	(\$ 1,105,769.00)
Purchase	3/22/2022	5,000	\$ 161.8055	(\$ 809,027.50)
<i>Purchase in Lookback Period</i>	<i>5/16/2022</i>	<i>2,500</i>	<i>\$ 110.7306</i>	<i>(\$ 276,826.60)</i>
Net Proceeds of Transactions				(\$ 1,914,796.50)
Value of 12,000 retained shares @ \$ 122.8643 per share				\$ 1,474,372.00
(Loss)/Gain for 136800-136801^b				(\$ 440,424.50)

141D00-141D01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/19/2021	2,600	\$ 176.6290	(\$ 459,235.40)	
Purchase	10/12/2021	1,400	\$ 162.8500	(\$ 227,990.00)	
Purchase	1/26/2022	1,600	\$ 140.5533	(\$ 224,885.20)	
Net Proceeds of Transactions				(\$ 912,110.60)	
Value of 5,600 retained shares @ \$ 122.8643 per share				\$ 688,040.27	
(Loss)/Gain for 141D00-141D01^b				(\$ 224,070.33)	

141H00-141H01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/17/2020	2,400	\$ 158.6403	(\$ 380,736.60)	
Purchase	12/16/2020	1,600	\$ 159.8855	(\$ 255,816.80)	
Net Proceeds of Transactions				(\$ 636,553.40)	
Value of 4,000 retained shares @ \$ 122.8643 per share				\$ 491,457.33	
(Loss)/Gain for 141H00-141H01^b				(\$ 145,096.07)	

141N00-141N04					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	3/25/2021	860,000	\$ 152.3130	(\$ 130,989,180.00)	
Net Proceeds of Transactions				(\$ 130,989,180.00)	
Value of 860,000 retained shares @ \$ 122.8643 per share				\$ 105,663,326.67	
(Loss)/Gain for 141N00-141N04^b				(\$ 25,325,853.33)	

141N00-141N05					
Transaction Type	Date	Quantity	Price ^a	Amount	
					Page 38

Purchase	3/4/2020	9,000	\$ 97.3285	(\$ 875,956.50)
Purchase	9/15/2020	3,600	\$ 157.5647	(\$ 567,233.06)
Purchase	9/28/2020	3,000	\$ 157.3285	(\$ 471,985.40)
Purchase	10/27/2020	3,800	\$ 162.9865	(\$ 619,348.70)
Purchase	10/29/2020	3,200	\$ 160.3225	(\$ 513,031.90)
Purchase	11/20/2020	2,400	\$ 155.8510	(\$ 374,042.40)
Purchase	10/14/2021	3,500	\$ 165.1666	(\$ 578,083.22)
Purchase	11/10/2021	50,520	\$ 174.1025	(\$ 8,795,658.30)
Sale	11/26/2021	(6,520)	\$ 176.5459	\$ 1,151,079.24
Net Proceeds of Transactions				(\$ 11,644,260.25)
Value of 72,500 retained shares @ \$ 122.8643 per share				\$ 8,907,664.17
(Loss)/Gain for 141N00-141N05^b				(\$ 2,736,596.08)

142F00-142F01					
	Transaction Type	Date	Quantity	Price ^a	Amount
Purchase		12/18/2020	5,620	\$ 162.4710	(\$ 913,087.02)
Purchase		8/19/2021	1,820	\$ 159.8945	(\$ 291,007.99)
Purchase		1/20/2022	1,440	\$ 157.8340	(\$ 227,280.96)
Net Proceeds of Transactions					(\$ 1,431,375.97)
Value of 8,880 retained shares @ \$ 122.8643 per share					\$ 1,091,035.28
(Loss)/Gain for 142F00-142F01^b					(\$ 340,340.69)

221800-221801					
	Transaction Type	Date	Quantity	Price ^a	Amount
Purchase		1/29/2021	400	\$ 161.5670	(\$ 64,626.80)
Purchase		2/1/2021	500	\$ 164.0343	(\$ 82,017.13)
Purchase		2/2/2021	500	\$ 169.4995	(\$ 84,749.75)
Purchase		2/3/2021	400	\$ 168.4500	(\$ 67,380.00)
Purchase		2/5/2021	200	\$ 166.3603	(\$ 33,272.05)
Purchase		2/23/2021	200	\$ 158.2195	(\$ 31,643.90)
Purchase		3/1/2021	200	\$ 156.3795	(\$ 31,275.90)
Purchase		4/29/2021	500	\$ 173.3028	(\$ 86,651.38)
Purchase		6/7/2021	200	\$ 159.9995	(\$ 31,999.90)
Purchase		8/25/2021	300	\$ 164.8213	(\$ 49,446.38)

Purchase	10/7/2021	100	\$ 165.6140	(\$ 16,561.40)
Purchase	12/1/2021	300	\$ 176.3085	(\$ 52,892.55)
Sale	12/14/2021	(100)	\$ 168.0100	\$ 16,801.00
Sale	12/15/2021	(100)	\$ 167.0000	\$ 16,700.00
Sale	12/16/2021	(200)	\$ 172.3498	\$ 34,469.95
Purchase	12/28/2021	200	\$ 169.9000	(\$ 33,980.00)
<i>Sale of Class Shares in Lookback Period</i>	<i>5/6/2022</i>	<i>(1,600)</i>	<i>\$ 142.5495</i>	<i>\$ 228,079.27</i>
Net Proceeds of Transactions				(\$ 370,446.91)
Value of 2,000 retained shares @ \$ 122.8643 per share				\$ 245,728.67
(Loss)/Gain for 221800-221801^b				(\$ 124,718.24)

222100-222101				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		16,000		
Purchase	2/4/2020	1,000	\$ 101.5548	(\$ 101,554.80)
Purchase	3/17/2020	6,800	\$ 90.2978	(\$ 614,025.21)
Purchase	3/20/2020	1,800	\$ 96.4065	(\$ 173,531.70)
Purchase	4/8/2020	1,800	\$ 100.9610	(\$ 181,729.80)
Sale	6/15/2020	(900)	\$ 126.2892	\$ 113,660.30
Sale	6/24/2020	(3,100)	\$ 139.0000	\$ 430,900.00
Sale	6/25/2020	(300)	\$ 136.8237	\$ 41,047.11
Sale	7/15/2020	(1,000)	\$ 152.5813	\$ 152,581.25
Purchase	1/25/2021	1,800	\$ 166.4385	(\$ 299,589.29)
Purchase	2/25/2021	1,400	\$ 157.2345	(\$ 220,128.25)
Purchase	3/5/2021	300	\$ 148.8300	(\$ 44,649.00)
Purchase	3/9/2021	1,300	\$ 152.7448	(\$ 198,568.18)
Purchase	4/29/2021	2,000	\$ 174.0831	(\$ 348,166.11)
Purchase	8/13/2021	1,300	\$ 164.5183	(\$ 213,873.75)
Purchase	8/19/2021	1,300	\$ 161.3399	(\$ 209,741.88)
Purchase	9/7/2021	3,000	\$ 175.9870	(\$ 527,961.14)
Sale	10/11/2021	(2,200)	\$ 163.8692	\$ 360,512.24
Purchase	10/29/2021	1,100	\$ 165.5604	(\$ 182,116.42)
Purchase	11/18/2021	1,400	\$ 183.9995	(\$ 257,599.29)

Purchase	11/24/2021	1,000	\$ 179.0321	(\$ 179,032.10)
Purchase	12/1/2021	2,000	\$ 176.9030	(\$ 353,805.94)
Purchase	1/26/2022	1,400	\$ 143.0571	(\$ 200,280.00)
Purchase	1/27/2022	2,000	\$ 141.8130	(\$ 283,626.00)
Sale	2/3/2022	(5,880)	\$ 139.8196	\$ 822,138.98
Purchase	2/17/2022	2,600	\$ 157.8631	(\$ 410,444.00)
Purchase	2/24/2022	1,880	\$ 141.8967	(\$ 266,765.81)
<i>Purchase in Lookback Period</i>	<i>5/13/2022</i>	<i>5,000</i>	<i>\$ 111.4753</i>	<i>(\$ 557,376.38)</i>
Net Proceeds of Transactions				(\$ 3,346,348.79)
Value of 23,800 retained shares @ \$ 122.8643 per share				\$ 2,924,171.13
(Loss)/Gain for 222100-222101^b				(\$ 422,177.66)

222200-222201					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/6/2021	10,000	\$ 181.9859	(\$ 1,819,859.30)	
Purchase	8/26/2021	5,000	\$ 165.4774	(\$ 827,387.18)	
Purchase	1/26/2022	3,000	\$ 144.7845	(\$ 434,353.50)	
Net Proceeds of Transactions				(\$ 3,081,599.98)	
Value of 18,000 retained shares @ \$ 122.8643 per share				\$ 2,211,558.00	
(Loss)/Gain for 222200-222201^b				(\$ 870,041.98)	

22B200-22B201					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	1/20/2022	5,460	\$ 156.7660	(\$ 855,942.36)	
Purchase	1/25/2022	460	\$ 142.2425	(\$ 65,431.55)	
Purchase	2/1/2022	800	\$ 150.1500	(\$ 120,120.00)	
Purchase	2/15/2022	960	\$ 157.5460	(\$ 151,244.16)	
Purchase	2/22/2022	540	\$ 150.4785	(\$ 81,258.39)	
Purchase	3/1/2022	820	\$ 152.7325	(\$ 125,240.65)	
Purchase	3/8/2022	660	\$ 136.6835	(\$ 90,211.11)	
Purchase	3/15/2022	600	\$ 142.8500	(\$ 85,710.00)	
Purchase	4/5/2022	140	\$ 167.7415	(\$ 23,483.81)	
<i>Purchase in Lookback Period</i>	<i>4/12/2022</i>	<i>760</i>	<i>\$ 153.6925</i>	<i>(\$ 116,806.30)</i>	
<i>Purchase in Lookback Period</i>	<i>5/4/2022</i>	<i>2,720</i>	<i>\$ 122.9991</i>	<i>(\$ 334,557.52)</i>	

Purchase in Lookback Period	5/13/2022	1,880	\$ 110.2466	(\$ 207,263.56)
Sale of Shares Purchased in Lookback Period	5/20/2022	(1,000)	\$ 109.0107	\$ 109,010.72
Sale of Shares Purchased in Lookback Period	5/31/2022	(4,360)	\$ 116.1451	\$ 506,392.51
Sale of Class Shares in Lookback Period	5/31/2022	(10,440)	\$ 128.7416	\$ 1,344,062.08
(Loss)/Gain for 22B200-22B201^b				(\$ 254,579.95)

22B300-22B301					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	2/4/2022	2,760	\$ 155.1649	(\$ 428,255.15)	
Purchase	2/9/2022	640	\$ 162.0683	(\$ 103,723.68)	
Purchase	2/11/2022	3,200	\$ 157.2002	(\$ 503,040.53)	
Purchase	2/14/2022	500	\$ 154.6144	(\$ 77,307.18)	
Purchase	2/25/2022	200	\$ 150.3903	(\$ 30,078.06)	
Purchase	3/23/2022	560	\$ 165.3640	(\$ 92,603.86)	
Purchase	4/1/2022	360	\$ 164.1460	(\$ 59,092.56)	
<i>Sale of Class Shares in Lookback Period</i>	5/13/2022	(300)	\$ 136.2630	\$ 40,878.89	
<i>Sale of Class Shares in Lookback Period</i>	5/27/2022	(520)	\$ 128.9722	\$ 67,065.52	
<i>Purchase in Lookback Period</i>	6/3/2022	700	\$ 122.7795	(\$ 85,945.65)	
Net Proceeds of Transactions				(\$ 1,186,156.61)	
Value of 7,400 retained shares @ \$ 122.8643 per share				\$ 909,196.07	
(Loss)/Gain for 22B300-22B301^b				(\$ 276,960.54)	

242B00-242B01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	12/3/2019	6,400	\$ 88.0000	(\$ 563,200.00)	
Purchase	12/5/2019	400	\$ 87.2060	(\$ 34,882.40)	
Purchase	1/23/2020	600	\$ 94.2545	(\$ 56,552.70)	
Purchase	1/27/2020	39,600	\$ 91.4170	(\$ 3,620,113.20)	
Purchase	3/5/2020	2,600	\$ 96.2015	(\$ 250,123.90)	
Purchase	4/7/2020	4,200	\$ 100.5800	(\$ 422,436.00)	
Purchase	5/8/2020	800	\$ 118.9805	(\$ 95,184.40)	
Purchase	6/9/2020	4,000	\$ 126.4870	(\$ 505,948.00)	
Purchase	7/6/2020	3,600	\$ 152.8520	(\$ 550,267.20)	

Purchase	8/5/2020	1,800	\$ 160.2515	(\$ 288,452.70)
Purchase	9/3/2020	1,800	\$ 168.4000	(\$ 303,120.00)
Purchase	10/5/2020	2,600	\$ 159.9600	(\$ 415,896.00)
Purchase	11/5/2020	2,000	\$ 166.1000	(\$ 332,200.00)
Purchase	12/3/2020	4,400	\$ 159.3365	(\$ 701,080.60)
Purchase	1/6/2021	4,000	\$ 156.9190	(\$ 627,676.00)
Purchase	2/3/2021	1,400	\$ 165.6265	(\$ 231,877.10)
Purchase	3/3/2021	1,600	\$ 150.2500	(\$ 240,400.00)
Purchase	3/12/2021	1,400	\$ 154.4745	(\$ 216,264.30)
Purchase	4/8/2021	1,000	\$ 165.5450	(\$ 165,545.00)
Purchase	5/5/2021	2,600	\$ 163.5270	(\$ 425,170.20)
Purchase	6/7/2021	3,600	\$ 159.8340	(\$ 575,402.40)
Purchase	7/2/2021	12,000	\$ 175.5490	(\$ 2,106,588.00)
Purchase	8/4/2021	8,600	\$ 167.7360	(\$ 1,442,529.60)
Purchase	8/23/2021	4,000	\$ 163.2935	(\$ 653,174.00)
Purchase	9/3/2021	13,000	\$ 173.9025	(\$ 2,260,732.50)
Purchase	10/5/2021	9,200	\$ 161.0500	(\$ 1,481,660.00)
Purchase	11/3/2021	9,360	\$ 169.2000	(\$ 1,583,712.00)
Purchase	12/3/2021	11,200	\$ 169.4895	(\$ 1,898,282.40)
Sale	12/22/2021	(3,600)	\$ 171.0370	\$ 615,733.20
Purchase	1/5/2022	4,000	\$ 164.3570	(\$ 657,428.00)
Purchase	1/7/2022	4,840	\$ 162.5540	(\$ 786,761.36)
Purchase	2/3/2022	7,800	\$ 138.8455	(\$ 1,082,994.90)
Purchase	3/3/2022	10,600	\$ 147.8985	(\$ 1,567,724.10)
Purchase	4/5/2022	9,800	\$ 164.0550	(\$ 1,607,739.00)
<i>Purchase in Lookback Period</i>	5/4/2022	7,000	\$ 125.9285	(\$ 881,499.50)
<i>Purchase in Lookback Period</i>	6/3/2022	8,000	\$ 122.3500	(\$ 978,800.00)
<i>Purchase in Lookback Period</i>	6/14/2022	3,000	\$ 104.1600	(\$ 312,480.00)
Net Proceeds of Transactions				(\$ 27,135,384.76)
Value of 191,200 retained shares @ \$ 122.8643 per share				\$ 23,491,660.53
(Loss)/Gain for 242B00-242B01^b				(\$ 3,643,724.23)

242U00-242U01

Transaction Type	Date	Quantity	Amount
------------------	------	----------	--------

			Price ^a	
Purchase	5/4/2021	2,400	\$ 166.1195	(\$ 398,686.80)
Purchase	5/7/2021	640	\$ 165.2735	(\$ 105,775.03)
Purchase	5/12/2021	340	\$ 160.2837	(\$ 54,496.45)
Purchase	5/28/2021	260	\$ 161.9595	(\$ 42,109.47)
Purchase	6/7/2021	560	\$ 160.2255	(\$ 89,726.29)
Purchase	6/17/2021	620	\$ 171.6544	(\$ 106,425.70)
Purchase	7/6/2021	540	\$ 180.4986	(\$ 97,469.26)
Purchase	7/21/2021	900	\$ 178.8810	(\$ 160,992.86)
Purchase	8/16/2021	900	\$ 162.2988	(\$ 146,068.94)
Purchase	8/24/2021	620	\$ 165.2025	(\$ 102,425.55)
Purchase	10/20/2021	760	\$ 172.6075	(\$ 131,181.70)
Purchase	12/13/2021	400	\$ 171.8975	(\$ 68,759.00)
Purchase	1/6/2022	1,860	\$ 163.4510	(\$ 304,018.86)
Sale	1/25/2022	(700)	\$ 142.2425	\$ 99,569.75
Sale	2/3/2022	(3,000)	\$ 141.7375	\$ 425,212.50
Purchase	2/18/2022	520	\$ 154.2365	(\$ 80,203.00)
Purchase	3/9/2022	1,020	\$ 138.2661	(\$ 141,031.41)
<i>Sale of Class Shares in Lookback Period</i>	5/19/2022	(8,640)	\$ 132.8939	\$ 1,148,203.05
(Loss)/Gain for 242U00-242U01^b				(\$ 356,385.03)

266400-266401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	5/19/2021	2,000	\$ 160.8400	(\$ 321,680.06)
Net Proceeds of Transactions				(\$ 321,680.06)
Value of 2,000 retained shares @ \$ 122.8643 per share				\$ 245,728.67
(Loss)/Gain for 266400-266401^b				(\$ 75,951.39)

302900-302901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/1/2021	7,000	\$ 162.2085	(\$ 1,135,459.50)
Purchase	2/4/2021	5,000	\$ 166.4175	(\$ 832,087.50)
Purchase	2/9/2021	5,000	\$ 165.6245	(\$ 828,122.50)
Purchase	3/11/2021	1,800	\$ 155.2130	(\$ 279,383.40)

Sale	10/8/2021	(2,300)	\$ 165.9370	\$ 381,655.04
Sale	3/18/2022	(6,200)	\$ 157.0690	\$ 973,827.80
Net Proceeds of Transactions				(\$ 1,719,570.06)
Value of 10,300 retained shares @ \$ 122.8643 per share				\$ 1,265,502.63
(Loss)/Gain for 302900-302901^b				(\$ 454,067.42)

332000-332001				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		3,000		
Sale of Pre-Class Shares	3/21/2019	(400)	\$ 90.1852	\$ 36,074.06
Sale of Pre-Class Shares	6/18/2019	(500)	\$ 96.0107	\$ 48,005.33
Purchase	11/20/2019	600	\$ 87.7040	(\$ 52,622.40)
Purchase	1/16/2020	400	\$ 93.4231	(\$ 37,369.22)
Sale	2/13/2020	(360)	\$ 107.8015	\$ 38,808.54
Sale	6/2/2020	(480)	\$ 123.2675	\$ 59,168.40
Purchase	6/12/2020	320	\$ 131.0730	(\$ 41,943.36)
Purchase	6/17/2020	540	\$ 132.1639	(\$ 71,368.49)
Purchase	6/18/2020	300	\$ 132.5875	(\$ 39,776.25)
Purchase	6/24/2020	980	\$ 137.8700	(\$ 135,112.60)
Purchase	6/26/2020	500	\$ 138.7404	(\$ 69,370.18)
Purchase	7/15/2020	640	\$ 154.0000	(\$ 98,560.00)
Sale	10/14/2020	(900)	\$ 172.3500	\$ 155,115.00
Purchase	10/16/2020	780	\$ 168.5345	(\$ 131,456.91)
Purchase	10/23/2020	980	\$ 158.4401	(\$ 155,271.27)
Purchase	1/29/2021	740	\$ 161.5796	(\$ 119,568.88)
Purchase	3/2/2021	620	\$ 157.1735	(\$ 97,447.57)
Purchase	4/14/2021	1,400	\$ 168.9992	(\$ 236,598.91)
Purchase	4/16/2021	2,080	\$ 168.7094	(\$ 350,915.51)
Purchase	4/26/2021	960	\$ 167.5000	(\$ 160,800.00)
Purchase	5/10/2021	900	\$ 164.1160	(\$ 147,704.40)
Purchase	8/5/2021	1,200	\$ 167.8110	(\$ 201,373.20)
Purchase	8/19/2021	2,100	\$ 160.7298	(\$ 337,532.65)
Sale	10/20/2021	(1,700)	\$ 172.4398	\$ 293,147.62

Purchase	11/18/2021	1,700	\$ 178.6021	(\$ 303,623.52)
Sale	12/16/2021	(2,400)	\$ 173.2634	\$ 415,832.11
Purchase	12/21/2021	800	\$ 166.4133	(\$ 133,130.60)
Net Proceeds of Transactions				(\$ 1,959,474.25)
Value of 12,700 retained shares @ \$ 122.8643 per share				\$ 1,560,377.03
(Loss)/Gain for 332000-332001^b				(\$ 399,097.22)

332200-332201				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		4,500		
Sale of Pre-Class Shares	6/11/2019	(1,000)	\$ 94.2175	\$ 94,217.50
Purchase	11/21/2019	1,000	\$ 87.1245	(\$ 87,124.50)
Sale	6/2/2020	(800)	\$ 122.5140	\$ 98,011.20
Purchase	9/8/2020	900	\$ 161.2485	(\$ 145,123.65)
Purchase	12/4/2020	600	\$ 158.7042	(\$ 95,222.50)
Purchase	1/29/2021	1,100	\$ 161.5290	(\$ 177,681.94)
Purchase	2/19/2021	420	\$ 166.4115	(\$ 69,892.83)
Purchase	3/9/2021	620	\$ 150.8995	(\$ 93,557.69)
Purchase	4/15/2021	800	\$ 168.5705	(\$ 134,856.40)
Sale	7/7/2021	(600)	\$ 185.8340	\$ 111,500.40
Purchase	8/19/2021	1,060	\$ 160.7936	(\$ 170,441.17)
Purchase	8/24/2021	1,000	\$ 164.5394	(\$ 164,539.42)
Sale	10/20/2021	(1,400)	\$ 172.5420	\$ 241,558.80
Sale	12/16/2021	(1,900)	\$ 173.3150	\$ 329,298.50
Purchase	1/25/2022	600	\$ 142.1753	(\$ 85,305.18)
Net Proceeds of Transactions				(\$ 443,376.37)
Value of 3,400 retained shares @ \$ 122.8643 per share				\$ 417,738.73
(Loss)/Gain for 332200-332201^b				(\$ 25,637.64)

332700-332701				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/19/2020	2,200	\$ 95.2634	(\$ 209,579.45)
Purchase	3/27/2020	1,100	\$ 95.9448	(\$ 105,539.30)
Purchase	5/20/2020	2,100	\$ 123.8935	(\$ 260,176.35)

Purchase	8/4/2020	2,000	\$ 157.3999	(\$ 314,799.81)
Purchase	12/22/2020	3,000	\$ 160.0675	(\$ 480,202.50)
Purchase	2/26/2021	2,400	\$ 153.6282	(\$ 368,707.71)
Purchase	4/15/2021	3,200	\$ 168.5556	(\$ 539,377.80)
Purchase	7/8/2021	1,000	\$ 182.1831	(\$ 182,183.05)
Purchase	8/5/2021	1,200	\$ 167.8110	(\$ 201,373.20)
Purchase	8/19/2021	2,000	\$ 160.6493	(\$ 321,298.59)
Purchase	9/8/2021	4,800	\$ 176.3430	(\$ 846,446.59)
Sale	10/20/2021	(3,000)	\$ 172.2440	\$ 516,732.14
Purchase	12/21/2021	6,000	\$ 166.7632	(\$ 1,000,578.98)
Purchase	12/28/2021	1,000	\$ 170.1825	(\$ 170,182.50)
Purchase	3/14/2022	800	\$ 146.5149	(\$ 117,211.91)
<i>Purchase in Lookback Period</i>	5/10/2022	1,400	\$ 111.3119	(\$ 155,836.69)
Net Proceeds of Transactions				(\$ 4,600,925.60)
Value of 29,800 retained shares @ \$ 122.8643 per share				\$ 3,661,357.13
(Loss)/Gain for 332700-332701^b				(\$ 939,568.47)

375200-375203				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	7/26/2021	13,580	\$ 184.8978	(\$ 2,510,912.26)
Purchase	7/27/2021	23,720	\$ 181.3396	(\$ 4,301,374.72)
Purchase	7/28/2021	1,380	\$ 181.2765	(\$ 250,161.58)
Purchase	7/29/2021	2,480	\$ 174.1360	(\$ 431,857.35)
Purchase	7/29/2021	760	\$ 167.5000	(\$ 127,300.00)
Purchase	7/30/2021	1,520	\$ 166.8750	(\$ 253,650.00)
Purchase	8/3/2021	140	\$ 165.0000	(\$ 23,100.00)
Purchase	8/11/2021	580	\$ 165.0431	(\$ 95,724.97)
Purchase	8/12/2021	760	\$ 163.7377	(\$ 124,440.68)
Purchase	8/16/2021	1,520	\$ 161.8487	(\$ 246,009.99)
Purchase	8/19/2021	740	\$ 159.9976	(\$ 118,398.19)
Purchase	9/1/2021	2,420	\$ 175.8685	(\$ 425,601.88)
Purchase	9/3/2021	860	\$ 172.4856	(\$ 148,337.58)
Purchase	9/9/2021	1,640	\$ 176.3519	(\$ 289,217.08)

Purchase	9/9/2021	1,520	\$ 176.3519	(\$ 268,054.85)
Purchase	10/19/2021	80	\$ 172.4595	(\$ 13,796.76)
Purchase	10/29/2021	2,060	\$ 164.7039	(\$ 339,289.94)
Purchase	12/13/2021	1,340	\$ 169.8437	(\$ 227,590.52)
Purchase	12/15/2021	1,020	\$ 166.8705	(\$ 170,207.90)
Purchase	12/16/2021	320	\$ 169.6116	(\$ 54,275.72)
Purchase	1/10/2022	2,640	\$ 157.5044	(\$ 415,811.62)
Purchase	1/21/2022	1,500	\$ 149.7456	(\$ 224,618.36)
Purchase	3/8/2022	600	\$ 134.9219	(\$ 80,953.14)
<i>Purchase in Lookback Period</i>	4/29/2022	4,340	\$ 127.2505	(\$ 552,267.06)
<i>Purchase in Lookback Period</i>	5/2/2022	1,380	\$ 119.9974	(\$ 165,596.42)
<i>Purchase in Lookback Period</i>	5/5/2022	1,340	\$ 115.3995	(\$ 154,635.28)
<i>Purchase in Lookback Period</i>	5/6/2022	1,340	\$ 114.5023	(\$ 153,433.06)
<i>Purchase in Lookback Period</i>	5/9/2022	1,300	\$ 109.9799	(\$ 142,973.93)
<i>Purchase in Lookback Period</i>	5/11/2022	1,660	\$ 105.2584	(\$ 174,728.93)
Net Proceeds of Transactions				(\$ 11,140,685.09)
Value of 63,180 retained shares @ \$ 122.8643 per share				\$ 7,762,568.58
(Loss)/Gain for 375200-375203^b				(\$ 3,378,116.51)

379400-379404				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/29/2021	92,080	\$ 152.7085	(\$ 14,061,398.68)
Purchase	4/21/2021	780	\$ 165.8000	(\$ 129,324.00)
Purchase	6/8/2021	5,300	\$ 161.1212	(\$ 853,942.17)
Purchase	2/1/2022	6,320	\$ 150.1500	(\$ 948,948.00)
Sale	3/21/2022	(7,360)	\$ 160.0225	\$ 1,177,765.45
<i>Purchase in Lookback Period</i>	4/27/2022	4,560	\$ 140.1915	(\$ 639,273.24)
Net Proceeds of Transactions				(\$ 14,815,847.40)
Value of 97,120 retained shares @ \$ 122.8643 per share				\$ 11,932,584.05
(Loss)/Gain for 379400-379404^b				(\$ 2,883,263.35)

431000-431001				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	1/5/2021	1,600	\$ 159.6875	(\$ 255,500.00)

Purchase	2/19/2021	800	\$ 165.8828	(\$ 132,706.20)
Purchase	7/22/2021	600	\$ 179.3210	(\$ 107,592.60)
Purchase	1/4/2022	400	\$ 166.8388	(\$ 66,735.52)
Net Proceeds of Transactions				(\$ 562,534.32)
Value of 3,400 retained shares @ \$ 122.8643 per share				\$ 417,738.73
(Loss)/Gain for 431000-431001^b				(\$ 144,795.59)

431A00-431A01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	2/1/2021	600	\$ 165.4864	(\$ 99,291.82)	
Purchase	2/19/2021	400	\$ 166.4115	(\$ 66,564.60)	
Purchase	3/3/2021	1,000	\$ 152.0111	(\$ 152,011.10)	
Purchase	4/23/2021	2,200	\$ 165.8524	(\$ 364,875.20)	
Purchase	6/11/2021	1,800	\$ 167.2735	(\$ 301,092.30)	
Purchase	8/12/2021	2,000	\$ 165.2300	(\$ 330,460.00)	
<i>Sale of Class Shares in Lookback Period</i>	5/2/2022	<i>(8,000)</i>	<i>\$ 147.4850</i>	<i>\$ 1,179,880.00</i>	
(Loss)/Gain for 431A00-431A01^b					(\$ 134,415.02)

431D00-431D01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/24/2020	600	\$ 155.3406	(\$ 93,204.36)	
Purchase	12/2/2020	400	\$ 161.0165	(\$ 64,406.60)	
Purchase	1/12/2022	200	\$ 166.1235	(\$ 33,224.70)	
Net Proceeds of Transactions					(\$ 190,835.66)
Value of 1,200 retained shares @ \$ 122.8643 per share					\$ 147,437.20
(Loss)/Gain for 431D00-431D01^b					(\$ 43,398.46)

431J00-431J01					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	7/23/2021	600	\$ 182.3798	(\$ 109,427.88)	
<i>Sale of Class Shares in Lookback Period</i>	5/2/2022	<i>(600)</i>	<i>\$ 147.4850</i>	<i>\$ 88,491.00</i>	
(Loss)/Gain for 431J00-431J01^b					(\$ 20,936.88)

Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	6/28/2021	400	\$ 171.5290	(\$ 68,611.59)
<i>Sale of Class Shares in Lookback Period</i>	5/3/2022	(400)	\$ 146.2621	\$ 58,504.84
(Loss)/Gain for 432C00-432C01^b				(\$ 10,106.75)

432L00-432L01				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	7/23/2021	940	\$ 182.0000	(\$ 171,080.00)
Purchase	8/5/2021	100	\$ 167.8110	(\$ 16,781.10)
Purchase	8/20/2021	220	\$ 159.9555	(\$ 35,190.21)
Purchase	9/14/2021	140	\$ 173.2610	(\$ 24,256.54)
Purchase	10/4/2021	200	\$ 160.0000	(\$ 32,000.00)
Purchase	10/22/2021	160	\$ 170.9900	(\$ 27,358.40)
Purchase	12/22/2021	320	\$ 169.1500	(\$ 54,128.00)
Purchase	12/29/2021	280	\$ 170.8400	(\$ 47,835.20)
Sale	1/19/2022	(320)	\$ 158.7425	\$ 50,797.60
Sale	2/9/2022	(1,000)	\$ 161.9700	\$ 161,970.00
<i>Purchase in Lookback Period</i>	4/7/2022	200	\$ 157.8760	(\$ 31,575.20)
<i>Purchase in Lookback Period</i>	6/15/2022	300	\$ 103.8600	(\$ 31,158.00)
Net Proceeds of Transactions				(\$ 195,861.85)
Value of 1,040 retained shares @ \$ 122.8643 per share				\$ 127,778.91
(Loss)/Gain for 432L00-432L01^b				(\$ 68,082.94)

432P00-432P01				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	8/11/2021	400	\$ 166.5375	(\$ 66,615.00)
Purchase	9/3/2021	80	\$ 172.6970	(\$ 13,815.76)
Purchase	11/8/2021	140	\$ 176.1620	(\$ 24,662.68)
Purchase	1/19/2022	140	\$ 158.7425	(\$ 22,223.95)
Purchase	1/21/2022	520	\$ 148.7500	(\$ 77,350.00)
Purchase	2/3/2022	180	\$ 141.7375	(\$ 25,512.75)
Purchase	2/24/2022	160	\$ 139.6795	(\$ 22,348.72)
<i>Purchase in Lookback Period</i>	5/9/2022	800	\$ 110.2500	<i>(\$ 88,200.00)</i>

Purchase in Lookback Period	5/25/2022	300	\$ 103,8120	(\$ 31,143.60)
Net Proceeds of Transactions				(\$ 252,528.86)
Value of 1,620 retained shares @ \$ 122.8643 per share				\$ 199,040.22
(Loss)/Gain for 432P00-432P01 ^b				(\$ 53,488.64)

433800-433801				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		700		
Purchase	6/7/2021	500	\$ 159.8340	(\$ 79,917.00)
Net Proceeds of Transactions				(\$ 79,917.00)
Value of 500 retained shares @ \$ 122.8643 per share				\$ 61,432.17
(Loss)/Gain for 433800-433801 ^b				(\$ 18,484.83)

437200-437201				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	5/3/2019	800	\$ 97.9925	(\$ 78,394.00)
Purchase	5/23/2019	200	\$ 91.8295	(\$ 18,365.90)
Purchase	7/23/2019	160	\$ 99.2190	(\$ 15,875.04)
Purchase	12/23/2019	440	\$ 89.4050	(\$ 39,338.20)
Purchase	3/5/2020	240	\$ 97.3550	(\$ 23,365.20)
Purchase	6/10/2020	520	\$ 133.1715	(\$ 69,249.18)
Purchase	9/16/2020	360	\$ 157.1220	(\$ 56,563.91)
Purchase	11/9/2020	280	\$ 161.4435	(\$ 45,204.18)
Purchase	11/9/2020	280	\$ 162.8895	(\$ 45,609.06)
Sale	11/10/2020	(280)	\$ 153.4600	\$ 42,968.80
Purchase	11/19/2020	340	\$ 155.4203	(\$ 52,842.89)
Purchase	11/30/2020	360	\$ 157.5797	(\$ 56,728.70)
Purchase	4/29/2021	640	\$ 175.3400	(\$ 112,217.60)
Purchase	11/17/2021	320	\$ 178.1171	(\$ 56,997.46)
Net Proceeds of Transactions				(\$ 627,782.51)
Value of 4,660 retained shares @ \$ 122.8643 per share				\$ 572,547.79
(Loss)/Gain for 437200-437201 ^b				(\$ 55,234.72)

437400-437401
Page 51

Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/16/2020	13,000	\$ 85.1525	(\$ 1,106,982.50)
Purchase	3/26/2020	10,000	\$ 95.0105	(\$ 950,105.00)
Sale	8/4/2020	(1,000)	\$ 155.5409	\$ 155,540.90
Purchase	2/9/2021	12,000	\$ 165.7841	(\$ 1,989,409.00)
Purchase	2/10/2021	12,000	\$ 163.3750	(\$ 1,960,499.41)
Purchase	2/23/2021	2,360	\$ 156.2287	(\$ 368,699.69)
Purchase	3/4/2021	12,400	\$ 150.7000	(\$ 1,868,680.00)
Purchase	3/8/2021	14,700	\$ 150.7191	(\$ 2,215,570.50)
Purchase	4/6/2021	3,520	\$ 161.9630	(\$ 570,109.76)
Purchase	6/8/2021	10,060	\$ 161.1305	(\$ 1,620,972.83)
Sale	6/18/2021	(5,000)	\$ 173.9995	\$ 869,997.50
Sale	6/21/2021	(2,600)	\$ 173.8210	\$ 451,934.60
Sale	6/23/2021	(2,040)	\$ 175.2500	\$ 357,510.00
Sale	7/7/2021	(2,000)	\$ 186.2758	\$ 372,551.50
Sale	7/12/2021	(1,920)	\$ 187.2120	\$ 359,447.04
Sale	7/13/2021	(1,280)	\$ 187.8582	\$ 240,458.46
Purchase	8/2/2021	11,160	\$ 166.5320	(\$ 1,858,497.54)
Purchase	8/20/2021	2,200	\$ 160.1290	(\$ 352,283.80)
Sale	8/31/2021	(2,920)	\$ 171.2400	\$ 500,020.80
Sale	8/31/2021	(1,040)	\$ 171.5817	\$ 178,444.92
Sale	9/2/2021	(1,360)	\$ 174.7380	\$ 237,643.68
Sale	9/9/2021	(2,000)	\$ 176.2750	\$ 352,550.00
Purchase	10/11/2021	2,000	\$ 163.7500	(\$ 327,500.00)
Sale	11/8/2021	(2,400)	\$ 175.9353	\$ 422,244.64
Sale	11/19/2021	(3,000)	\$ 186.8081	\$ 560,424.30
Purchase	12/6/2021	13,020	\$ 170.5809	(\$ 2,220,963.32)
Purchase	12/6/2021	3,600	\$ 170.5809	(\$ 614,091.24)
Purchase	12/27/2021	2,320	\$ 170.6843	(\$ 395,987.48)
Purchase	12/28/2021	2,460	\$ 170.2770	(\$ 418,881.42)
Purchase	12/30/2021	2,400	\$ 169.6475	(\$ 407,154.00)
Purchase	1/10/2022	2,800	\$ 157.4911	(\$ 440,975.05)
Purchase	1/11/2022	2,600	\$ 162.7100	(\$ 423,046.00)

Purchase	1/14/2022	2,200	\$ 160.1500	(\$ 352,330.00)
Purchase	1/18/2022	2,580	\$ 158.7977	(\$ 409,698.14)
Purchase	1/19/2022	2,000	\$ 158.4394	(\$ 316,878.76)
Purchase	1/21/2022	2,660	\$ 145.2619	(\$ 386,396.66)
Purchase	1/21/2022	2,600	\$ 146.9147	(\$ 381,978.30)
Purchase	1/24/2022	6,400	\$ 139.0000	(\$ 889,600.00)
Purchase	1/25/2022	3,000	\$ 139.9201	(\$ 419,760.36)
Sale	2/1/2022	(2,500)	\$ 149.1670	\$ 372,917.50
Sale	2/4/2022	(12,000)	\$ 155.6065	\$ 1,867,278.00
Sale	2/4/2022	(2,000)	\$ 153.9770	\$ 307,954.06
Sale	2/10/2022	(3,000)	\$ 158.3500	\$ 475,050.00
Purchase	3/4/2022	3,000	\$ 144.5735	(\$ 433,720.50)
Purchase	3/7/2022	2,000	\$ 140.4403	(\$ 280,880.50)
Purchase	3/8/2022	2,400	\$ 135.0000	(\$ 324,000.00)
Sale	3/10/2022	(2,600)	\$ 145.6850	\$ 378,781.00
Sale	3/10/2022	(2,500)	\$ 146.9229	\$ 367,307.19
Sale	3/21/2022	(3,000)	\$ 160.9500	\$ 482,850.00
Sale	3/28/2022	(2,500)	\$ 167.0368	\$ 417,592.11
Sale	3/29/2022	(2,600)	\$ 170.3840	\$ 442,998.40
Sale	4/5/2022	(4,500)	\$ 167.7415	\$ 754,836.75
<i>Purchase in Lookback Period</i>	4/25/2022	3,500	\$ 143.4393	(\$ 502,037.50)
<i>Purchase in Lookback Period</i>	4/28/2022	3,000	\$ 141.9410	(\$ 425,823.00)
<i>Purchase in Lookback Period</i>	4/29/2022	2,600	\$ 127.2234	(\$ 330,780.96)
<i>Purchase in Lookback Period</i>	4/29/2022	1,600	\$ 126.7971	(\$ 202,875.30)
<i>Purchase in Lookback Period</i>	5/2/2022	4,400	\$ 122.4010	(\$ 538,564.40)
<i>Purchase in Lookback Period</i>	5/2/2022	3,000	\$ 122.4010	(\$ 367,203.00)
<i>Purchase in Lookback Period</i>	5/5/2022	2,960	\$ 123.0000	(\$ 364,080.00)
<i>Purchase in Lookback Period</i>	5/6/2022	3,100	\$ 115.0000	(\$ 356,500.00)
<i>Sale of Shares Purchased in Lookback Period</i>	5/23/2022	(24,160)	\$ 107.7040	\$ 2,602,128.64
<i>Sale of Class Shares in Lookback Period</i>	5/23/2022	(7,840)	\$ 131.3594	\$ 1,029,857.65
<i>Sale of Class Shares in Lookback Period</i>	6/1/2022	(3,800)	\$ 128.5605	\$ 488,529.95
<i>Sale of Class Shares in Lookback Period</i>	6/9/2022	(9,000)	\$ 127.7076	\$ 1,149,368.00
Net Proceeds of Transactions				(\$ 10,711,562.81)

Value of 77,040 retained shares @ \$ 122.8643 per share	\$ 9,465,468.24
(Loss)/Gain for 437400-437401 ^b	(\$ 1,246,094.57)

437900-437901					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/3/2020	5,200	\$ 150.7355	(\$ 783,824.60)	
Purchase	11/9/2020	800	\$ 162.0987	(\$ 129,678.92)	
Sale	3/5/2021	(1,200)	\$ 148.4524	\$ 178,142.82	
Purchase	4/28/2021	5,200	\$ 173.0003	(\$ 899,601.38)	
Sale	5/3/2021	(5,200)	\$ 172.3560	\$ 896,251.36	
Purchase	7/29/2021	3,200	\$ 181.6630	(\$ 581,321.60)	
Sale	8/18/2021	(2,000)	\$ 161.1945	\$ 322,389.00	
Sale	8/23/2021	(6,000)	\$ 162.3360	\$ 974,016.00	
Purchase	10/29/2021	4,000	\$ 166.2339	(\$ 664,935.56)	
Purchase	2/2/2022	4,000	\$ 152.4215	(\$ 609,686.03)	
Sale	2/4/2022	(2,000)	\$ 150.9025	\$ 301,805.00	
Sale	3/8/2022	(2,000)	\$ 137.7027	\$ 275,405.45	
<i>Sale of Class Shares in Lookback Period</i>	<i>5/6/2022</i>	<i>(4,000)</i>	<i>\$ 142.5495</i>	<i>\$ 570,198.18</i>	
(Loss)/Gain for 437900-437901 ^b					(\$ 150,840.28)

439000-439001					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	1/4/2021	1,220	\$ 163.5000	(\$ 199,470.00)	
Purchase	10/20/2021	200	\$ 172.6075	(\$ 34,521.50)	
Sale	1/3/2022	(300)	\$ 167.6385	\$ 50,291.55	
Sale	1/25/2022	(100)	\$ 142.2425	\$ 14,224.25	
Purchase	2/4/2022	80	\$ 155.6065	(\$ 12,448.52)	
Net Proceeds of Transactions					(\$ 181,924.22)
Value of 1,100 retained shares @ \$ 122.8643 per share					\$ 135,150.77
(Loss)/Gain for 439000-439001 ^b					(\$ 46,773.45)

439600-439601					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	11/10/2020	300	\$ 154.7510	(\$ 46,425.30)	

Purchase	5/26/2021	300	\$ 163.4920	(\$ 49,047.60)
Net Proceeds of Transactions				(\$ 95,472.90)
Value of 600 retained shares @ \$ 122.8643 per share				\$ 73,718.60
(Loss)/Gain for 439600-439601^b				(\$ 21,754.30)

439900-439901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/16/2021	800	\$ 155.9756	(\$ 124,780.50)
Purchase	8/6/2021	1,200	\$ 167.4383	(\$ 200,925.90)
Net Proceeds of Transactions				(\$ 325,706.40)
Value of 2,000 retained shares @ \$ 122.8643 per share				\$ 245,728.67
(Loss)/Gain for 439900-439901^b				(\$ 79,977.73)

443800-443801				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	1/19/2021	740	\$ 155.8715	(\$ 115,344.91)
Purchase	1/20/2021	540	\$ 160.7914	(\$ 86,827.36)
Purchase	1/26/2021	400	\$ 165.6463	(\$ 66,258.51)
Sale	9/27/2021	(120)	\$ 167.5635	\$ 20,107.62
Sale	12/8/2021	(220)	\$ 175.1850	\$ 38,540.70
Net Proceeds of Transactions				(\$ 209,782.45)
Value of 1,340 retained shares @ \$ 122.8643 per share				\$ 164,638.21
(Loss)/Gain for 443800-443801^b				(\$ 45,144.24)

451900-451901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	9/3/2019	9,800	\$ 89.6141	(\$ 878,217.89)
Purchase	10/23/2019	1,200	\$ 87.6928	(\$ 105,231.36)
Purchase	11/27/2019	1,000	\$ 90.2375	(\$ 90,237.50)
Purchase	3/17/2020	3,000	\$ 85.8997	(\$ 257,699.24)
Purchase	4/2/2020	3,000	\$ 95.7308	(\$ 287,192.50)
Purchase	4/8/2020	22,000	\$ 100.6519	(\$ 2,214,341.00)
Purchase	4/17/2020	30,000	\$ 118.8620	(\$ 3,565,860.96)
Purchase	4/21/2020	10,000	\$ 114.8588	(\$ 1,148,588.00)

Purchase	5/6/2020	60,000	\$ 117,6164	(\$ 7,056,983.70)
Purchase	5/11/2020	30,000	\$ 120,0262	(\$ 3,600,785.70)
Purchase	6/9/2020	10,000	\$ 127,2345	(\$ 1,272,345.25)
Purchase	8/11/2020	6,000	\$ 155,5930	(\$ 933,557.94)
Purchase	9/9/2020	14,000	\$ 160,6774	(\$ 2,249,484.23)
Purchase	9/17/2020	10,000	\$ 150,0410	(\$ 1,500,410.00)
Purchase	11/6/2020	20,000	\$ 162,5141	(\$ 3,250,282.50)
Purchase	12/3/2020	20,000	\$ 160,7036	(\$ 3,214,071.10)
Purchase	12/21/2020	4,000	\$ 161,0117	(\$ 644,046.90)
Purchase	1/14/2021	4,000	\$ 157,7018	(\$ 630,807.22)
Sale	8/10/2021	(8,000)	\$ 167,6891	\$ 1,341,512.64
Sale	10/11/2021	(14,000)	\$ 164,2574	\$ 2,299,603.67
Purchase	1/5/2022	8,000	\$ 166,1314	(\$ 1,329,050.84)
Purchase	1/10/2022	6,000	\$ 157,9114	(\$ 947,468.34)
Purchase	2/8/2022	20,000	\$ 156,4833	(\$ 3,129,665.80)
Purchase	3/11/2022	22,000	\$ 146,3519	(\$ 3,219,741.36)
Purchase	3/16/2022	40,000	\$ 148,7636	(\$ 5,950,542.60)
Purchase	3/18/2022	20,000	\$ 160,8231	(\$ 3,216,461.60)
<i>Purchase in Lookback Period</i>	5/11/2022	92,000	\$ 108,9369	(\$ 10,022,198.94)
<i>Purchase in Lookback Period</i>	5/20/2022	36,000	\$ 109,3907	(\$ 3,938,064.48)
<i>Purchase in Lookback Period</i>	6/14/2022	30,000	\$ 102,8818	(\$ 3,086,454.00)
Net Proceeds of Transactions				(\$ 47,051,957.22)
Value of 352,000 retained shares @ \$ 122.8643 per share				\$ 43,248,245.33
(Loss)/Gain for 451900-451901^b				(\$ 3,803,711.88)

572Q00-572Q01				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	9/13/2021	44,600	\$ 172,8585	(\$ 7,709,489.10)
Purchase	9/16/2021	140	\$ 174,4120	(\$ 24,417.68)
Purchase	9/20/2021	580	\$ 167,7865	(\$ 97,316.17)
Sale	9/22/2021	(940)	\$ 169,0025	\$ 158,862.35
Purchase	9/24/2021	40,040	\$ 171,2760	(\$ 6,857,891.04)
Purchase	9/27/2021	600	\$ 170,2900	(\$ 102,174.00)

Purchase	10/5/2021	500	\$ 161.0500	(\$ 80,525.00)
Purchase	10/8/2021	1,060	\$ 164.4310	(\$ 174,296.86)
Purchase	10/14/2021	360	\$ 164.9930	(\$ 59,397.48)
Purchase	10/18/2021	640	\$ 172.3370	(\$ 110,295.68)
Purchase	10/22/2021	720	\$ 166.7775	(\$ 120,079.80)
Purchase	10/29/2021	260	\$ 168.6215	(\$ 43,841.59)
Purchase	11/5/2021	640	\$ 175.9495	(\$ 112,607.68)
Purchase	11/10/2021	20	\$ 174.1025	(\$ 3,482.05)
Purchase	11/19/2021	1,000	\$ 183.8285	(\$ 183,828.50)
Sale	12/8/2021	(60)	\$ 176.1580	\$ 10,569.48
Sale	12/9/2021	(2,060)	\$ 174.1710	\$ 358,792.26
Sale	12/13/2021	(1,860)	\$ 169.5675	\$ 315,395.55
Purchase	12/16/2021	1,420	\$ 168.8710	(\$ 239,796.82)
Purchase	12/23/2021	1,140	\$ 171.0685	(\$ 195,018.09)
Purchase	1/10/2022	980	\$ 161.4860	(\$ 158,256.28)
Sale	1/12/2022	(20)	\$ 165.2070	\$ 3,304.14
Purchase	1/28/2022	1,420	\$ 143.9780	(\$ 204,448.76)
Purchase	2/9/2022	1,000	\$ 161.1895	(\$ 161,189.50)
Purchase	3/4/2022	820	\$ 145.6410	(\$ 119,425.62)
Sale	3/9/2022	(320)	\$ 139.2790	\$ 44,569.28
Sale	3/11/2022	(220)	\$ 145.5245	\$ 32,015.39
Purchase	3/14/2022	880	\$ 141.8530	(\$ 124,830.64)
Purchase	3/25/2022	1,040	\$ 164.7735	(\$ 171,364.44)
Purchase	4/4/2022	1,220	\$ 168.3465	(\$ 205,382.73)
<i>Purchase in Lookback Period</i>	4/8/2022	2,440	\$ 154.4605	(\$ 376,883.62)
<i>Purchase in Lookback Period</i>	4/13/2022	40	\$ 155.5410	(\$ 6,221.64)
<i>Purchase in Lookback Period</i>	4/21/2022	1,120	\$ 148.2960	(\$ 166,091.52)
<i>Purchase in Lookback Period</i>	5/11/2022	2,520	\$ 105.3720	(\$ 265,537.44)
<i>Purchase in Lookback Period</i>	5/31/2022	1,200	\$ 120.2095	(\$ 144,251.40)
<i>Sale of Shares Purchased in Lookback Period</i>	6/2/2022	(600)	\$ 122.2020	\$ 73,321.20
<i>Purchase in Lookback Period</i>	6/8/2022	2,740	\$ 121.1800	(\$ 332,033.20)
<i>Sale of Shares Purchased in Lookback Period</i>	6/9/2022	(360)	\$ 116.1500	\$ 41,814.00
Net Proceeds of Transactions				(\$ 16,335,847.06)

Value of 95,600 retained shares @ \$ 122.8643 per share	\$ 11,745,830.27
(Loss)/Gain for 572Q00-572Q01 ^b	(\$ 4,590,016.79)

574900-574901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	11/16/2021	2,000	\$ 177.1408	(\$ 354,281.50)
Sale	12/29/2021	(400)	\$ 169.4335	\$ 67,773.39
Net Proceeds of Transactions				(\$ 286,508.11)
Value of 1,600 retained shares @ \$ 122.8643 per share				\$ 196,582.93
(Loss)/Gain for 574900-574901 ^b				(\$ 89,925.18)

576700-576701				
Transaction Type	Date	Quantity	Price ^a	Amount
Pre-Class Shares		30,700		
Purchase	3/26/2019	3,400	\$ 89.6500	(\$ 304,810.00)
Purchase	4/9/2019	2,400	\$ 91.7920	(\$ 220,300.80)
Purchase	5/10/2019	3,000	\$ 94.4990	(\$ 283,497.00)
Purchase	6/5/2019	5,200	\$ 86.9250	(\$ 452,010.00)
Purchase	7/17/2019	2,400	\$ 99.6015	(\$ 239,043.60)
Purchase	8/5/2019	10,400	\$ 88.2565	(\$ 917,867.60)
Purchase	8/12/2019	2,600	\$ 89.2460	(\$ 232,039.60)
Purchase	9/3/2019	5,600	\$ 88.5510	(\$ 495,885.60)
Purchase	10/4/2019	4,000	\$ 86.9825	(\$ 347,930.00)
Purchase	10/18/2019	5,200	\$ 87.8755	(\$ 456,952.60)
Purchase	1/7/2020	3,200	\$ 95.2250	(\$ 304,720.00)
Purchase	2/18/2020	1,000	\$ 107.7835	(\$ 107,783.50)
Purchase	3/2/2020	5,200	\$ 97.6975	(\$ 508,027.00)
Purchase	3/10/2020	5,000	\$ 94.5910	(\$ 472,955.00)
Purchase	3/19/2020	2,000	\$ 94.0465	(\$ 188,093.00)
Purchase	3/24/2020	7,200	\$ 97.0050	(\$ 698,436.00)
Purchase	4/2/2020	1,200	\$ 95.9415	(\$ 115,129.80)
Purchase	4/8/2020	2,400	\$ 102.1500	(\$ 245,160.00)
Purchase	4/21/2020	1,800	\$ 116.4060	(\$ 209,530.80)
Purchase	5/4/2020	2,600	\$ 115.7995	(\$ 301,078.70)

Purchase	6/12/2020	4,180	\$ 127.2510	(\$ 531,909.18)
Purchase	8/10/2020	400	\$ 157.4080	(\$ 62,963.20)
Purchase	8/17/2020	4,000	\$ 159.1205	(\$ 636,482.00)
Purchase	8/28/2020	4,000	\$ 170.0900	(\$ 680,360.00)
Purchase	12/2/2020	2,000	\$ 160.1765	(\$ 320,353.00)
Purchase	1/7/2021	2,400	\$ 158.1080	(\$ 379,459.20)
Purchase	1/27/2021	5,400	\$ 161.6290	(\$ 872,796.60)
Purchase	2/19/2021	10,800	\$ 162.4950	(\$ 1,754,946.00)
Purchase	3/10/2021	5,000	\$ 152.8820	(\$ 764,410.00)
Purchase	3/26/2021	5,000	\$ 152.6015	(\$ 763,007.50)
Purchase	4/26/2021	8,800	\$ 170.4500	(\$ 1,499,960.00)
Purchase	5/21/2021	9,000	\$ 162.5000	(\$ 1,462,500.00)
Purchase	6/22/2021	8,800	\$ 175.2720	(\$ 1,542,393.60)
Purchase	7/13/2021	14,200	\$ 183.8680	(\$ 2,610,925.60)
Purchase	8/23/2021	27,520	\$ 163.2935	(\$ 4,493,837.12)
Purchase	9/24/2021	14,440	\$ 171.2760	(\$ 2,473,225.44)
Purchase	10/22/2021	14,000	\$ 166.7775	(\$ 2,334,885.00)
Purchase	11/24/2021	18,400	\$ 179.0205	(\$ 3,293,977.20)
Purchase	12/15/2021	3,800	\$ 173.3150	(\$ 658,597.00)
Purchase	1/21/2022	7,000	\$ 142.6430	(\$ 998,501.00)
Purchase	2/22/2022	6,360	\$ 150.1975	(\$ 955,256.10)
Purchase	3/10/2022	6,600	\$ 146.8175	(\$ 968,995.50)
<i>Purchase in Lookback Period</i>	4/6/2022	8,000	\$ 158.7560	(\$ 1,270,048.00)
Net Proceeds of Transactions				(\$ 37,160,990.84)
Value of 257,900 retained shares @ \$ 122.8643 per share				\$ 31,686,711.57
(Loss)/Gain for 576700-576701^b				(\$ 5,474,279.27)

579000-579002				
	Transaction Type	Date	Quantity	Price ^a
Purchase		7/22/2021	3,200	\$ 180.6885
Purchase		3/14/2022	3,000	\$ 145.8952
Net Proceeds of Transactions				(\$ 1,015,888.75)
Value of 6,200 retained shares @ \$ 122.8643 per share				\$ 761,758.87

(**Loss**)/Gain for 579000-579002^b

(\$ 254,129.88)

Grand Total for 45 Funds

(**Loss**)/Gain^b

(\$ 60,199,163.19)

^a Any shares sold within 90 days after the end of the class period have been valued at the higher price between the actual sale price and the average closing price from the end of the class period to the date of the sale.

^b Losses calculated on a last-in first-out (LIFO) basis.

Amazon Inc. (AMZN)
Universal-Investment-Luxembourg S.A.

Class Period: 2/1/2019 - 4/5/2022

Hold Price: \$ 122.8643

707200-707203					
Transaction Type	Date	Quantity	Price ^a	Amount	
Purchase	10/1/2020	600	\$ 160.4200	(\$ 96,252.00)	
Purchase	10/6/2020	800	\$ 158.2961	(\$ 126,636.89)	
Purchase	10/28/2020	400	\$ 160.1919	(\$ 64,076.74)	
Purchase	5/4/2021	600	\$ 167.5000	(\$ 100,500.00)	
Sale	10/25/2021	(800)	\$ 166.8325	\$ 133,465.96	
<i>Purchase in Lookback Period</i>	5/23/2022	300	\$ 108.4610	(\$ 32,538.30)	
Net Proceeds of Transactions					(\$ 253,999.67)
Value of 1,600 retained shares @ \$ 122.8643 per share					\$ 196,582.93
(Loss)/Gain for 707200-707203^b					(\$ 57,416.73)

711000-711001					
Transaction Type	Date	Quantity	Price ^a	Amount	
Pre-Class Shares		4,680			
Purchase	7/16/2019	780	\$ 101.0222	(\$ 78,797.34)	
Purchase	10/24/2019	540	\$ 88.8915	(\$ 48,001.41)	
Purchase	1/17/2020	1,780	\$ 93.5060	(\$ 166,440.68)	
Sale	2/20/2020	(1,300)	\$ 108.3110	\$ 140,804.30	
Purchase	3/17/2020	1,220	\$ 88.7918	(\$ 108,325.94)	
Purchase	3/19/2020	4,000	\$ 92.5995	(\$ 370,398.00)	
Sale	4/8/2020	(960)	\$ 100.6715	\$ 96,644.64	
Sale	4/17/2020	(1,940)	\$ 117.7350	\$ 228,405.90	
Sale	4/21/2020	(900)	\$ 119.3250	\$ 107,392.50	
Sale	5/20/2020	(1,220)	\$ 124.2558	\$ 151,592.02	
Sale	6/3/2020	(2,000)	\$ 123.5107	\$ 247,021.43	
Sale of Pre-Class Shares	6/3/2020	(340)	\$ 123.5107	\$ 41,993.64	
Purchase	7/28/2020	1,200	\$ 152.8850	(\$ 183,462.00)	
Purchase	8/12/2020	960	\$ 156.9441	(\$ 150,666.30)	
Purchase	9/1/2020	580	\$ 174.6180	(\$ 101,278.44)	

Purchase	9/29/2020	1,000	\$ 158.7995	(\$ 158,799.50)
Purchase	10/27/2020	800	\$ 161.8715	(\$ 129,497.20)
Purchase	10/29/2020	800	\$ 159.8490	(\$ 127,879.20)
Purchase	10/30/2020	700	\$ 154.5848	(\$ 108,209.37)
Purchase	11/19/2020	500	\$ 155.5315	(\$ 77,765.75)
Purchase	12/21/2020	1,000	\$ 160.3090	(\$ 160,309.00)
Purchase	1/14/2021	1,320	\$ 156.3735	(\$ 206,413.02)
Purchase	1/20/2021	700	\$ 160.5510	(\$ 112,385.70)
Purchase	1/22/2021	700	\$ 164.8103	(\$ 115,367.18)
Purchase	1/29/2021	780	\$ 161.4690	(\$ 125,945.82)
Purchase	4/1/2021	800	\$ 158.0500	(\$ 126,440.00)
Purchase	4/29/2021	2,300	\$ 174.8755	(\$ 402,213.71)
Purchase	4/30/2021	800	\$ 176.4938	(\$ 141,195.00)
Purchase	6/9/2021	2,200	\$ 164.0575	(\$ 360,926.50)
Purchase	6/25/2021	1,500	\$ 170.0730	(\$ 255,109.50)
Purchase	7/9/2021	1,800	\$ 185.6143	(\$ 334,105.71)
Purchase	7/30/2021	1,200	\$ 167.9615	(\$ 201,553.80)
Purchase	8/20/2021	1,000	\$ 159.8153	(\$ 159,815.25)
Purchase	8/24/2021	700	\$ 164.3083	(\$ 115,015.78)
Purchase	9/17/2021	500	\$ 174.3248	(\$ 87,162.39)
Purchase	11/22/2021	800	\$ 184.1911	(\$ 147,352.90)
Purchase	11/26/2021	1,300	\$ 180.2000	(\$ 234,260.00)
Purchase	12/6/2021	800	\$ 169.9625	(\$ 135,970.00)
Purchase	12/9/2021	1,200	\$ 174.1710	(\$ 209,005.20)
Purchase	12/17/2021	1,200	\$ 165.8594	(\$ 199,031.30)
Purchase	12/20/2021	2,000	\$ 166.8500	(\$ 333,700.00)
Purchase	1/5/2022	700	\$ 165.8794	(\$ 116,115.55)
Purchase	1/10/2022	1,000	\$ 161.4860	(\$ 161,486.00)
Purchase	1/20/2022	600	\$ 157.3966	(\$ 94,437.94)
Sale	2/4/2022	(4,400)	\$ 155.6065	\$ 684,668.60
Sale	2/4/2022	(4,000)	\$ 155.4679	\$ 621,871.72
<i>Sale of Class Shares in Lookback Period</i>		5/23/2022	(10,100)	\$ 131.3594 \$ 1,326,729.88
Net Proceeds of Transactions				(\$ 2,739,707.38)

Value of 14,940 retained shares @ \$ 122.8643 per share	\$ 1,835,593.14
(Loss)/Gain for 711000-711001 ^b	(\$ 904,114.24)

769300-769301				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	7/22/2019	22,860	\$ 99.2815	(\$ 2,269,575.09)
Purchase	3/12/2020	1,200	\$ 86.0385	(\$ 103,246.20)
Purchase	4/27/2020	1,660	\$ 119.7798	(\$ 198,834.40)
Purchase	7/9/2021	3,760	\$ 186.0670	(\$ 699,611.90)
Purchase	11/10/2021	2,680	\$ 176.3203	(\$ 472,538.34)
Purchase	2/1/2022	3,800	\$ 150.1562	(\$ 570,593.50)
<i>Purchase in Lookback Period</i>	4/20/2022	5,780	\$ 154.2181	(\$ 891,380.36)
<i>Purchase in Lookback Period</i>	4/21/2022	5,800	\$ 149.4394	(\$ 866,748.23)
Net Proceeds of Transactions				(\$ 4,314,399.43)
Value of 35,960 retained shares @ \$ 122.8643 per share				\$ 4,418,201.43
(Loss)/Gain for 769300-769301 ^b				\$ 103,801.99

770000-770001				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/12/2021	27,900	\$ 162.2761	(\$ 4,527,502.67)
Sale	2/22/2021	(900)	\$ 160.4065	\$ 144,365.85
Sale	4/1/2021	(1,200)	\$ 155.9577	\$ 187,149.28
Sale	1/5/2022	(1,800)	\$ 166.4447	\$ 299,600.40
Sale	1/19/2022	(2,000)	\$ 158.7425	\$ 317,485.00
Purchase	1/26/2022	1,400	\$ 141.3489	(\$ 197,888.52)
Sale	2/16/2022	(1,000)	\$ 157.0500	\$ 157,050.01
Sale	2/22/2022	(8,800)	\$ 150.6090	\$ 1,325,359.19
Net Proceeds of Transactions				(\$ 2,294,381.46)
Value of 13,600 retained shares @ \$ 122.8643 per share				\$ 1,670,954.93
(Loss)/Gain for 770000-770001 ^b				(\$ 623,426.53)

770100-770101				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/12/2021	2,600	\$ 162.2742	(\$ 421,912.90)

Sale	4/1/2021	(300)	\$ 155.9568	\$ 46,787.05
Sale	10/18/2021	(200)	\$ 170.4404	\$ 34,088.08
Sale	2/22/2022	(900)	\$ 150.6110	\$ 135,549.88
Net Proceeds of Transactions				(\$ 205,487.89)
Value of 1,200 retained shares @ \$ 122.8643 per share				\$ 147,437.20
(Loss)/Gain for 770100-770101^b				(\$ 58,050.69)

770200-770201				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/12/2021	5,600	\$ 162.2750	(\$ 908,740.18)
Sale	4/1/2021	(700)	\$ 155.9593	\$ 109,171.54
Sale	1/24/2022	(500)	\$ 139.0000	\$ 69,500.00
Sale	2/16/2022	(400)	\$ 157.0730	\$ 62,829.20
Sale	2/22/2022	(1,400)	\$ 150.6081	\$ 210,851.31
Net Proceeds of Transactions				(\$ 456,388.13)
Value of 2,600 retained shares @ \$ 122.8643 per share				\$ 319,447.27
(Loss)/Gain for 770200-770201^b				(\$ 136,940.86)

770300-770301				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/12/2021	10,600	\$ 162.2757	(\$ 1,720,122.51)
Sale	3/26/2021	(400)	\$ 152.2030	\$ 60,881.20
Sale	2/22/2022	(3,400)	\$ 150.6092	\$ 512,071.25
<i>Sale of Class Shares in Lookback Period</i>	4/6/2022	(600)	\$ 161.7369	\$ 97,042.11
<i>Purchase in Lookback Period</i>	4/8/2022	400	\$ 156.7600	(\$ 62,704.00)
Net Proceeds of Transactions				(\$ 1,050,127.95)
Value of 6,200 retained shares @ \$ 122.8643 per share				\$ 761,758.87
(Loss)/Gain for 770300-770301^b				(\$ 288,369.08)

770900-770901				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/17/2020	32,800	\$ 91.8687	(\$ 3,013,292.54)
Purchase	3/19/2020	10,760	\$ 96.0633	(\$ 1,033,640.62)
Purchase	3/20/2020	4,140	\$ 96.3150	(\$ 398,744.10)

Purchase	3/27/2020	4,560	\$ 95.7582	(\$ 436,657.48)
Purchase	4/6/2020	4,900	\$ 98.0165	(\$ 480,280.61)
Sale	6/12/2020	(6,280)	\$ 127.2877	\$ 799,366.91
Sale	6/24/2020	(3,480)	\$ 139.0000	\$ 483,720.00
Sale	7/15/2020	(2,000)	\$ 154.0034	\$ 308,006.81
Sale	7/15/2020	(3,000)	\$ 153.7485	\$ 461,245.50
Sale	7/16/2020	(3,000)	\$ 148.4637	\$ 445,391.00
Purchase	12/2/2020	5,000	\$ 160.5473	(\$ 802,736.50)
Purchase	1/20/2021	6,000	\$ 161.3711	(\$ 968,226.33)
Purchase	1/25/2021	5,400	\$ 166.8178	(\$ 900,816.26)
Purchase	2/1/2021	4,000	\$ 164.8684	(\$ 659,473.48)
Sale	3/10/2021	(4,080)	\$ 152.7455	\$ 623,201.82
Purchase	3/31/2021	12,000	\$ 155.1762	(\$ 1,862,114.16)
Purchase	4/29/2021	12,860	\$ 174.0831	(\$ 2,238,708.09)
Purchase	8/20/2021	5,660	\$ 159.9073	(\$ 905,075.49)
Purchase	8/23/2021	8,000	\$ 163.5708	(\$ 1,308,566.04)
Purchase	8/23/2021	10,000	\$ 163.5708	(\$ 1,635,707.55)
Sale	9/27/2021	(17,400)	\$ 169.8137	\$ 2,954,758.64
Sale	10/11/2021	(15,520)	\$ 163.7882	\$ 2,541,992.77
Purchase	11/18/2021	15,000	\$ 183.9995	(\$ 2,759,992.43)
Purchase	11/24/2021	2,580	\$ 179.0321	(\$ 461,902.82)
Purchase	11/26/2021	17,080	\$ 180.3723	(\$ 3,080,758.12)
Purchase	12/22/2021	2,800	\$ 171.6968	(\$ 480,751.10)
Sale	2/3/2022	(37,600)	\$ 139.8196	\$ 5,257,215.27
Purchase	2/24/2022	11,800	\$ 150.0306	(\$ 1,770,361.43)
Sale	4/5/2022	(9,540)	\$ 165.1045	\$ 1,575,096.83
<i>Purchase in Lookback Period</i>	5/13/2022	1,520	\$ 111.4753	(\$ 169,442.42)
<i>Sale of Shares Purchased in Lookback Period</i>	5/23/2022	(1,520)	\$ 106.6360	\$ 162,086.72
<i>Sale of Class Shares in Lookback Period</i>	5/23/2022	(1,580)	\$ 131.3594	\$ 207,547.84
<i>Sale of Class Shares in Lookback Period</i>	5/31/2022	(1,500)	\$ 128.7416	\$ 193,112.37
<i>Sale of Class Shares in Lookback Period</i>	6/1/2022	(2,600)	\$ 128.5605	\$ 334,257.33
<i>Sale of Class Shares in Lookback Period</i>	6/3/2022	(1,900)	\$ 128.3346	\$ 243,835.80
<i>Sale of Class Shares in Lookback Period</i>	6/3/2022	(1,180)	\$ 128.3346	\$ 151,434.87

Net Proceeds of Transactions	(\$ 8,617,621.36)
Value of 64,680 retained shares @ \$ 122.8643 per share	\$ 7,946,865.08
(Loss)/Gain for 770900-770901 ^b	(\$ 670,756.28)

771400-771401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	10/28/2019	660	\$ 88.6982	(\$ 58,540.78)
Sale	11/6/2019	(660)	\$ 89.8058	\$ 59,271.82
Sale of Pre-Class Shares	11/6/2019	(5,040)	\$ 89.8058	\$ 452,621.15
Purchase	3/26/2020	6,640	\$ 96.1833	(\$ 638,656.98)
Purchase	6/3/2020	2,040	\$ 124.1852	(\$ 253,337.84)
Sale	7/10/2020	(1,400)	\$ 159.6480	\$ 223,507.20
Sale	2/9/2021	(3,280)	\$ 165.4158	\$ 542,563.78
Sale	2/12/2021	(4,000)	\$ 162.3577	\$ 649,430.61
Purchase	5/4/2021	3,800	\$ 166.7788	(\$ 633,759.25)
Purchase	5/11/2021	4,040	\$ 156.7437	(\$ 633,244.45)
Sale	8/12/2021	(3,400)	\$ 164.7830	\$ 560,262.10
Sale	8/20/2021	(4,440)	\$ 159.8969	\$ 709,942.10
Purchase	8/24/2021	4,400	\$ 165.3225	(\$ 727,418.80)
Purchase	10/11/2021	2,200	\$ 164.2475	(\$ 361,344.50)
Purchase	12/15/2021	1,960	\$ 165.8752	(\$ 325,115.39)
Purchase	3/4/2022	4,560	\$ 144.8203	(\$ 660,380.75)
Sale	3/16/2022	(4,940)	\$ 148.1501	\$ 731,861.72
<i>Purchase in Lookback Period</i>	4/22/2022	4,080	\$ 148.5588	(\$ 606,119.92)
Net Proceeds of Transactions				(\$ 814,959.41)
Value of 8,180 retained shares @ \$ 122.8643 per share				\$ 1,005,030.25
(Loss)/Gain for 771400-771401 ^b				\$ 190,070.83

772400-772401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	3/25/2020	1,260	\$ 95.4823	(\$ 120,307.73)
Sale	9/22/2020	(160)	\$ 151.7450	\$ 24,279.20
Purchase	10/7/2020	520	\$ 158.1173	(\$ 82,220.98)
Purchase	10/27/2020	340	\$ 161.2500	(\$ 54,825.00)

Purchase	10/30/2020	200	\$ 157.8875	(\$ 31,577.50)
Purchase	11/3/2020	360	\$ 152.4205	(\$ 54,871.38)
Purchase	11/4/2020	2,200	\$ 161.3431	(\$ 354,954.72)
Purchase	1/5/2021	700	\$ 160.9255	(\$ 112,647.85)
Sale	1/22/2021	(1,420)	\$ 165.2155	\$ 234,606.01
Sale	2/23/2021	(1,200)	\$ 157.2173	\$ 188,660.76
Sale	3/8/2021	(800)	\$ 150.9358	\$ 120,748.65
Purchase	7/6/2021	1,600	\$ 176.5000	(\$ 282,400.00)
Purchase	8/26/2021	1,200	\$ 164.9500	(\$ 197,940.00)
Purchase	9/14/2021	1,200	\$ 172.5000	(\$ 207,000.00)
Sale	12/9/2021	(500)	\$ 174.1710	\$ 87,085.50
Sale	1/11/2022	(2,000)	\$ 161.5000	\$ 323,000.00
<i>Sale of Class Shares in Lookback Period</i>	5/20/2022	(440)	\$ 132.1031	\$ 58,125.38
Net Proceeds of Transactions				(\$ 462,239.66)
Value of 3,060 retained shares @ \$ 122.8643 per share				\$ 375,964.86
(Loss)/Gain for 772400-772401^b				(\$ 86,274.80)

775400-775401				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/4/2020	1,760	\$ 102.4835	(\$ 180,370.96)
Purchase	2/11/2020	1,840	\$ 107.5400	(\$ 197,873.60)
Purchase	2/25/2020	460	\$ 99.1500	(\$ 45,609.00)
Purchase	3/5/2020	500	\$ 96.2015	(\$ 48,100.75)
Sale	5/4/2020	(680)	\$ 115.6995	\$ 78,675.66
Sale	5/28/2020	(1,720)	\$ 120.5143	\$ 207,284.52
Purchase	7/13/2020	500	\$ 155.2000	(\$ 77,600.00)
Purchase	7/27/2020	580	\$ 152.7605	(\$ 88,601.09)
Purchase	8/24/2020	280	\$ 165.5535	(\$ 46,354.98)
Purchase	11/27/2020	1,900	\$ 159.9648	(\$ 303,933.20)
Purchase	11/27/2020	1,480	\$ 160.4935	(\$ 237,530.38)
Purchase	4/7/2021	820	\$ 163.9695	(\$ 134,454.99)
Purchase	5/3/2021	780	\$ 174.2365	(\$ 135,904.47)
Purchase	6/9/2021	560	\$ 164.3395	(\$ 92,030.10)

Purchase	7/19/2021	1,240	\$ 176.1729	(\$ 218,454.38)
Sale	9/28/2021	(1,320)	\$ 165.8346	\$ 218,901.63
Sale	11/1/2021	(940)	\$ 166.0697	\$ 156,105.49
Purchase	1/14/2022	980	\$ 160.1500	(\$ 156,947.00)
Purchase	1/21/2022	500	\$ 148.5180	(\$ 74,259.00)
Purchase	2/3/2022	500	\$ 140.9001	(\$ 70,450.03)
<i>Sale of Class Shares in Lookback Period</i>	4/29/2022	(3,380)	\$ 148.8371	\$ 503,069.26
<i>Sale of Class Shares in Lookback Period</i>	5/2/2022	(6,640)	\$ 147.4850	\$ 979,300.40
(Loss)/Gain for 775400-775401^b				\$ 34,863.02

780600-780601				
Transaction Type	Date	Quantity	Price ^a	Amount
Purchase	2/2/2022	200	\$ 150.6125	(\$ 30,122.50)
<i>Sale of Class Shares in Lookback Period</i>	5/31/2022	(200)	\$ 128.7416	\$ 25,748.32
(Loss)/Gain for 780600-780601^b				(\$ 4,374.18)

793400-793401				
Transaction Type	Date	Quantity	Price ^a	Amount
No Transactions				
(Loss)/Gain for 793400-793401^b				\$ 0.00

Grand Total for 13 Funds				
(Loss)/Gain^b (\$ 2,500,987.56)				

^a Any shares sold within 90 days after the end of the class period have been valued at the higher price between the actual sale price and the average closing price from the end of the class period to the date of the sale.

^b Losses calculated on a last-in first-out (LIFO) basis.

Exhibit D

SHAREHOLDER AND SECURITIES FRAUD RESUME



INTRODUCTION

Founded as a trial lawyers' firm with a complex litigation focus by Ron Motley, Joe Rice and nearly 50 other lawyers, Motley Rice LLC has become one of the nation's largest plaintiffs' law firms.

Motley Rice LLC ("Motley Rice") is led by lawyers who received their training and trial experience in complex litigation involving in-depth investigations, discovery battles and multi-week trials.

From asbestos and tobacco to counter-terrorism and human rights cases, Motley Rice attorneys have shaped developments in U.S. jurisprudence over several decades. Shareholder litigation has earned an increasing portion of our firm's focus in recent years as threats to global retirement security have increased. Motley Rice seeks to create a better, more secure future for pensioners, unions, government entities and institutional investors through improved corporate governance and accountability.

APPROACH TO SECURITIES LITIGATION

As concerns about our global financial system have intensified, so has our focus on securities litigation as a practice area. As one presenter at the 2009 International Foundation of Employee Benefit Plans annual conference noted, "2008 likely will go down in history as one of the worst years for retirement security in the United States."

Our securities litigation philosophy is straightforward – obtain the best possible results for our clients and any class of investors we represent. Unlike some other firms, we are extremely selective about the cases that we recommend our clients pursue, recognizing that many securities fraud class action cases filed each year are unworthy of an institutional investor's involvement for a variety of reasons.

Our attorneys have substantial experience analyzing securities cases and advising institutional investor clients, whether to seek lead-plaintiff appointment (alone or with a similarly-minded group), remain an absent class member, or consider an opt-out case based on the particular factual and legal circumstances of the case.

When analyzing new filings, our attorneys draw upon their securities, business, and litigation experience, which is supplemented by our in-house team of paralegals and business analysts. In addition, the firm has developed close working relationships with widely-respected forensic accountants and expert witnesses, whose involvement at the earliest stages of complex cases can be critical to determining the best course of action. If Motley Rice believes that a case deserves an institutional investor's involvement, we provide our clients with a detailed written analysis of potential claims and loss-recoupment strategies.

Motley Rice attorneys have secured important corporate governance reforms and returned money to shareholders in shareholder derivative cases, served as lead or co-lead counsel in several significant, multi-million dollar securities fraud class actions, and taken leadership roles in cases involving fiduciaries who failed to maximize shareholder value and fulfill disclosure obligations in a variety of merger and acquisition cases.



OUR BACKGROUND IN COMPLEX LITIGATION

Motley Rice attorneys have been at the forefront of some of the most significant and monumental civil actions over the last 30 years. Our experience in complex trial litigation includes class actions and individual cases involving securities and consumer fraud, occupational disease and toxic tort, medical drugs and devices, environmental damage, terrorist attacks and human rights abuses.

Tobacco Master Settlement Agreement

In the 1990s, Motley Rice attorneys and more than half of the states' attorneys general took on the tobacco industry. Armed with evidence acquired from whistleblowers, individual smokers' cases and tobacco liability class actions, the attorneys led the campaign in the courtroom and at the negotiation table to recoup state healthcare funds and exact marketing restrictions from cigarette manufacturers. The effort resulted in significant restrictions on cigarette marketing to children and culminated in the \$246 billion Master Settlement Agreement, the largest civil settlement in U.S. history.

Asbestos Litigation

From the beginning, our lawyers were integral to the story of how "a few trial lawyers and their asbestos-affected clients came out . . . to challenge giant asbestos corporations and uncover the greatest and longest business cover-up of an epidemic disease, caused by a product, in American history."¹ In addition to representing thousands of workers and family members impacted by asbestos, Motley Rice has represented numerous public entities, and litigated claims alleging various insurers of asbestos defendants engaged in unfair settlement practices in connection with the resolution of underlying asbestos personal injury claims. This litigation resulted in, among other things, an eleven-state settlement with Travelers Insurance Company.

Anti-Terrorism and Human Rights

In *In re Terrorist Attacks on September 11, 2001*, Motley Rice attorneys brought a landmark lawsuit against the alleged private and state sponsors of al Qaeda and Osama bin Laden in an action filed on behalf of more than 6,500 family members, survivors, and those killed on 9/11—including the representation of more than 900 refugees and their families. In prosecuting this action, Motley Rice has undertaken a global investigation into terrorism financing.

Our attorneys also initiated the *In re September 11 Litigation* and negotiated settlements for 56 families that opted out of the Victim Compensation Fund that far exceeded existing precedents at the time for wrongful death cases against the airline industry.

BP PLC Oil Spill Litigation

In April 2010, the Deepwater Horizon disaster spilled approximately 4.9 million gallons of oil into the water, killed 11 oil rig workers, devastated the Gulf's natural resources and profoundly harmed the economic and emotional well-being of hundreds of thousands of people. The Deepwater Horizon Economic and Property Damages Settlement is the largest civil class action settlement in U.S. history. Motley Rice co-founder Joseph Rice is a Plaintiffs' Steering Committee member and served as one of the primary negotiators of that Settlement and the Medical Benefits Settlement. In addition, Rice led negotiations in the \$1.028 billion settlement between the PSC and Halliburton Energy Services for its alleged role in the oil spill. Motley Rice attorneys continue to hold leadership roles in the litigation and are currently working to ensure that all qualifying oil spill victims are fairly compensated.

Volkswagen 'Clean Diesel' Litigation

In 2015, Volkswagen Group's admission that it had programmed more than 11 million vehicles to cheat emissions tests and bypass standards sparked worldwide outrage. Motley Rice co-founder Joe Rice served as one of the lead negotiators in the nearly \$15 billion settlement deal reached in 2016 for U.S. owners and lessees of 2.0-liter TDI vehicles, the largest auto-related consumer class action settlement in U.S. history. Rice and other Motley Rice attorneys also helped recover up to \$4.4 billion with regards to affected 3.0-liter vehicles.

Transvaginal Mesh Litigation

Motley Rice attorneys represent thousands of women and have played a leading role in litigation alleging debilitating and life-altering complications caused by defective transvaginal mesh devices. In 2014, Joe Rice, with co-counsel, negotiated the original settlement deal reached in *In re American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation* that numerous subsequent settlements with the manufacturer were modeled after.

Opioid Litigation

At the forefront of litigation targeting the alleged overprescribing and deceptive marketing of addictive opioid painkillers, Motley Rice, led by attorney Linda Singer, the former Attorney General for the District of Columbia, serves as lead counsel for the first jurisdictions to file complaints in the most recent wave of litigation against pharmaceutical companies regarding the opioid crisis—the City of Chicago and Santa Clara County. In addition, the firm's co-founder Joe Rice serves as co-lead counsel in the *National Prescription Opiate Litigation* coordinated in the Northern District of Ohio. The firm represents 40 jurisdictions.

¹ Ralph Nader, commenting on the story told by the book *Outrageous Misconduct*.

Securities Fraud Class Actions

In Re 3M Co. Securities Litigation, No. 2:19-cv-15982 (D.N.J.). Motley Rice serves as co-lead counsel for securities fraud litigation filed by investors who allege 3M Co., and its executives failed to inform them of the scope of potential liability for its products containing toxic PFAS chemicals. Internal documents show that 3M knew for decades that PFAS chemicals posed a danger to the public, but the company continued to use them without warning the public. Shareholders allege that 3M and its executives did not adequately inform investors of the risks and potential liability the company faced, even as state and federal investigations and lawsuits expanded to address growing concerns between February 2017 and May 2019. Minnesota, New Jersey, and New Hampshire have sued the company for PFAS contamination in their water systems. The case is currently in discovery.

In re Twitter Inc. Securities Litigation, No. 3:16-cv-05314 (N.D.Cal.). Motley Rice serves as lead counsel for Twitter Inc. shareholders who allege they were misled about the social media network's daily user growth during 2015. Twitter executives announced toward the end of 2014 that they expected the company's number of active users would grow to more than half a billion in the intermediate term, and would reach heights of more than a billion long term. When the public, however, later learned that actual user growth was slower than anticipated, the company's price per share drastically declined. The case is currently in discovery.

In re Citigroup Inc. Securities Litigation, No. 07 Civ. 9901 (SHS) (DCF) (S.D.N.Y.). Motley Rice served as co-counsel in this securities fraud action alleging that Citigroup responded to the widely-known financial crisis by concealing both the extent of its ownership of toxic assets—most prominently, collateralized debt obligations (CDO) backed by nonprime mortgages—and the risks associated with them. By alleged misrepresentations and omissions of what amounted to more than two years of income and an entire significant line of business, Citigroup allegedly artificially manipulated and inflated its stock prices throughout the class period. Citigroup's alleged actions caused its stock price to trade in a range of \$42.56 to \$56.41 per share for most of the class period. These disclosures helped place Citigroup in serious danger of insolvency, a danger that was averted only through a \$300 billion dollar emergency government bailout. On August 1, 2013, the Court approved the settlement resolving all claims in the Citigroup action in exchange for payment of \$590 million for the benefit of the class.

Alaska Electrical Pension Fund v. Pharmacia Corp., No. 03-1519 (D.N.J.). Motley Rice served as co-class counsel in federal securities fraud litigation alleging that the defendants misrepresented clinical trial results of Celebrex® to make its safety profile appear better than rival drugs. In January 2013, the lawsuit settled in mediation for \$164 million.

Bennett v. Sprint Nextel Corporation, No. 2:09-cv-02122-EFM-KMH (D. Kan.). As co-lead counsel, Motley Rice represented the PACE Industry Union-Management Pension Fund (PIUMPF) and two other institutional investors who purchased Sprint Nextel common stock between October 26, 2006 and February 27, 2008. The class action complaint alleged that the defendants made materially false and misleading statements regarding Sprint's business and financial results. As a result, the complaint alleged that Sprint stock traded at artificially inflated prices during the class period and that, when the market learned the truth, the value of Sprint's shares plummeted. In August 2015, the court granted final approval to a \$131 million settlement.

In re Barrick Gold Securities Litigation, No. 1:13-cv-03851-RMB (S.D.N.Y.). As sole lead counsel, Motley Rice represented Co-Lead Plaintiffs Union Asset Management Holding AG and LRI Invest S.A. in a class action on behalf of investors who purchased shares of Barrick Gold Corporation, the world's largest gold mining company. The suit alleged that Barrick Gold had fraudulently underreported the cost and the time to develop its Pascua-Lama gold mine on the border between Argentina and Chile, and misrepresented its compliance with applicable environmental regulations and the sufficiency of its internal controls. Barrick Gold eventually abandoned its development of the Pascua-Lama mine after an injunction was issued by a Chilean court following the company's failure to comply with environmental regulations, and causing Barrick Gold to take an impairment charge of over \$5 billion. A \$140 million settlement was reached, and received final approval in December 2016.

Minneapolis Firefighters' Relief Association v. Medtronic, Inc., No. 08-6324 (PAM/AJB) (D. Minn.). Motley Rice is co-lead counsel for a class of investors who purchased Medtronic common stock in this case that survived the defendants' motion to dismiss. The suit alleges that Medtronic engaged in a pervasive campaign of illegal off-label marketing in which the company advised doctors to use Medtronic's Infuse Bone Graft in ways not FDA-approved, leading to severe complications in patients. Medtronic's stock price dropped significantly after investors learned that the FDA and Department of Justice were investigating Medtronic's off-label marketing. The \$85 million settlement was approved on Nov. 8, 2012.

Cornwell v. Credit Suisse Group, No. 08 Civ. 3758 (VM) (S.D.N.Y.). Motley Rice served as co-counsel in an action against Credit Suisse Group alleging the defendants issued materially false and misleading statements regarding the company's business and financial results and failed to write down impaired securities containing mortgage-related debt. Subsequently, Credit Suisse's stock price relative to other market events declined 2.83 percent when impaired securities came to light. A \$70 million settlement was approved in July 2011.

CASES

In re Forest Laboratories, Inc. Securities Litigation, No. 05 Civ. 2827 (RMB) (S.D.N.Y.). Motley Rice represented PIUMPF in a securities fraud class action alleging that the company and its officers misrepresented the safety, efficacy, and side effects of several drugs. Motley Rice, in cooperation with other class counsel, helped the parties reach a \$65 million settlement that was approved on May 15, 2009.

City of Brockton Retirement System v. Avon Products, Inc., No. 11 Civ. 4665 (PGG) (S.D.N.Y.). Motley Rice serves as sole lead counsel representing lead plaintiffs in a class action on behalf of all persons who acquired Avon common stock between July 31, 2006 and Oct. 26, 2011. The action alleges that the defendants falsely assured investors they had effective internal controls and accounting systems, as required under the Foreign Corrupt Practices Act (FCPA). In October 2008, Avon disclosed that it had begun an investigation into possible FCPA violations in China in June 2008. The action alleges that, unbeknownst to investors, Avon had an illegal practice of paying bribes in violation of the FCPA extending as far back as 2004 and which continued even after its October 2008 disclosure. Despite its certifications of the effectiveness of its internal controls, Avon's internal controls were allegedly severely deficient, allowing the company to engage in millions of dollars of improper payments in more than a dozen countries. On August 24, 2016, the court approved a final settlement of \$62 million.

City of Sterling Heights General Employees' Retirement System v. Hospira, Inc., No. 11 C 8332 (N.D. Ill.). Motley Rice serves as co-lead counsel representing investors in this lawsuit against Hospira, the world's largest manufacturer of generic injectable pharmaceuticals, including generic acute-care and oncology injectables and integrated infusion therapy and medication management systems. The lawsuit alleges that Hospira and certain executive officers engaged in a fraudulent scheme to artificially inflate the company's stock price by concealing significant deteriorating conditions, manufacturing and quality control deficiencies at its largest manufacturing facility located in Rocky Mount, N.C., and the costly effects of these deficiencies on production capacity. These deteriorating conditions culminated in a series of regulatory actions by the FDA which the defendants allegedly misrepresented to their investors. The case settled for \$60 million in 2014.

Hill v. State Street Corporation, No. 09-cv-12146-NG (D. Mass.). Motley Rice represented institutional investors as co-lead counsel against State Street. The action alleged that State Street defrauded institutional investors – including the state of California's two largest pension funds, California Public Employees' Retirement System (CalPERS) and California State Teachers' Retirement System (CalSTRS) – by misrepresenting its exposure to toxic assets and overcharging them for foreign exchange trades. On January 8, 2015, the court approved a \$60 million settlement.

In re Hewlett-Packard Co. Securities Litigation, No. SACV 11-1404 AG (RNBx) (C.D. Cal.). Motley Rice served as co-lead counsel representing investors who purchased Hewlett-Packard common stock between November 22, 2010 and August 18, 2011. The lawsuit alleged that Hewlett-Packard misled investors about its ability to release over a hundred million webOS-enabled devices by the end of 2011. After Hewlett-Packard abandoned webOS development in August 2011, the company's stock price declined significantly. The court granted final approval to a \$57 million settlement on September 15, 2014.

South Ferry LP #2 v. Killinger, No. C04-1599C-(W.D. Wash.) (regarding Washington Mutual). Motley Rice served as co-lead counsel on behalf of a class of investors who purchased WaMu common stock between April 15, 2003, and June 28, 2004. The suit alleged that WaMu misrepresented its ability to hedge risk and withstand changes in interest rates, as well as its integration of differing technologies resulting from various acquisitions. The Court granted class certification in January 2011 and approved the \$41.5 million settlement on June 5, 2012.

In re Dell, Inc. Securities Litigation, No. A-06-CA-726-SS (W.D. Tex.). Motley Rice was appointed lead counsel for the lead plaintiff, Union Asset Management Holding AG, which sued on behalf of a class of purchasers of Dell common stock. The suit alleged that Dell and certain senior executives lied to investors and manipulated financial announcements to meet performance objectives that were tied to executive compensation. The defendants' alleged fraud ultimately caused the price of Dell's stock to decline by over 40 percent. After the case was dismissed by the district court, Motley Rice attorneys launched an appeal to the Fifth Circuit Court of Appeals. After fully briefing the case and oral arguments, the parties settled the case for \$40 million.

Freedman v. St. Jude Medical, Inc., No. 12-3070 (RHK/JJG) (D. Minn.). Motley Rice served as co-lead counsel representing co-lead plaintiff Första AP-fonden, a Swedish pension fund, in this securities fraud class action against St. Jude Medical, Inc., a manufacturer of medical devices for cardiac rhythm management and the treatment of atrial fibrillation. This action alleged that defendants made false and misleading statements and concealed material information relating to the safety, durability, and manufacturing processes of the company's new generation of cardiac rhythm management devices marketed under the name "Durata." A \$39.5 million settlement was approved in November 2016.

Hatamian v. Advanced Micro Devices, Inc., No. 4:14-cv-00226-YGR (N.D. Cal.). Motley Rice served as co-lead counsel representing Lead Plaintiffs KBC Asset Management NV and Arkansas Teacher Retirement System in this securities fraud class action on behalf of investors that purchased AMD common stock between April 4, 2011, and October 18, 2012. AMD, a multinational semiconductor manufacturer, allegedly misrepresented and concealed problems affecting the production, launch, demand, and sales of its new "Llano" microprocessor. These problems allegedly led

AMD to miss the critical sales period for Llano-based computers and ultimately take a \$100 million write-down of by-then obsolete Llano inventory, causing AMD's stock price to fall, and damaging the company's investors. The court granted class certification on March 16, 2016. For the next two years, Class Counsel obtained and reviewed approximately 2.5 million pages of documents; participated in 34 depositions of fact, expert, and confidential witnesses; retained industry and financial experts; briefed competing motions for summary judgment; and engaged in multiple mediations with defendants. On March 6, 2018, the court approved a \$29.5 million settlement.

Ross v. Career Education Corp. No. 1:12-cv-00276 (N.D. Ill.). On April 16, 2014, the U.S. District Court for the Northern District of Illinois issued an order granting final judgment and dismissing with prejudice *Ross v. Career Education Corp.* Motley Rice served as co-lead counsel in the lawsuit, which alleged that Career Education and certain of its executive officers violated the federal securities laws by misleading the company's investors about its placement practices and reporting. The court approved a final settlement of \$27.5 million.

In re MBNA Corporation Securities Litigation, No. 05-CV-00272-GMS (D. Del.). Motley Rice served as co-lead counsel on behalf of investors who purchased MBNA common stock. The suit alleged that MBNA manipulated its financial statements in violation of GAAP, and MBNA executives sold over one million shares of stock based on inside information for net proceeds of more than \$50 million, knowing these shares would drop in value once MBNA's true condition was revealed to the market. The case was settled with many motions pending. The \$25 million settlement was approved on October 6, 2009.

Bodner v. Aegerion Pharmaceuticals, Inc., et al., 14-cv-10105 (D.Mass.) Motley Rice served as co-lead counsel on behalf of investors who purchased Aegerion common stock. The suit alleged that Aegerion issued false and misleading statements and failed to disclose, among other things, that (i) the Company illegally marketed the drug JUXTAPID beyond its FDA-approved label, and (ii) the Company was experiencing a higher than expected drop-out rate of patients taking JUXTAPID. A \$22.25 million settlement was approved on November 30, 2017.

Welmon v. Chicago Bridge & Iron Co., N.V., No. 06-CV-01283 (JES) (S.D.N.Y.). Motley Rice represented the co-lead plaintiff in this case that alleged that the defendants issued numerous materially false and misleading statements which caused CB&I's securities to trade at artificially inflated prices. The litigation resulted in a \$10.5 million settlement that was approved on June 3, 2008.

In re NPS Pharmaceuticals, Inc. Securities Litigation, No. 2:06-cv-00570-PGC-PMW (D. Utah). Motley Rice represented the lead plaintiff as sole lead counsel in a class action brought on behalf of stockholders of NPS Pharmaceuticals, Inc., concerning the drug PREOS. NPS claimed that PREOS would be a "billion dollar drug" that could effectively treat "millions of women around the world who have osteoporosis." The complaint alleged fraudulent misrepresentations regarding PREOS's efficacy, market potential, prospects for FDA approval and dangers of hypercalcemic toxicity. The case settled after the lead plaintiff moved for class certification and the parties engaged in document production and protracted settlement negotiations. The \$15 million settlement was approved on June 18, 2009.

In re Synovus Financial Corp., No. 1:09-cv-01811 (N.D. Ga.). Motley Rice and our client, Sheet Metal Workers' National Pension Fund, serve as court-appointed co-lead counsel and co-lead plaintiff for investors in Synovus Financial Corp. The lawsuit alleges that the bank artificially inflated its stock price by concealing its troubled lending relationship with the Sea Island Company, a resort real estate and hospitality company to whom Synovus allegedly made hundreds of millions of dollars of "insider loans" with "little more than a handshake" facilitated by personal relationships among certain senior executives and board members. In 2014, the court approved a final settlement of \$11.75 million.

In re Molson Coors Brewing Co. Securities Litigation, No. 1:05-cv-00294 (D. Del.). Motley Rice served as co-lead counsel for co-lead plaintiffs Drywall Acoustic Lathing and Insulation Local 675 Pension Fund and Metzler Investment GmbH in litigation against Molson Coors Brewing Co. and several of its officers and directors. The lawsuit alleged that, following the February 9, 2005, merger of Molson, Inc. and the Adolph Coors Company, the defendants fraudulently misrepresented the financial and operational performance of the combined company prior to reporting a net loss for the first quarter of 2005. Following protracted negotiations, the parties reached a \$6 million settlement in May 2009.

Marsden v. Select Medical Corporation, No. 04-cv-4020 (E.D. Pa.). Motley Rice served as co-lead counsel on behalf of stockholders of Select Medical, a healthcare provider specializing in long-term care hospital facilities. The suit alleged that Select Medical exploited its business structure to improperly maximize Medicare reimbursements, misled investors and that the company's executives engaged in massive insider trading for proceeds of over \$100 million. A \$5 million settlement was reached and approved on April 15, 2009.

CASES

Shareholder Derivative Litigation

Walgreens / Controlled Substances Violations: *In re Walgreen Co. Derivative Litigation*. On October 4, 2013, Motley Rice filed a consolidated complaint for a group of institutional investors against the board of directors of Walgreen Co. The complaint alleges that Walgreen's board engaged in a scheme to maximize revenues by encouraging the company's pharmacists to fill improper or suspicious prescriptions for Schedule-II drugs, particularly oxycodone, in Florida. The complaint followed the June 2013 announcement of an \$80 million settlement between Walgreens and the Drug Enforcement Administration relating to the misconduct. A settlement was approved in December 2014, in which Walgreens agreed to, among other things, extended compliance-related commitments, including maintaining a Department of Pharmaceutical Integrity.

Manville Personal Injury Settlement Trust v. Gemunder, No. 10-CI-01212 (Ky. Cir. Ct.) (regarding Omnicare, Inc.). On April 14, 2010, Motley Rice, sole lead counsel in this action, filed a shareholder derivative complaint on behalf of plaintiff Manville Personal Injury Settlement Trust. Plaintiff's claims stem from a November 3, 2009, announcement by the U.S. Department of Justice that Omnicare, Inc. had agreed to pay \$98 million to settle state and federal investigations into three kickback schemes through which the company paid or solicited payments in violation of state and federal anti-kickback laws. The court denied the defendants' motions to dismiss in their entirieties on April 27, 2011. The defendants sought an interlocutory appeal, which was denied on October 6, 2011. Following significant discovery, which included plaintiff's counsel's review and analysis of approximately 1.4 million pages of documents, the parties reached agreement on a settlement, which received final approval from the court on October 28, 2013. Under the settlement, a \$16.7 million fund (less court awarded fees and costs) will be created to be used over a four year period by Omnicare to fund certain corporate governance measures and provide funding for the company's compliance committee in connection with the performance of its duties. Additionally, the settlement calls for Omnicare to adopt and/or maintain corporate governance measures relating to, among other things, employee training and ensuring the appropriate flow of information to the compliance committee.

Service Employees International Union v. Hills, No. A0711383 (Ohio Ct. Com. Pl.) (regarding Chiquita Brands International, Inc.). In this shareholder derivative litigation, SEIU retained Motley Rice to bring an action on behalf of Chiquita Brands International. The plaintiff alleged that the defendants breached their fiduciary duties by paying bribes to terrorist organizations in violation of U.S. and Columbian law. In October 2010, the plaintiffs resolved their state court action as part of a separate federal derivative claim.

Mercier v. Whittle, No. 2008-CP-23-8395 (S.C. Ct. Com. Pl.) (regarding the South Financial Group). This shareholder derivative action was brought on behalf of South Financial Group, Inc., following the company's decision to apply for federal bailout money from the Troubled Asset Relief Program (TARP) while allegedly accelerating the retirement of its former chairman and CEO to protect his multi-million dollar golden parachute, which would be prohibited under TARP. The litigation was settled prior to trial and achieved, among other benefits, payment back to the company from chairman Whittle, increased board independence and enhanced shareholder rights.

Manville Personal Injury Settlement Trust v. Farmer, No. A 0806822 (Ohio Ct. Com. Pl.) (regarding Cintas Corporation). In this shareholder derivative action brought on behalf of Cintas Corporation, the plaintiff alleged that the defendants breached their fiduciary duties by, among other things, failing to cause the company to comply with applicable worker safety laws and regulations. In November 2009, the court approved a settlement agreement that provided for the implementation of corporate governance measures designed to increase the flow of employee safety information to the company's board; ensure the company's compliance with a prior agreement between itself and OSHA relating to workplace safety violations; and secure the attendance of the company's chief health and safety officer at shareholder meetings.

Corporate Takeover Litigation

In re The Shaw Group, Inc., Shareholders Litigation, No. 614399 (19th Jud. Dist. La.). Motley Rice attorneys served as co-lead counsel in the class action brought by our client, a European asset management company, on behalf of the public shareholders of The Shaw Group, Inc. The lawsuit challenged Shaw's proposed sale to Chicago Bridge & Iron Company N.V. in a transaction valued at approximately \$3.04 billion. The plaintiffs alleged that the defendants breached their fiduciary duties to Shaw's shareholders by agreeing to a transaction that was financially unfair and the result of an improper sales process, which the defendants pursued at a time when Shaw's stock was poised for significant growth. The plaintiffs also alleged that the transaction offered substantial benefits to Shaw insiders not shared with the company's public shareholders. In December 2012, the parties reached a settlement with two components. Shaw agreed to make certain additional disclosures to shareholders of financial analyses indicating a potential share price impact of certain alternative transactions of as much as \$19.00 per share versus the status quo. To provide a remedy for Shaw shareholders who believed the company was worth more than CB&I was paying for it, the settlement contained a second component – universal appraisal rights for all Shaw shareholders who properly dissented from the proposed merger, and the opportunity for Shaw dissenters to pursue that remedy on a class-wide basis. The court granted final approval of the settlement on June 28, 2013.

In re Coventry Health Care, Inc. Securities Litigation, No. 7905-CS (Del. Ch.). Motley Rice represented three public pension funds as court-appointed sole lead counsel in a shareholder class action challenging the \$7.2 billion acquisition of Coventry Health Care, Inc., by Aetna, Inc. The plaintiffs alleged that the defendants breached their fiduciary duties to Coventry's shareholders through a flawed sales process involving a severely conflicted financial advisor and at a time when the company was poised for remarkable growth as a result of recent government healthcare reforms. The case settled for improvements to the deal's terms and enhanced disclosures.

In re Allion Healthcare, Inc. Shareholders Litigation, No. 5022-cc (Del. Ch.). Motley Rice attorneys served as co-lead counsel representing a group of institutional shareholders in their challenge to the going-private buy-out of Allion Healthcare, Inc., by private equity firm H.I.G. Capital, LLC, and a group of insider stockholders led by the company's CEO, who controlled about 41 percent the company's shares. The shareholders alleged that the CEO used his stock holdings and influence over board members to accomplish the buyout at the expense of Allion's public shareholders. After a lengthy mediation, the shareholders succeeded in negotiating a settlement resulting in a \$4 million increase in the merger consideration available to shareholders. In January 2011, the Delaware Court of Chancery approved the settlement.

In re RehabCare Group, Inc. Shareholders Litigation, No. 6197-VCL (Del. Ch.). Motley Rice represented institutional shareholders in their challenge to the acquisition of healthcare provider RehabCare Group, Inc., by Kindred Healthcare, Inc. As co-lead counsel, Motley Rice uncovered important additional facts about the relationship between RehabCare, Kindred, and the exclusive financial advisor for the transaction, as well as how those relationships affected the process RehabCare's board of directors undertook to sell the company. After extensive discovery, the parties reached a settlement in which RehabCare agreed to make a \$2.5 million payment for the benefit of RehabCare shareholders. In addition, RehabCare and Kindred agreed to waive certain standstill agreements with potential higher bidders for the company; lower the merger agreement's termination fee from \$26 million to \$13 million to encourage any potential higher bidders; eliminate the requirement that Kindred have a three-business day period during which it has the right to match any superior proposal; and make certain additional public disclosures about the proposed merger. The Delaware Court of Chancery granted final approval of the settlement on Sept. 8, 2011.

In re Atheros Communications Inc. Shareholder Litigation, No. 6124-VCN (Del. Ch.). In this action involving Qualcomm Incorporated's proposed acquisition of Atheros Communications, Inc., for approximately \$3.1 billion, Motley Rice served as co-lead counsel representing investors alleging that, among other things, Atheros' preliminary proxy statement was materially misleading to the company's shareholders, who

were responsible for voting on the proposed acquisition. In March 2011, the Court issued a preliminary injunction delaying the shareholder vote, ruling that Atheros' proxy statement was materially misleading because, even though the proxy stated that the company's CEO "had not had any discussions with Qualcomm regarding the terms of his potential employment," it failed to disclose that he in fact "had overwhelming reason to believe he would be employed by Qualcomm after the transaction closed." The proxy also failed to inform shareholders of an almost entirely contingent \$24 million fee to the company's financial adviser, Catalyst Partners, LLP.

In re Winn-Dixie Stores, Inc. Shareholder Litigation, No. 16-2011-CA-010616 (Fla. 4th Cir. Ct.). Motley Rice served as co-lead counsel in litigation challenging the \$560 million buyout of Winn-Dixie Stores, Inc. by BI-LO, LLC, achieving a settlement that allows for shareholders to participate in a \$9 million common fund or \$2.5 million opt-in appraisal proceeding.

Maric Capital Master Fund, Ltd. v. PLATO Learning, Inc., No. 5402-VCS (Del. Ch.). The firm's institutional investor client won a partial preliminary injunction against the proposed acquisition of PLATO Learning, Inc., by a private equity company. In its ruling, the Delaware Court of Chancery found that the target company's proxy statement was misleading to its shareholders and omitted material information. The court's opinion has since been published and has been cited by courts and the legal media.

In re Lear Corporation Shareholder Litigation, No. 2728-N (Del. Ch.). In this deal case, Motley Rice helped thwart a merger out of line with shareholder interests. Motley Rice represented an institutional investor in this case and, along with Delaware co-counsel, was appointed co-chair of the Plaintiffs' Executive Committee. Motley Rice and its co-counsel conducted expedited discovery and the briefing. The court ultimately granted in part and denied in part the plaintiffs' motion for a preliminary injunction. In granting the injunction, the court found a reasonable probability of success in the plaintiffs' disclosure claim concerning the Lear CEO's conflict of interest in securing his retirement through the proposed takeover. Lear shareholders overwhelmingly rejected the merger.

Helaba Invest Kapitalanlagegesellschaft mbH v. Fialkow, No. 2683-VCL (Del. Ch.) (regarding National Home Health Care Corp.). This action was brought on behalf of the shareholders of National Home Health Care Corporation in response to the company's November 2006 announcement that it had entered into a merger agreement with affiliates of Angelo Gordon. The matter settled prior to trial and was approved on April 18, 2008. The defendants agreed to additional consideration and proxy disclosures for the class.

Schultze Asset Management, LLC v. Washington Group International, Inc., No. 3261-VCN (Del. Ch.). This action followed Washington Group's announcement that it had agreed to be acquired by URS Corporation. The action alleged that Washington Group and its board of directors breached their fiduciary duties

CASES

by failing to maximize shareholder value, choosing financial projections that unfairly undervalued the company and pursuing a flawed decision-making process. Motley Rice represented the parties, which ultimately settled the lawsuit with Washington Group. Washington Group agreed to make further disclosures to its shareholders regarding the proposed alternative transactions it had rejected prior to its accepting URS's proposal and agreed to make disclosures regarding how the company was valued in the proposed transaction with URS. These additional disclosures prompted shareholders to further question the fairness of the URS proposal. Ultimately, URS increased its offer for Washington Group to the benefit of minority stockholders.

In re The DirecTV Group, Inc. Shareholder Litigation, No. 4581-VCP (Del. Ch.). As court-appointed co-lead counsel, Motley Rice attorneys represented a group of institutional investors on behalf of the minority shareholders of DirecTV Group. A settlement was reached and approved by the court on Nov. 30, 2009. It provided for material changes to the merger agreement and the governing documents of the post-merger DirectTV.

State Law Securities Cases

In re Tremont Group Holdings, Inc. Securities Litigation, No. 09 Civ. 03137 (S.D.N.Y.). Motley Rice represents an individual investor in consolidated litigation regarding investments made in Bernard L. Madoff Investment Securities, LLC, through a variable universal life insurance policy.

Brown v. Charles Schwab & Co., No. 2:07-cv-03852-DCN (D.S.C.). Motley Rice attorneys served as class counsel in this case, one of the first to interpret the civil liabilities provision of the Uniform Securities Act of 2002. The U.S. District Court for the District of South Carolina certified a class of investors with claims against broker-dealer Charles Schwab & Co., Inc., for its role in allegedly aiding the illegal sale of securities as part of a \$66 million Ponzi scheme. A subclass of 38 plaintiffs in this case reached a settlement agreement with Schwab under which they receive approximately \$5.7 million, an amount representing their total unrecovered investment losses plus attorneys' fees.

Opt-Out/Individual Actions

In re Vivendi Universal, S.A. Securities Litigation, No. 02 Civ. 5571 (S.D.N.Y.). In this action, Motley Rice represents more than 20 foreign institutional investors who were excluded from the class. The firm's clients include the Swedish public pension fund Första AP-fonden (AP1), one of five buffer funds in the Swedish pay-as-you-go pension system. In light of a recent Supreme Court ruling preventing foreign clients from gaining relief, Motley Rice has worked with institutional investor plaintiffs to file suit in France. ***The French action is pending. In re Merck & Co., Inc., Securities Derivative & "ERISA" Litigation***, MDL No. 1658 (SRC) (D.N.J.). Motley Rice and co-counsel represented several foreign institutional investors who opted out of the federal securities fraud class action against Merck & Co., Inc., related to misrepresentations and omissions about the company's blockbuster drug, Vioxx. Private settlements were reached in these cases in 2016.

ACCOLADES FOR THE FIRM



Chambers USA

2021 Product Liability: Plaintiffs – Nationwide, Band 1



"Best Law Firm"

U.S. News – Best Lawyers®

Mass tort litigation / class actions–plaintiffs

2021 • 2020 • 2019 • 2018 • 2017 • 2016 • 2015

2014 • 2013 • 2012 • 2011 • 2010



The Legal 500 United States

Litigation editions

Mass tort and class action: plaintiff representation–toxic tort

2020 • 2019 • 2018 • 2017 • 2016 • 2015 • 2014

2013 • 2012 • 2011 • 2009 • 2007



"Elite Trial Lawyers"

The National Law Journal Law Firm of the Year

2021 Government Representation

2021 Mass Torts

2020 Pharmaceuticals Firm of the Year

2020 Insurance Liability Firm of the Year

2019 Bankruptcy Law (finalist)



Practice Group of the Year

Law360

2020 • 2019 • 2015 Product Liability

2018 Consumer Protection

2015 • 2013 "Most Feared Plaintiffs Firm"



Securities Class Action Services Top 50

International Securities Services

2017 • 2016 • 2015 • 2014 • 2011 • 2010 • 2009

For full methodologies and selection criteria, visit www.motleyrice.com/award-methodology

Please remember that every case is different. Although they endorse certain lawyers, *The Legal 500 United States* and *Chambers USA* and other similar organizations listed above are not Motley Rice clients. Any result we achieve for one client in one matter does not necessarily indicate similar results can be obtained for other clients.

OUR LEGACY:

Ronald L. Motley (1944-2013)

EDUCATION:

J.D., University of South Carolina School of Law, 1971

B.A., University of South Carolina, 1966

Ron Motley fought for greater justice, accountability and recourse, and has been widely recognized as one of the most accomplished and skilled trial lawyers in the U.S. During a career that spanned more than four decades, his persuasiveness before a jury and ability to break new legal and evidentiary ground brought to justice two once-invincible giant industries whose malfeasance took the lives of millions of Americans— asbestos and tobacco. Armed with a combination of legal and trial skills, personal charisma, nose-to-the-grindstone hard work and record of success, Ron built Motley Rice into one of the nation's largest plaintiffs' law firms.

Noted for his role in spearheading the historic litigation against the tobacco industry, Ron served as lead trial counsel for 26 State Attorneys General in the lawsuits. His efforts to uncover corporate and scientific wrongdoing resulted in the Master Settlement Agreement, the largest civil settlement in U.S. history and in which the tobacco industry agreed to reimburse states for smoking-related health care costs.

Through his pioneering discovery and collaboration, Ron revealed asbestos manufacturers and the harmful and disabling effects of occupational, environmental and household asbestos exposure. He represented thousands of asbestos victims and achieved numerous trial breakthroughs, including the class actions and mass consolidations of *Cimino, et al. v. Raymark, et al.* (U.S.D.C. TX); *Abate, et al. v. ACAndS, et al.* (Baltimore); and *In re Asbestos Personal Injury Cases* (Mississippi).

In 2002, Ron once again advanced cutting-edge litigation as lead counsel for *In re Terrorist Attacks on September 11, 2001*, MDL #1570, a lawsuit filed by more than 6,500 family members, survivors and those who lost their lives. The suit seeks justice and ultimately bankruptcy for al Qaeda's financiers, including many individuals, banks, corporations and charities that provided resources and monetary aid. He also served as lead counsel in numerous individual aviation security liability and damages cases under the *In re September 11 Litigation* filed against the aviation and aviation security industries by victims' families.

Ron brought the landmark case of *Oran Almog v. Arab Bank* against the alleged financial sponsors of Hamas and other terrorist organizations in Israel and was a firm leader in the BP Deepwater Horizon litigation and claims efforts involving people and businesses in Gulf Coast communities suffering as a result of the oil spill. Two settlements were reached with BP, one of which is the largest civil class action settlement in U.S. history.

Recognized as an AV®-rated attorney by Martindale-Hubbell®, Ron served on the AAJ Board of Governors from 1977 to 2012 and was chair of its Asbestos Litigation Group from 1978 to 2012. In 2002, Ron founded the Mark Elliott Motley Foundation,

Inc., in loving memory of his son to help meet the health, education and welfare needs of children and young adults in the Charleston, S.C. community.

PUBLICATIONS:

- Ron authored or co-authored more than two dozen publications, including:
- "Decades of Deception: Secrets of Lead, Asbestos and Tobacco" (*Trial Magazine*, October 1999)
- "Asbestos Disease Among Railroad Workers: 'Legacy of the Laggin' Wagon'" (*Trial Magazine*, December 1981)
- "Asbestos and Lung Cancer" (*New York State Journal of Medicine*, June 1980; Volume 80: No.7, New York State Medical Association, New York)
- "Occupational Disease and Products Liability Claims" (*South Carolina Trial Lawyers Bulletin*, September and October 1976)

FEATURED IN:

- Shackelford, Susan. "Major Leaguer" (*South Carolina Super Lawyers*, April 2008)
- Senior, Jennifer. "A Nation Unto Himself" (*The New York Times*, March 2004)
- Freedman, Michael. "Turning Lead into Gold," (*Forbes*, May 2001)
- Zegart, Dan. *Civil Warriors: The Legal Siege on the Tobacco Industry* (Delacorte Press, 2000)
- Ansen, David. "Smoke Gets in Your Eyes" (*Newsweek*, 1999)
- Mann, Michael & Roth, Eric. "The Insider" (Blue Lion Entertainment, November 5, 1999)
- Brenner, Marie. "The Man Who Knew Too Much" (*Vanity Fair*, May 1996)
- Reisig, Robin. "The Man Who Took on Manville" (*The American Lawyer*, January 1983)

AWARDS AND ACCOLADES:

Ron won widespread honors for his ability to win justice for his clients and for his seminal impact on the course of civil litigation. For his trial achievements, *BusinessWeek* characterized Ron's courtroom skills as "dazzling" and *The National Law Journal* ranked him, "One of the most influential lawyers in America."

South Carolina Association for Justice

2013 Founders' Award

American Association for Justice

2010 Lifetime Achievement Award

2007 David S. Shrager President's Award

1998 Harry M. Philo Trial Lawyer of the Year

The Trial Lawyer Magazine

2012 inducted into Trial Lawyer Hall of Fame

2011 *The Roundtable: America's 100 Most Influential Trial Lawyers*

The Best Lawyers in America®

1993-2013 mass tort litigation/class actions – plaintiffs, personal injury litigation – plaintiffs product liability litigation – plaintiffs

THE FIRM'S MEMBERS

Best Lawyers®

2012 Charleston, SC "Lawyer of the Year" mass tort litigation/class actions – plaintiffs

2010 Charleston, SC "Lawyer of the Year" personal injury

Benchmark Plaintiff

2012-2013 National "Litigation Star": civil rights/human rights, mass tort/product liability, securities

2012-2013 South Carolina "Litigation Star": human rights, product liability, securities, toxic tort

SC Lawyers Weekly

2011 Leadership in Law Honoree

The Legal 500 United States

2011-2013 Mass tort and class action: plaintiff representation – toxic tort

Chambers USA

2007, 2010-2012 Product liability and mass torts: plaintiffs.

"...An accomplished trial lawyer and a formidable opponent."

2008-2013 South Carolina Super Lawyers® list

2008 Top 10 South Carolina Super Lawyers list

2008, 2009, 2011, 2012 Top 25 South Carolina Super Lawyers list

The Lawdragon™ 500

2005-2012 Leading Lawyers in America list – plaintiffs'

National Association of Attorneys General

1998 President's Award—for his "courage, legal skills and dedication to our children and the public health of our nation."

The Campaign for Tobacco-Free Kids

1999 Youth Advocates of the Year Award

ASSOCIATIONS:

American Association for Justice

South Carolina Association for Justice

American Bar Association

South Carolina Bar Association

Civil Justice Foundation

Inner Circle of Advocates

International Academy of Trial Lawyers

- *Although it endorses this lawyer, The Legal 500 United States is not a Motley Rice client.

Joseph F. Rice

LICENSED IN: DC, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Supreme Court

U.S. Court of Appeals for the Third, Fourth and Fifth Circuits

U.S. District Court for the District of Nebraska and the District of South Carolina

EDUCATION:

J.D., University of South Carolina School of Law, 1979

B.S., University of South Carolina, 1976

Motley Rice co-founder Joe Rice is recognized as a skillful and innovative negotiator of complex litigation settlements, having served as the lead negotiator in some of the largest civil actions our courts have seen in the last 20 years. *Corporate Legal Times* reported that national defense counsel and legal scholars described Joe as one of the nation's "five most feared and respected plaintiffs' lawyers in corporate America." As the article notes, "For all his talents as a shrewd negotiator ... Rice has earned most of his respect from playing fair and remaining humble."

Joe was recognized by some of the nation's best-regarded defense lawyers as being "the smartest dealmaker they ever sat across the table from," *Thomson Reuters* has reported. Professor Samuel Issacharoff of the New York University School of Law, a well-known professor and expert in class actions and complex litigation, has commented that he is "the best strategic thinker on the end stages of litigation that I've ever seen."

Since beginning to practice law in 1979, Joe has continued to reinforce his reputation as a skillful negotiator, including through his involvement structuring some of the most significant resolutions of asbestos liabilities on behalf of those injured by asbestos-related products. He negotiates for the firm's clients at all levels, including securities and consumer fraud, anti-terrorism, human rights, environmental, medical drugs and devices, as well as catastrophic injury and wrongful death cases.

National Prescription Opiate MDL:

Most recently, Joe was appointed co-lead counsel in the *National Prescription Opiate MDL* aimed at combatting the alleged over-distribution and deceptive marketing of prescription opioids. Joe, with other members of the Plaintiffs' Executive Committee, led negotiations for a \$260 million settlement that was reached on the eve of the MDL's first bellwether trial. The deal resolved claims filed by Ohio's Cuyahoga and Summit counties against opioid manufacturers and distributors Teva, Cardinal Health, AmerisourceBergen and McKesson. Motley Rice continues to represent dozens of governmental entities, including the first jurisdictions to file cases in the current wave of litigation.

Vehicle Recalls:

Joe served as one of the lead negotiators in the \$15 billion Volkswagen Diesel Emissions Fraud class action settlement for 2.0-liter vehicles, the largest auto-related consumer class action settlement in U.S. history, as well as the 3.0-liter settlement. Under his leadership, Motley Rice also helped negotiate a pair of Takata bankruptcy resolutions that secured

TEAM BIOS:

funds for victims who were harmed by the company's deadly, explosive airbags. Joe also serves as a member of the Plaintiffs' Executive Committee for *In re General Motors LLC Ignition Switch Litigation*, and was appointed to the Plaintiffs' Steering Committee for *In re Chrysler-Dodge-Jeep Ecodiesel Marketing, Sales Practices, and Products Liability Litigation*.

Medical Drugs and Devices:

Joe led negotiations on behalf of thousands of women who allege complications and severe health effects caused by transvaginal mesh and sling products, including litigation that has five MDLs pending in the state of West Virginia. He is also a member of the Plaintiffs' Steering Committee for the Lipitor® MDL, filed for patients who allege the cholesterol drug caused their Type 2 diabetes.

BP Oil Spill:

Joe served as a co-lead negotiator for the Plaintiffs' Steering Committee in reaching the two settlements with BP, one of which is the largest civil class action settlement in U.S. history. The Economic and Property Damages Rule 23 Class Action Settlement is estimated to make payments totaling between \$7.8 billion and \$18 billion to class members. Joe was also one of the lead negotiators of the \$1.028 billion settlement reached between the Plaintiffs' Steering Committee and Halliburton Energy Services, Inc., for Halliburton's role in the disaster.

9/11:

Joe held a crucial role in executing strategic mediations and/or resolutions on behalf of 56 families of 9/11 victims who opted out of the government-created September 11 Victim Compensation Fund. In addition to providing answers, accountability and recourse to victims' families, the resulting settlements with multiple defendants shattered a settlement matrix developed and utilized for decades. The litigation also helped provide public access to evidence uncovered for the trial.

Tobacco:

As lead private counsel for 26 jurisdictions, including numerous State Attorneys General, Joe was integral to the crafting and negotiating of the landmark Master Settlement Agreement, in which the tobacco industry agreed to reimburse states for smoking-related health costs. This remains the largest civil settlement in U.S. history.

Asbestos:

Joe held leadership and negotiating roles involving the bankruptcies of several large organizations, including AWI, Federal Mogul, Johns Manville, Celotex, Garlock, W.R. Grace, Babcock & Wilcox, U.S. Gypsum, Owens Corning and Pittsburgh Corning. He has also worked on numerous Trust Advisory Committees. Today, he maintains a critical role in settlements involving asbestos manufacturers emerging from bankruptcy and has been recognized for his work in structuring significant resolutions in complex personal injury litigation for asbestos liabilities on behalf of victims injured by asbestos-related products. Joe has served as co-chair of Perrin Conferences' Asbestos Litigation Conference, the largest national asbestos-focused conference.

Securities and Consumer Fraud:

Joe is often sought by investment funds for guidance on litigation strategies to increase shareholder value, enhance corporate governance reforms and recover assets. He was an integral part of the shareholder derivative action against Omnicare, Inc., *Manville Personal Injury Settlement Trust v. Gemunder*, which resulted in a significant settlement for shareholders as well as new corporate governance policies for the corporation.

Joe serves on the Board of Advisors for Emory University's Institute for Complex Litigation and Mass Claims, which facilitates bipartisan discussion of ways to improve the civil justice system through the hosting of judicial seminars, bar conferences, academic programs, and research. In 1999 and 2000, he served on the faculty at Duke University School of Law as a Senior Lecturing Fellow, and taught classes on the art of negotiating at the University of South Carolina School of Law, Duke University School of Law and Charleston School of Law.

In 2013, he and the firm created the Ronald L. Motley Scholarship Fund at The University of South Carolina School of Law in memory and honor of co-founding member and friend, Ron Motley.

AWARDS AND ACCOLADES:

Chambers USA

2019-2021 Product Liability: Plaintiffs – Nationwide, Band 1

2016, 2018 Product Liability: Plaintiffs – Nationwide, Band 2

Best Lawyers®

2013 "Lawyer of the Year" Charleston, SC: Mass tort litigation/class actions – plaintiffs

2007-2022 Mass tort litigation/class actions – plaintiffs; Personal injury litigation – plaintiffs

South Carolina Super Lawyers® list

2008-2021 Class action/mass torts; Securities litigation; General litigation

Lawdragon

2016, 2018-2021 Lawdragon 500

2019-2021 Lawdragon 500 Plaintiff Consumer Lawyers

2019-2021 Lawdragon 500 Plaintiff Financial Lawyers

South Carolina Association for Justice

2018 Founders' Award

Law360

2015 "Product Liability MVP"

Benchmark Litigation

2012-2013 National "Litigation Star": mass tort/product liability

2012-2017 South Carolina "Litigation Star": environmental, mass tort/product liability

The Legal 500 United States

2011-2012, 2014-2021 Legal 500 Leading Lawyer list Dispute resolution – product liability, mass tort and class action – toxic tort – plaintiff

TEAM BIOS:

The National Trial Lawyers

2020 Elite Trial Lawyers Lifetime Achievement Award

2014 Litigation Trailblazers

2010 Top 100 Trial Lawyers™ – South Carolina

SC Lawyers Weekly

2018 Hall of Fame honoree

2012 Leadership in Law Award

National Association of Attorneys General

1998 President's Award

University of South Carolina School of Law Alumni Association

2011 Platinum Compleat Lawyer Award

MUSC Children's Hospital

2010 Johnnie Dodds Award: in honor of his longtime support of the annual Bulls Bay Golf Challenge Fundraiser and continued work on behalf of our community's children

University of South Carolina

2011 Garnet Award: in recognition of Joe and his family for their passion for and devotion to Gamecock athletics

SC Junior Golf Association Programs

2011 Tom Fazio Service to Golf Award: in recognition of promotional efforts

COMMUNITY INVOLVEMENT:

Dee Norton Lowcountry Children's Center, Co-chair for inaugural Campaign for the Next Child

First Tee of Greater Charleston, Board of Advisors

American Heart Association of the Lowcountry, 2018 Heart Walk Chair

ASSOCIATIONS:

American Association for Justice

American Bar Association

American Inns of Court

American Constitution Society for Law and Policy

South Carolina Association for Justice

* Although they endorse this lawyer, neither *The Legal 500 United States* nor Professor Samuel Issacharoff are Motley Rice clients. Any result this endorsed lawyer may achieve on behalf of one client in one matter does not necessarily indicate similar results can be obtained for other clients.

Frederick C. Baker

LICENSED IN: NY, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the First, Second, Third, Fourth, Fifth, Tenth and Eleventh Circuits

U.S. District Court for the Southern District of New York and the District of South Carolina

EDUCATION:

J.D. / LL.M., Duke University School of Law, 1993

B.A., University of North Carolina at Chapel Hill, 1985

A veteran litigator with strong roots in complex litigation, Fred Baker works on a broad range of environmental, medical costs recovery, consumer and products liability cases and holds numerous leadership roles within the firm. He represents individuals, institutional investors, and governmental entities in a wide variety of cases.

Fred leads the firm's tobacco litigation, and was a member of the legal team that litigated the groundbreaking tobacco litigation on behalf of several State Attorneys General. Fred has also participated in the litigation of individual tobacco cases, entity tobacco cases and a tobacco class action.

In addition to his tobacco casework, Fred is part of the opioid litigation team which represents dozens of governmental entities, including states, cities, towns, counties and townships in litigation targeting the alleged misrepresentation and fraudulent distribution of harmful and addictive opioids by manufacturers and distributors.

Fred was also a key member of the firm's representation of people and businesses in Gulf Coast communities suffering as a result of the BP Deepwater Horizon oil spill. He held a central role in the negotiation process involving the two settlements reached with BP, one of which is the largest civil class action settlement in U.S. history. In addition, his environmental experience also includes representing a state government in a case against poultry integrators that alleged poultry waste polluted natural resources.

Fred has served as counsel in a number of class actions, including the two class action settlements arising out of the 2005 Graniteville train derailment chlorine spill. He was also closely involved in the litigation surrounding the statutory direct action settlement reached in the Manville bankruptcy court and a related West Virginia unfair trade practices insurance class action.

Fred began practicing with Motley Rice attorneys in 1994 and chairs the firm's attorney hiring committee.

AWARDS AND ACCOLADES:

Best Lawyers®

2020–2022 Charleston, S.C. Mass tort litigation / class actions – plaintiffs

Lawdragon

2019 Lawdragon 500 Plaintiff Financial Lawyers

South Carolina Lawyers Weekly

2016 Leadership in Law Honoree

TEAM BIOS:

Louis M. Bograd

LICENSED IN: DC, KY

ADMITTED TO PRACTICE BEFORE:

U.S. Supreme Court; U.S. Court of Appeals for the First, Third, Fourth, Fifth, Sixth, Eighth, Ninth, Tenth, and D.C. Circuits; U.S. District Court for the District of Columbia

EDUCATION:

J.D., Yale Law School, 1984

A.B., Princeton University, 1981

Louis Bograd is a nationally recognized authority on issues of federal preemption, drug and device litigation, and jurisdiction. He has devoted much of his professional career to litigating appeals on complex issues involving products liability, Medicaid lien reimbursements, constitutional rights, and civil liberties. At Motley Rice, Lou continues his focus on appellate issues and mass torts, further enhancing the firm's active and growing complex litigation practice. Lou serves as co-chair of the Law & Briefing Committee for the *National Prescription Opiate* MDL, which is focused on combatting the alleged deceptive marketing and over-distribution of opioids.

Prior to joining Motley Rice, Lou served as an appellate advocate and Chief Litigation Counsel for the Center for Constitutional Litigation where he led work in mass torts, the Class Action Fairness Act, and dispositive motions concerning consumer protection and products liability. Lou argued for plaintiffs before the U.S. Supreme Court regarding federal preemption of claims against generic drug manufacturers in *Pliva, Inc. v. Mensing* and has also participated in numerous other Supreme Court cases as counsel for petitioners, respondents, and amici curiae.

Lou has spoken on various legal topics at many seminars, CLE programs, and legal conferences across the country sponsored by, among others, the American Association for Justice, state trial lawyers associations, and Mass Torts Made Perfect. Lou has also presented at judicial education programs sponsored by the Pound Institute, the Brookings Institution, the American Enterprise Institute, the Northwestern University School of Law, and the George Mason University School of Law.

Lou's legal career began at Arnold & Porter LLP in Washington, D.C., where he managed and directed work on transfusion-associated HIV/AIDS cases on behalf of the American Red Cross. He subsequently served on the American Civil Liberties Union Foundation's national legal staff and as the legal director of the Alliance for Justice. Lou has also taught advanced torts and products liability law as an Adjunct Professor at the University of Kentucky College of Law.

SELECTED PUBLICATIONS:

- Louis M. Bograd & Andre M. Mura, *Buckman Stops Here! Limits on Preemption of State Tort Claims Involving Allegations of Fraud on the PTO or the FDA*, 41 Rutgers L. J. 309 (2009)
- Louis M. Bograd, *Be Careful What You Wish For: Drugmakers, the First Amendment, and Preemption*, 51 TRIAL 24 (Nov. 2015)
- Louis M. Bograd, *Preemption's Uncertain Path*, 47 TRIAL 20 (Nov. 2011)

- Louis M. Bograd, *W(h)ither Preemption?*, 45 TRIAL 24 (Nov. 2009)
- Louis M. Bograd, *Taking on Big Pharma- and the FDA*, 43 TRIAL 30 (Mar. 2007)

ASSOCIATIONS:

American Association for Justice Chair, Preemption Litigation Group; Member, Legal Affairs Committee

Max N. Gruetzmacher

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

U.S. District Court for the District of South Carolina, and the Northern District of Illinois

EDUCATION:

J.D., Marquette University Law School, 2008

B.A., University of Wisconsin-Madison, 2004

Max Gruetzmacher focuses his practice on securities and consumer fraud, representing large public pension funds, unions and other institutional investors in securities and consumer fraud class actions and shareholder derivative suits, as well as consumers, businesses, and governmental entities in other types of complex civil litigation.

Max also brings substantial experience counseling the firm's attorneys and clients with respect to e-discovery strategy throughout the various stages of litigation, from pre-filing through trial.

Prior to joining the firm, Max gained experience in a variety of legal practice areas, including defense of pharmaceutical mass torts cases, of banks in mortgage-backed securities cases, and in appellate criminal defense.

ASSOCIATIONS:

South Carolina Bar Association

Charleston County Bar Association

Serena P. Hallowell

LICENSED IN: NY

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the First, Ninth, and Eleventh Circuits; U.S. District Court for the Southern and Eastern Districts of New York

EDUCATION:

J.D., Boston University School of Law, 2003

B.A., Occidental College, 1999

With nearly 20 years of complex litigation and securities experience, Serena Hallowell has been recognized by her peers as a leader in the plaintiffs' securities bar and a Plaintiffs' Lawyer "Trailblazer" in 2019 by *National Law Journal* for her work in securities opt-out litigation. As lead of Motley Rice's direct-action litigation efforts, and a leader of the firm's securities fraud team, Serena litigates for some of the world's largest institutional investors, including pension funds, hedge funds, mutual funds, family offices, and other large institutional investors. She also regularly advises institutional investors and public entities regarding recovery opportunities in connection with fraud-related conduct.

TEAM BIOS:

Prior to her time at Motley Rice, Serena was the head of a direct-action practice and member of the securities class action group as a partner of a large securities law firm in New York. In that capacity, she was a key member of several litigation teams that achieved multi-million settlements for clients, aggregating close to \$500 million. Notable cases Serena was a leading/key member of prior to joining Motley Rice include:

- *In re Barrick Gold Securities Litigation* (\$140 million settlement*)
- *In re Computer Sciences Corp. Securities Litigation* (\$97.5 million settlement*) ("rocket docket" jurisdiction and estimated to be the third largest all cash settlement in the Fourth Circuit)
- *Public Employees' Retirement System of Mississippi v. Endo* (\$50 million settlement*) (state court Section 11 action believed to be the largest class settlement obtained pursuant to the Securities Act of 1933 in connection with a secondary public offering)
- *In re Intuitive Surgical Securities Litigation*, No. 5:13-cv-01920 (N.D. Cal.) (\$42.5 million settlement* for the class, including the Employees' Retirement System of the State of Hawaii)
- *In re NII Holdings, Inc. Securities Litigation* (\$41.5 million settlement*) ("rocket docket" jurisdiction where settlement was obtained even after company filed bankruptcy)

Serena has also led opt-out cases against companies, including Valeant Pharmaceuticals, Perrigo Company, and Teva Pharmaceuticals for a variety of institutional investors seeking to recoup losses stemming from alleged fraud-related conduct. With respect to Valeant, Serena and her team pursued claims under the New Jersey RICO statute, and was the first opt-out plaintiff to successfully defeat a motion to dismiss those claims. Certain Valeant actions have since been resolved and Serena continues to prosecute matters on behalf of others.

Serena was selected to *The National Law Journal's* "Elite Women of the Plaintiffs Bar" in 2020 for having consistently excelled in high-stakes matters on behalf of plaintiffs. She was also recognized by them as a Plaintiffs' Lawyer "Trailblazer" in 2019 in part for her work on behalf of opt-out plaintiffs. Legal publication *Law360* named her as a "Securities MVP" in 2019, and the 2020 *Chambers USA* report recognized her in the area of New York securities litigation for plaintiffs. *The Legal 500* also recommended her in the field of securities litigation in 2016 and 2017.

Serena is a frequent speaker in legal circles throughout the country on matters related to securities litigation and diversity and inclusion in the legal and financial sectors. She uses her platform to champion women's rights and promote diversity in the financial realm, including advocating for women and minority-led investment firms.

Serena has performed *pro bono* work for immigrant detainees through the American Immigrant Representation Project, in addition to volunteering with the Securities Arbitration Clinic at Brooklyn Law School, among other positions. She is conversational in Hindi and Urdu.

SELECTED PUBLICATIONS:

- 'Mutual Funds Should Consider Shareholder Litigation,' *Law360* (Oct. 8, 2019)
- 'Around the World in a Decade: The Evolving Landscape of Securities Litigation Post-Morrison,' *NAPPA* (Nov. 26, 2019)
- 'Emulex Highlights Greater Scrutiny of Issues at High Court,' *Law360* (April 25, 2019)
- 'China Agritech's Positive Implications for Plaintiffs,' *Law360* (July 3, 2018)
- 'Direct Actions: A Path to Recovery for Foreign Purchases of Securities,' *The NAPPA Report* (Oct. 31, 2017) 'Investor Recovery Strategies Following ANZ Securities,' *Law360* (July 12, 2017)
- 'Does 'Dukes' Require Full 'Daubert' Scrutiny at Class Certification?' *New York Law Journal* (Nov. 25, 2011)

AWARDS AND ACCOLADES:

Chambers USA

2020–2021 Litigation: Securities: Plaintiffs – New York, Up and Coming

Benchmark Litigation

2020–2021 Future Star

National Law Journal

2020 Elite Women of the Plaintiffs' Bar

2019 Plaintiffs' Lawyers Trailblazers

Lawdragon 500

2019–2021 Leading Plaintiff Financial Lawyers

2019–2020 Leading Lawyers in America

Law360

2019 Securities MVP

2016 Rising Star

The Legal 500

2016–2017 Recommended in the Field of Securities Litigation

ASSOCIATIONS:

New York City Bar Association, Securities Litigation Committee

Federal Bar Council

South Asian Bar Association

National Association of Public Pension Attorneys

National Association of Women Lawyers

The National Association of Shareholder & Consumer Attorneys, Secretary

TEAM BIOS:

Mathew P. Jasinski

LICENSED IN: CT, NY

ADMITTED TO PRACTICE BEFORE:

U.S. Supreme Court; U.S. Court of Appeals for the First, Second, and Third Circuits; U.S. District Court for the District of Connecticut and Southern District of New York

EDUCATION:

J.D. with high honors, University of Connecticut School of Law, 2006

B.A. summa cum laude, University of Connecticut, 2003

Mathew Jasinski represents consumers, businesses, and governmental entities in class action and complex cases involving consumer protection, unfair trade practices, commercial, environmental and securities litigation. He also represents whistleblowers in *qui tam* cases under the False Claims Act.

Mathew's litigation experience includes all aspects of trial work, from case investigation to appeal. He has represented plaintiffs in class actions involving such claims as breach of contract and unfair trade practices. He has experience in complex commercial cases regarding claims of fraud and breach of fiduciary duty and has represented an institutional investor in its efforts to satisfy a judgment obtained against the operator of a Ponzi scheme. Mathew obtained a seven-figure arbitration award in a case involving secondary liability for an investment advisor's conduct under the Uniform Securities Act. Please remember that every case is different. Any result we achieve for one client in one matter does not necessarily indicate similar results can be obtained for other clients.

Mathew also serves the firm's appellate group, having argued cases in the U.S. Courts of Appeals for the First and Second Circuits, the Connecticut Appellate Court, and the Connecticut Supreme Court. He also has worked on numerous appeals before other state and federal appellate courts across the country.

Prior to joining Motley Rice in 2009, Mathew practiced complex commercial and business litigation at a large defense firm. He began his legal career as a law clerk for Justice David M. Borden (ret.) of the Connecticut Supreme Court. During law school, Mathew served as executive editor of the *Connecticut Law Review* and judging director of the Connecticut Moot Court Board. He placed first in various moot court and mock court competitions, including the Boston region mock trial competition of the American Association for Justice. As an undergraduate, Mathew served on the board of associate directors for the University of Connecticut's honors program and was recognized with the Donald L. McCullough Award for his student leadership.

Mathew continues to demonstrate civic leadership in the local Hartford community. He is vice chairman of the board of directors for the Hartford Symphony Orchestra, a deacon of the Asylum Hill Congregational Church, and a commissioner of the Hartford Parking Authority. Previously, Mathew served on the city's Charter Revision Commission and its Young Professionals

Task Force, an organization focused on engaging young professionals and positioning them for future business and community leadership.

PUBLISHED WORKS:

"On the Causes and Consequences of and Remedies for Interstate Malapportionment of the U.S. House of Representatives" (Jasinski and Ladewig, *Perspectives on Politics*, Vol. 6, Issue 1, March 2008)

"Hybrid Class Actions: Bridging the Gap Between the Process Due and the Process that Functions" (Jasinski and Narwold), *The Brief*, Fall 2009

AWARDS AND ACCOLADES:

Super Lawyers®

2013-2021 Connecticut Super Lawyers Rising Stars list
Business litigation; Class action/mass torts; Appellate

Lawdragon

2019-2021 Lawdragon 500 Plaintiff Financial Lawyers

Connecticut Law Tribune

2018 "New Leaders in Law"

Hartford Business Journal

2009 "Forty Under 40"

ASSOCIATIONS:

American Association for Justice

American Bar Association

Connecticut Bar Association

Oliver Ellsworth Inn of Court

Phi Beta Kappa

For full Super Lawyers selection methodology visit: www.superlawyers.com/about/selection_process.html

For current year CT data visit: www.superlawyers.com/connecticut/selection_details.html

Marlon E. Kimpson

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

U.S. District Court for the District of South Carolina, Eastern District of Michigan

EDUCATION:

J.D., University of South Carolina School of Law, 1999

B.A., Morehouse College, 1991

Marlon Kimpson represents victims of corporate malfeasance, from investors in securities fraud cases to consumers harmed by large data and privacy breaches, as well as people injured or killed in catastrophic incidents. Building upon the firm's relationships with unions and governmental entities, Marlon represents individuals, state and municipality pension funds, multi-employer plans, unions and other institutional investors in securities fraud class actions and in mergers and acquisition cases, seeking asset recovery and improved corporate governance.

TEAM BIOS:

Marlon has litigated securities cases including: *In re Atheros Communications, Inc., Shareholder Litigation*; *In re Celera Corporation Shareholder Litigation*; *In re RehabCare Group, Inc. Shareholders Litigation*; *In re Coventry Healthcare, Inc., Shareholder Litigation*; and *In re Big Lots, Inc., Shareholder Litigation*. In 2017, he helped secure a \$16 million settlement to resolve shareholders' claims in *Epstein v. World Acceptance Corp. et al.*, which alleged that World Acceptance misled investors about its lending practices and compliance with federal law. More recently, Marlon was local counsel for institutional investors in *In re SCANA Corporation Securities Litigation*, a complex securities fraud matter related to alleged misrepresentations and omissions concerning the design, construction, and abandonment of SCANA's nuclear construction project in South Carolina. The case resolved in 2020 with a \$192 million settlement. It is the largest securities class action recovery ever obtained in the District of South Carolina, the fifth largest securities class action recovery in the history of the Fourth Circuit, and among the top 100 securities class action recoveries nationwide.

Marlon is co-lead counsel and a member of the Plaintiffs' Steering Committee for multidistrict litigation, *In re: Blackbaud Inc. Customer Data Security Breach Litigation*, filed in the District of South Carolina for consumers affected by a 2020 ransomware attack and resulting data breach that targeted software company Blackbaud. He also represents Facebook users who allege the social media network violated privacy laws by allowing political data from Cambridge Analytica to harvest private information from more than 87 million of its users without their knowledge or permission.

In addition to securities and consumer fraud litigation, Marlon is part of the team representing dozens of governmental entities, including states, counties, cities, towns, and townships in litigation targeting the alleged deceptive marketing and over-distribution of highly addictive opioid drugs, a contended cause of the nationwide opioid crisis. He has also represented victims of catastrophic personal injury, asbestos exposure, and aviation disasters. He has litigated commercial and charter aviation cases with clients, defendants and accidents involving multiple countries. He also represented people and businesses in the Deepwater Horizon BP oil spill settlements claims programs.

Marlon currently serves as South Carolina State Senator of District 42, representing citizens of Charleston and Dorchester Counties. A frequent speaker, Marlon has presented at seminars and conferences across the country, including the Public Funds Summit, the National Association of State Treasurers, the South Carolina Black Lawyers' Association, the National Conference on Public Employee Retirement Systems (NCPERS) and the National Association of Securities Professionals (NASP).

After five years in commercial banking, Marlon entered the field of law and served as a law clerk to Judge Matthew J. Perry of the U.S. District Court of South Carolina. His legal work and

volunteer service also earned him the University of South Carolina School of Law bronze Compleat Award. Martindale-Hubbell® recognizes Marlon as a BV® rated attorney.

Marlon is active in his community and formerly served on the Board of Directors for the Peggy Browning Fund. He has also held leadership roles with the University of South Carolina Board of Visitors, the Charleston Black Lawyers Association and the South Carolina Election Commission. In 2017, the American Association of Justice Minority Caucus awarded Marlon with its Johnnie L. Cochran, Jr. Soaring Eagle Award reserved for lawyers of color who have made outstanding contributions to the legal profession and paved the way for others. In 2018, Marlon was chosen as a Leadership in Law Honoree by *South Carolina Lawyers Weekly*. He is a lifetime member of the NAACP and a member of Sigma Pi Phi Boulé and Omega Psi Phi Fraternity, Inc.

AWARDS AND ACCOLADES:

Best Lawyers®

2015–2022 Mass tort litigation/class actions – plaintiffs

Lawdragon

2019–2021 Lawdragon 500 Plaintiff Consumer Lawyers

2019–2021 Lawdragon 500 Plaintiff Financial Lawyers

South Carolina Lawyers Weekly

2018 Leadership in Law Honoree

American Association of Justice

2017 Johnnie L. Cochran, Jr. Soaring Eagle Award

Benchmark Plaintiff

2012 National "Litigation Star": mass tort/product liability

2012–2014 South Carolina "Litigation Star": environmental, mass tort, securities

Coastal Conservation League

2016 Coastal Stewardship Award

United Food and Commercial Workers

2016 Legislative Activist of the Year

ASSOCIATIONS:

American Association for Justice

South Carolina Association for Justice

National Association of Public Pension Attorneys

American Bar Association

National Bar Association

TEAM BIOS:

Gregg S. Levin

LICENSED IN: DC, MA, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the First, Second, Third, Fourth, Fifth, Seventh, Ninth and Eleventh Circuits

U.S. District Court for the District of Colorado, District of Massachusetts, and the Eastern District of Michigan

EDUCATION:

J.D., Vanderbilt University School of Law, 1987

B.A. *magna cum laude*, University of Rochester, 1984

With more than three decades of legal experience, Gregg Levin represents domestic and foreign institutional investors and union pension funds in corporate governance, directorial misconduct and securities fraud matters. His investigative, research and writing skills have supported Motley Rice as lead or co-lead counsel in numerous securities and shareholder derivative cases against Dell, Inc., UBS AG and Cintas Corporation. Gregg manages complaint and brief writing for class action deal cases, shareholder derivative suits and securities fraud class actions.

Prior to joining Motley Rice, Gregg was an associate with Grant & Eisenhofer in Delaware, where he represented institutional investors in securities fraud actions and shareholder derivative actions in federal and state courts across the country, including the WorldCom, Telxon and Global Crossing cases. He also served as corporate counsel to a Delaware Valley-based retail corporation from 1996-2003, where he handled corporate compliance matters and internal investigations.

In 2019, Gregg was appointed as a Vice President of the Institute for Law and Economic Policy, a foundation whose goals include supplementing the resource-limited SEC by educating the public on the importance of private securities fraud litigation in maintaining corporate accountability. Since its inception in the 1990s, the institute has presented and published papers that have been cited in more than 60 federal cases, including several in the U.S. Supreme Court. Appearing in the media to discuss a variety of securities matters, Gregg has also presented in educational forums, including at the Ethics and Transparency in Corporate America Webinar held by the National Association of State Treasurers.

PUBLISHED WORKS:

Gregg is a published author on corporate governance and accountability issues, having written significant portions of the treatise *Shareholder Activism Handbook* (Aspen Publishers, November 2005), as well as several other articles of interest to institutional investors, including:

- “*In re Cox Communications: A Suggested Step in the Wrong Direction*” (*Bank and Corporate Governance Law Reporter*, September 2005)
- “Does Corporate Governance Matter to Investment Returns?” (*Corporate Accountability Report*, September 23, 2005)
- “*In re Walt Disney Co. Deriv. Litig. and the Duty of Good Faith under Delaware Corporate Law*” (*Bank and Corporate Governance Law Reporter*, September 2006)

- “Proxy Access Takes Center Stage: The Second Circuit’s Decision in American Federation of State County and Municipal Employees, Employees Pension Plan v. American International Group, Inc.” (*Bloomberg Law Reports*, February 5, 2007)
- “Investor Litigation in the U.S. -- The System is Working” (*Securities Reform Act Litigation Reporter*, February 2007)

AWARDS AND ACCOLADES:

Lawdragon

2019 Lawdragon 500 Plaintiff Financial Lawyers

Joshua Littlejohn

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the Third and Fourth Circuits; U.S. District Court for the District of Colorado, District of South Carolina

EDUCATION:

J.D., Charleston School of Law, 2007

B.A., University of North Carolina at Asheville, 1999

With a broad base of experience in complex litigation—including securities fraud, corporate governance, whistleblower cases under Dodd-Frank and the False Claims Act, and catastrophic injury cases—Josh Littlejohn plays a key role on the Motley Rice securities litigation team, particularly in cases involving healthcare.

Josh represents public pension funds, unions and institutional investors in both federal and state courts. He also represents people with catastrophic injuries and corporate whistleblowers. Josh works directly with clients and has been involved in all aspects of the litigation process, including case evaluation, fact and expert discovery, resolution and trial.

Throughout his career Josh has been involved in numerous complex securities matters including litigation against 3M Corporation; MetLife Inc.; Alexion Pharmaceuticals; Wells Fargo & Company; 3D Systems Corporation; St. Jude Medical, Inc.; Omnicare; Pharmacia Corporation and NPS Pharmaceuticals. Currently, Josh is one of the lead lawyers in the groundbreaking securities fraud litigation against NASDAQ and the New York Stock Exchange, among other defendants, related to high frequency trading or “HFT.” This matter is currently in discovery in the U.S. District Court for the Southern District of New York. Along with other Motley Rice lawyers, Josh was South Carolina liaison counsel in a securities fraud class action that settled in 2020 filed by investors against SCANA Corporation over its failed nuclear reactor project. Josh regularly reviews and analyzes potential securities fraud class action, shareholder derivative, and SEC whistleblower matters on behalf of our clients and the firm.

In addition to securities matters, Josh is a leading member of the team representing former Greer Laboratories, Inc. corporate insiders who allege that Greer violated the False Claims Act by causing healthcare providers to seek reimbursement from Medicare and Medicaid for unlicensed biologic drugs. This matter is pending before the U.S. Court of Appeals for the Fourth Circuit.

TEAM BIOS:

Aside from various securities and whistleblower matters, Josh was recently part of the Motley Rice negotiating team that helped secure a resolution with a major U.S. auto manufacturer on behalf of Takata airbag victims. Early in his career at Motley Rice, Josh worked on discovery in mass tort litigation against large drug manufacturers.

AWARDS AND ACCOLADES:

Lawdragon

2019 Lawdragon 500 Plaintiff Financial Lawyers

Super Lawyers®

2013-2017 South Carolina Super lawyers Rising Star list
Securities litigation; Class action/mass torts; General litigation

ASSOCIATIONS:

American Bar Association

South Carolina Association for Justice

Donald A. Migliori

LICENSED IN: MA, MN, NY, RI, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the First, Fourth, and Eleventh Circuits, U.S. District Court for the District of Rhode Island, District of Massachusetts, and Northern, Southern and Eastern Districts of New York

EDUCATION:

M.A./J.D., Syracuse University, 1993

A.B., Brown University, 1988

Building upon his experience in complex asbestos cases, the historic tobacco lawsuits and the September 11, 2001 terrorist attacks litigation, Don Migliori is a multifaceted litigator who can navigate both the courtroom and the negotiating table. He represents victims of defective medical devices and drugs, occupational diseases, terrorism, aviation disasters, antitrust, and securities and consumer fraud in mass torts and other cutting-edge litigation that spans the country.

Don serves in leadership roles for a number of multidistrict litigations, including being a key member of Motley Rice's team that represents dozens of cities, towns, counties and townships in the *National Prescription Opiate* MDL against opioid manufacturers and distributors. He also represents states in similarly filed litigation. He played a significant role in negotiations on behalf of tens of thousands of women allegedly harmed by pelvic mesh/sling products and served as co-liaison counsel in the N.J. Bard pelvic mesh litigation in Atlantic County. Hundreds of cases have been filed in federal and state courts against multiple defendants.

He is also co-lead counsel for *In re Ethicon Physiomesh Flexible Composite Hernia Mesh Products Liability Litigation*, a member of the Plaintiffs' Steering Committee for *In re Bard IVC Filters Products Liability Litigation*, as well as the Depuy® Orthopaedics, Inc. ASR™ and Pinnacle® Hip Implant MDLs. Don has litigated against both Ethicon, a Johnson & Johnson subsidiary, and C.R. Bard previously in pelvic mesh litigation and also against C.R. Bard in the Composix® Kugel® hernia mesh

multidistrict litigation, *In re Kugel Mesh Hernia Patch Products Liability Litigation*, the first MDL before the federal court of Rhode Island. Don also serves as co-lead plaintiffs' counsel and liaison counsel in the federal MDL, and as liaison counsel for the Composix® Kugel® Mesh lawsuits consolidated in Rhode Island state court on behalf of thousands of individuals alleging injury by the hernia repair patch.

As liaison counsel for all wrongful death and personal injury cases in the September 11th aviation security litigation, Don played a central role in the extensive discovery, mediations and settlements of more than 50 cases of aviation liability and damages against numerous defendants. He also represented families of the victims who opted out of the Victim Compensation Fund to seek greater answers, accountability and recourse. Additionally, he manages associated litigation as a lead attorney for *In re Terrorist Attacks on September 11, 2001*, MDL #1570, a groundbreaking case designed to bankrupt the financiers of al Qaeda.

Don contributed his experience in connection with the commencement of and strategy for shareholder derivative litigation brought on behalf of Chiquita Brands International, Inc., alleging the defendants breached their fiduciary duties by paying bribes to terrorist organizations in violation of U.S. and Columbian law. He also served as trial counsel for PACE Industry Union-Management Pension Fund in a securities case against Forest Laboratories, Inc., and was involved in the initial liability discovery and trial strategy in an ongoing securities fraud class action involving Household International, Inc.

Don began working with Motley Rice attorneys in 1997 on behalf of the State Attorneys General in the historic lawsuit against Big Tobacco, resulting in the largest civil settlement in U.S. history. He tried several noteworthy asbestos cases on behalf of mesothelioma victims, including the state of Indiana's first contractor liability verdict and first premises liability verdict for wrongful exposure to asbestos. He continues to manage asbestos cases and actively litigates mesothelioma lawsuits and individual tobacco cases in the courtroom.

Don is a frequent speaker at legal seminars across the country and has appeared on numerous television and radio programs, as well as in print media to address legal issues related to terrorist financing, aviation security, class action litigation, premises liability and defective medical devices. A "Distinguished Practitioner in Residence" at Roger Williams University School of Law for the 2010-2011 academic year, Don taught mass torts as an adjunct professor for more than 10 years. Don is an AV® rated attorney by Martindale-Hubbell®.

AWARDS AND ACCOLADES:

Chambers USA

2021 Product Liability: Plaintiffs – Nationwide, Band 3

Best Lawyers®

2020 "Lawyer of the Year" Charleston, SC

Mass tort litigation/class actions – plaintiffs

2011-2022 Mass tort litigation/class actions – plaintiffs

TEAM BIOS:

Super Lawyers® lists

2018–2021 *South Carolina Super Lawyers*: Class action/mass torts; Personal Injury – products: plaintiff; Aviation and aerospace

2009–2017 *Rhode Island Super Lawyers*

2012–2013 *Top 10 Rhode Island Super Lawyers* lists

The National Trial Lawyers

2010–present *Top 100 Trial Lawyers™*: Rhode Island

Lawdragon

2018–2021 Lawdragon 500

2019–2021 Lawdragon 500 Plaintiff Consumer Lawyers

2019–2021 Lawdragon 500 Plaintiff Financial Lawyers

2010 Lawdragon 3,000

Rhode Island Lawyers Weekly

2020 Leader in the Law

2011 Lawyer of the Year

Massachusetts Lawyers Weekly

2011 Lawyers of the Year

Benchmark Plaintiff

2012–2014 Rhode Island “Litigation Star”: human rights and product liability

Providence Business News

2005 Forty Under 40

ASSOCIATIONS:

Law360 Product Liability Editorial Advisory Board, 2019, 2021

American Association for Justice, Board of Governors; former Executive Committee member

American Bar Association

Rhode Island Association for Justice, former President

The Fellows of the American Bar Foundation

Christopher F. Moriarty

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the First, Second, Third, Fourth, Fifth, and Tenth Circuits; U.S. District Court for the Northern District of Illinois, the Eastern District of Michigan, and the District of South Carolina

EDUCATION:

J.D., Duke University School of Law, 2011

M.A., Trinity College, University of Cambridge, 2007

B.A., Trinity College, University of Cambridge, 2003

Christopher Moriarty litigates securities fraud, corporate governance, and other complex class action litigation in the U.S. and counsels institutional investors on opportunities to seek recovery in securities-related actions in both the U.S. and internationally. His practice encompasses every aspect of litigation, from case-starting to settlement.

Notable securities fraud class actions include:

- *In re Barrick Gold Securities Litigation*, No. 13-cv-03851 (S.D.N.Y.) (\$140 million recovery*) (sole lead counsel);

- *City of Brockton Retirement System v. Avon Products, Inc.*, 11 Civ. 4655 (PGG) (S.D.N.Y.) (\$62 million recovery*) (sole lead counsel);
- *Hill v. State Street Corp.*, No. 09-cv-12136-GAO (D. Mass.) (\$60 million recovery*) (co-lead counsel);
- *In re Hewlett-Packard Co. Securities Litigation*, No. 11-cv-1404 (RNBx) (C.D. Cal.) (\$57 million recovery*) (co-lead counsel);
- *KBC Asset Mgmt. v. 3D Sys. Corp.*, No. 15-cv-02393-MGL (D.S.C.) (\$50 million recovery*) (co-lead counsel);
- *Första AP-Fonden and Danske Invest Management A/S v. St. Jude Medical, Inc.*, No. Civil No. 12-3070 (JNE/HB) (D. Minn.) (\$39.25 million recovery*) (co-lead counsel);
- *Ross v. Career Education Corp.*, No. 12-cv-00276 (N.D. Ill.) (\$27.5 million recovery*) (co-lead counsel);
- *KBC Asset Mgmt. NV v. Aegerion Pharms., Inc.*, No. 14-cv-10105-MLW (D. Mass.) (\$22.25 million recovery*) (co-lead counsel).

Christopher represents investors in shareholder derivative litigation, including in *In re Walgreen Co. Derivative Litigation*, No. 13-cv-05471 (N.D. Ill.) (securing corporate governance reforms to ensure compliance with the Controlled Substances Act*); antitrust class actions, including *In re Libor-Based Financial Instruments Antitrust Litigation*, No. 11-md-02262-NRB (S.D.N.Y.) (pending); and whistleblowers in proceedings before the U.S. Securities and Exchange Commission. His practice extends to securities-related litigation in several foreign jurisdictions, including England, France, and the Netherlands.

While in law school, Christopher was a member of the Moot Court Board, served as an Executive Editor of the *Duke Journal of Constitutional Law and Public Policy*, and taught a course on constitutional law to LL.M. students. Christopher has also drafted *amicus curiae* briefs in numerous constitutional law cases before the U.S. Supreme Court (which has cited his work) and the federal courts of appeal.

Christopher was called to the Bar in England and Wales by the Honourable Society of the Middle Temple.

AWARDS AND ACCOLADES:

South Carolina Super Lawyers® Rising Stars list

2016–2021 Securities litigation

ASSOCIATIONS:

South Carolina Association for Justice

American Bar Association

South Carolina Bar Association

Charleston County Bar Association

TEAM BIOS:

William H. Narwold

LICENSED IN: CT, DC, NY, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Supreme Court, U.S. Court of Appeals for the First, Second, Third, Fourth, Fifth, Sixth, Eighth, Ninth, Tenth, Eleventh, D.C., and Federal Circuits, U.S. District Court for the District of Connecticut, Eastern District of Michigan, Eastern and Southern Districts of New York, District of South Carolina

EDUCATION:

J.D. cum laude, University of Connecticut School of Law, 1979
B.A., Colby College, 1974

Bill Narwold has advocated for corporate accountability and fiduciary responsibility for nearly 40 years, representing consumers, governmental entities, unions and institutional investors. He litigates complex securities fraud, shareholder rights and consumer fraud lawsuits, as well as matters involving unfair trade practices, antitrust violations and whistleblower/qui tam claims.

Bill leads Motley Rice's securities and consumer fraud litigation teams and False Claim Act practice. He is also active in the firm's appellate practice. His experience includes being involved in more than 200 appeals before the U.S. Supreme Court, U.S. Courts of Appeal and multiple state courts.

Prior to joining Motley Rice in 2004, Bill directed corporate, securities, financial, and other complex litigation on behalf of private and commercial clients for 25 years at Cummings & Lockwood in Hartford, Connecticut, including 10 years as managing partner. Prior to his work in private practice, he served as a law clerk for the Honorable Warren W. Eginton of the U.S. District Court, District of Connecticut from 1979-1981.

Bill often acts as an arbitrator and mediator both privately and through the American Arbitration Association. He is a frequent speaker on legal matters, including class actions. Named one of 11 lawyers "who made a difference" by *The Connecticut Law Tribune*, Bill is recognized as an AV® rated attorney by Martindale-Hubbell®.

Bill has served the Hartford community with past involvements including the Greater Hartford Legal Assistance Foundation, Lawyers for Children America, and as President of the Connecticut Bar Foundation. For more than twenty years, Bill served as a Director and Chairman of Protein Sciences Corporation, a biopharmaceutical company in Meriden, Connecticut.

AWARDS AND ACCOLADES:**Best Lawyers®**

2013, 2015, 2017, 2019 Hartford, Conn. "Lawyer of the Year": Litigation-Banking and Finance

2005-2021 Antitrust Law; Litigation-Banking and finance, mergers and acquisitions, securities

Super Lawyers®

2009-2021 Connecticut Super Lawyers and New England Super Lawyers® lists
Securities litigation; Class action/mass torts

Lawdragon

2019-2021 Lawdragon 500 Plaintiff Financial Lawyers

Connecticut Bar Foundation

2008 Legal Services Leadership Award

ASSOCIATIONS:**American Bar Association**

Connecticut Bar Foundation, Past President

Taxpayers Against Fraud

University of Connecticut Law School Foundation, past Board of Trustees member

For full Super Lawyers selection methodology visit: www.superlawyers.com/about/selection_process.html

For current year CT data visit: www.superlawyers.com/connecticut/selection_details.html

William S. Norton

LICENSED IN: MA, NY, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Supreme Court; U.S. Court of Appeals for the First, Second, Third and Fourth Circuits; U.S. District Court for the District of Colorado, Northern District of Illinois, District of Massachusetts, Eastern and Southern Districts of New York, and District of South Carolina

EDUCATION:

J.D., Boston University School of Law, 2004

B.A./B.S. *magna cum laude*, University of South Carolina, 2001

Bill Norton litigates securities fraud, corporate governance, False Claims Act, SEC whistleblower and other complex class action, consumer, and commercial matters. Bill has represented institutional and individual investors in securities fraud and shareholders actions before federal, state, and appellate courts throughout the country. He has also represented whistleblowers before the U.S. Securities and Exchange Commission through the Dodd-Frank Whistleblower Program and *qui tam* relators in actions under the False Claims Act.

Securities Fraud Litigation

Bill represents institutional investors as a member of the lead counsel teams in litigation involving Alexion Pharmaceuticals, Inc., Intel Corporation, Qualcomm Inc., and Riot Blockchain, Inc. His previous securities fraud matters include:

- *In re SCANA Corporation Securities Litigation* (\$192.5 million recovery as Liaison Counsel*)
- *Bennett v. Sprint Nextel Corp.* (\$131 million recovery*)
- *City of Brockton Retirement System v. Avon Products, Inc.* (\$62 million recovery*)
- *Hill v. State Street Corporation* (\$60 million recovery*)
- *City of Sterling Heights General Employees' Retirement System v. Hospira, Inc.* (\$60 million recovery*)
- *In re Hewlett-Packard Company Securities Litigation* (\$57 million recovery*)
- *In re Medtronic, Inc. Securities Litigation* (\$43 million recovery*)
- *Hatamian v. Advanced Micro Devices, Inc.* (\$29.5 million recovery*)
- *Ross v. Career Education Corporation* (\$27.5 million recovery*)

TEAM BIOS:

Shareholder Derivative Litigation

Bill has represented shareholders in derivative actions, including:

- *Manville Personal Injury Settlement Trust v. Gemunder* (\$16.7 million payment and significant corporate governance reforms*)
- *In re Walgreen Co. Derivative Litigation* (corporate governance reforms concerning compliance with Controlled Substances Act*)

Merger and Acquisition Litigation

Bill has represented institutional shareholders in corporate M&A litigation, including:

- *In re Allion Healthcare, Inc. Shareholders Litigation* (\$4 million payment to shareholders*)
- *In re RehabCare Group, Inc., Shareholders Litigation* (\$2.5 million payment, modification of merger agreement, and additional disclosures to shareholders*)
- *In re Atheros Communications Shareholder Litigation* (preliminary injunction delaying shareholder vote and requiring additional disclosures to shareholders in \$3.1 billion merger*)
- *Maric Capital Master Fund, Ltd. v. PLATO Learning, Inc.* (preliminary injunction requiring additional disclosures to shareholders in \$143 million private-equity buyout*)

Other Commercial, Consumer Fraud, and Whistleblower Matters

Bill has represented clients in a variety of commercial, consumer fraud, and whistleblower matters, including:

- Satellite retailers in class action against EchoStar Corporation (\$83 million recovery*)
- Municipal bondholders in class action concerning alleged Ponzi scheme (\$7.8 million recovery*)
- A *qui tam* whistleblower in appeal, resulting in reinstatement of claim for employment retaliation*
- Consumers in class action against DirecTV regarding early cancellation fees
- German bank in litigation concerning collateralized debt obligations
- Investors in actions concerning variable life insurance policies funneled to the Madoff Ponzi scheme

Before joining Motley Rice, Bill practiced securities and commercial litigation in the New York office of an international law firm. In law school, Bill served as an Editor of the *Boston University Law Review* and was a G. Joseph Tauro Distinguished Scholar. He worked as a law clerk in the United States Attorney's Office for the District of Massachusetts, represented asylum seekers at Greater Boston Legal Services, and studied law at the University of Oxford. Before law school, Bill worked for the United States Attorney's Office for the District of South Carolina and volunteered with the Neighborhood Legal Assistance Program of Charleston. He graduated Phi Beta Kappa from the University of South Carolina Honors College. Bill is recognized as an AV®-rated attorney by Martindale-Hubbell®.

AWARDS AND ACCOLADES:

Lawdragon

2019 Lawdragon 500 Plaintiff Financial Lawyers

Super Lawyers®

2013-2019 South Carolina Super Lawyers Rising Stars list
Securities litigation; Class action/mass torts; General litigation

ASSOCIATIONS:

Federal Bar Association

American Bar Association

American Association for Justice

New York State Bar Association

South Carolina Bar Association

Charleston County Bar Association

Lance Oliver

LICENSED IN: AL, DC, FL, SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the District of Columbia, Fifth and the Eleventh Circuits; U.S. District Court for the District of Columbia, and the Middle and Southern Districts of Florida

EDUCATION:

J.D., Duke University School of Law, 2004

B.A., Samford University, 2001

Lance Oliver is a trial lawyer who litigates class actions, mass torts, and other complex matters. He has experience with all phases of litigation from filing the complaint, trying the case, and pursuing appeals. His practice focuses on securities and consumer fraud class actions, tobacco litigation, and other defective products.

Lance has recently acted as lead trial counsel in a number of *Engle* progeny cases in Florida, representing smokers and their families against tobacco manufacturers. He argued a successful appeal to the Fourth District Court of Appeals in Florida, securing a verdict for a smoker's widow in a wrongful death suit against tobacco giants Philip Morris and R.J. Reynolds in *Philip Morris USA Inc. et al. v. Marchese*. He also served as counsel in *Berger v. Philip Morris USA Inc.*, which resulted in a verdict for a client who fell victim at a young age to the manufacturer's marketing campaigns targeting children.

Lance has also devoted a substantial amount of time to litigating securities fraud class actions, and has served as co-lead counsel for the class in many securities fraud cases including *Alaska Electrical Pension Fund, et al. v. Pharmacia Corp., et al.*, a securities fraud class action that resulted in a settlement for plaintiffs. More recently, Lance selected the jury as co-trial counsel for the end-payor class in *In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation*, a pay-for-delay antitrust litigation.

Prior to joining Motley Rice in 2007, Lance served as an associate in the Washington, D.C., office of a national law firm, where he worked on complex products liability litigation at both the trial and appellate levels.

TEAM BIOS:

Lance is a member of the National Conference on Public Employee Retirement Systems (NCPERS) and the International Foundation of Employee Benefit Plans (IFEBP). After graduating from Duke Law School, he served as a law clerk to the Honorable James Hughes Hancock of the U.S. District Court, Northern District of Alabama. He is recognized as an AV® rated attorney by Martindale-Hubbell®. He serves on the Board of Directors for the Charleston chapter of the American Lung Association, as well as the Dee Norton Child Advocacy Center.

AWARDS AND ACCOLADES:

South Carolina Lawyers Weekly
2021 Leadership in Law Honoree

Lawdragon

2019–2021 Lawdragon 500 Plaintiff Financial Lawyers

South Carolina Super Lawyers® Rising Stars list
2013–2018 Securities litigation; Class action/mass torts

The National Trial Lawyers

2016 Top 100 Trial Lawyers™ South Carolina:

ASSOCIATIONS:

American Bar Association

Meghan S. B. Oliver

LICENSED IN: DC, SC, VA

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the Federal Circuit, U.S. District Court for the District of South Carolina

EDUCATION:

J.D., University of Virginia School of Law, 2004
B.A. with distinction, University of Virginia, 2000

Meghan Oliver's practice focuses on complex litigation and class actions, including work on securities fraud cases, general commercial litigation, and consumer fraud litigation.

She is actively involved in various class actions, including several against health insurers for drug and equipment overcharges, and one alleging that the Administrative Office of the U.S. Courts charges more for PACER services than is authorized by statute (*Nat'l Veterans Legal Services Program v. United States*, Case No. 16-745-ESH). She also represents large public pension funds, unions, and institutional investors in securities fraud class actions, including *In re Twitter, Inc. Securities Litigation*, No. 3:16-cv-05315-JST-SK and *In re Qualcomm Inc. Securities Litigation*, No. 17-CV-00121-JAH-WVG.

Additionally, Meghan helps to lead litigation filed for a class consisting of more than a million tax return preparers alleging the IRS charged unauthorized user fees for the issuance and renewal of preparer tax identification numbers, (*Steele v. United States*, Case No. 1:14-cv-1523-RCL).

She has also worked on several antitrust matters in the past, including *In re North Sea Brent Crude Oil Futures Litigation*, *In re Libor-Based Financial Instruments Antitrust Litigation*, and generic drug cases involving "reverse payment" agreements.

Prior to joining Motley Rice, Meghan worked as a business litigation and antitrust associate in Washington, D.C. There, she assisted in the trial of a multidistrict litigation antitrust case and assisted in multiple corporate internal investigations. She is a member of Phi Beta Kappa.

AWARDS AND ACCOLADES:

Lawdragon
2019–2021 Lawdragon 500 Plaintiff Financial Lawyers

ASSOCIATIONS:

American Bar Association

Michael J. Pendell

LICENSED IN: CT, NY

ADMITTED TO PRACTICE BEFORE:

U.S. District Court for the District of Connecticut, Southern and Eastern Districts of New York

EDUCATION:

J.D., *summa cum laude*, Albany Law School, 2007
B.A., *cum laude*, Emerson College, 2000

Michael Pendell focuses his practice on representing people affected by corporate wrongdoing, including whistleblowers, and people harmed by tobacco and dangerous pelvic mesh devices. He also represents pension fund trustees and other institutional investors in securities, consumer fraud, and other complex class actions.

Michael has been involved in the firm's representation of personal injury clients, including representing people allegedly harmed by tobacco products and thousands alleging harm by dangerous medical devices. He serves as trial counsel in the Engle-progeny litigation pending in Florida for smokers and families of deceased smokers against tobacco manufacturers. In transvaginal mesh litigation, he represents women implanted with Ethicon Gynecare Prolift transvaginal mesh devices and who claim serious injuries and complications from the devices.

Michael also has experience representing institutional and individual investors in claims involving common law fraud pursuant to state securities laws. He played a central role on the litigation team that obtained a seven-figure arbitration award in a case involving secondary liability for an investment advisor's conduct under the Uniform Securities Act. Michael also represents clients in complex commercial cases regarding claims of fraud, breach of contract, and tortious interference, as well as representing whistleblowers in multiple cases involving the False Claims Act, including litigation filed against Afognak Native Corp., alleging regulatory violations related to the Small Business Administration.

Michael, along with other Motley Rice attorneys, represented a union pension fund as co-lead counsel in a securities fraud class action to recoup losses against a telecom provider that allegedly provided false information regarding its financial results, causing artificially inflated stock prices that subsequently plummeted when the truth was made known. The settlement is pending court approval.

TEAM BIOS:

In addition to his whistleblower and securities casework, Michael is also a part of the firm's team that represents dozens of governmental entities, including states, cities, towns, counties and townships in litigation against several pharmaceutical drug manufacturers and distributors for the alleged deceptive marketing and distribution of highly addictive opioid prescription drugs.

Prior to joining Motley Rice, Michael served as an associate with a Connecticut-based law firm, where he first gained experience in both federal and state courts in such areas as commercial and construction litigation, media and administrative law, personal injury defense and labor and employment matters. He previously taught business law to BA and MBA candidates as an adjunct professor at Albertus Magnus College.

Michael served as a legal intern for the Honorable Randolph F. Trece of the U.S. District Court for the Northern District of New York and as a law clerk for the Major Felony Unit of the Albany County District Attorney's Office. He served as the executive editor for the *New York State Bar Association Government Law & Policy Journal* and senior editor for the *Albany Law Review*, which published his 2008 article entitled, "How Far is Too Far? The Spending Clause, the Tenth Amendment, and the Education State's Battle Against Unfunded Mandates."

AWARDS AND ACCOLADES:

Lawdragon

2019-2021 Lawdragon 500 Plaintiff Financial Lawyers

Super Lawyers®

2013-2018 Connecticut Super Lawyers Rising Stars list
Securities litigation; Business litigation; Personal injury – products: plaintiff

ASSOCIATIONS:

American Association for Justice

Connecticut Bar Association

New York State Bar Association

* Prior results do not guarantee a similar outcome. For full *Super Lawyers* selection methodology visit: www.superlawyers.com/about/selection_process.html
For CT-specific methodology visit: www.superlawyers.com/connecticut/selection_details.html

SENIOR COUNSEL

David D. Burnett

LICENSED IN: DC, NY

ADMITTED TO PRACTICE BEFORE: U.S. Court of Appeals for the Second Circuit; U.S. District Courts for the Southern and Eastern Districts of New York

EDUCATION:

J.D., University of Virginia School of Law, 2007

M.A., University of Texas at Austin, 2002

B.A. with high honors and distinction, University of Virginia, 1999

David Burnett applies more than a decade of experience in finance and plaintiffs-side commercial litigation to investigate complex economic and scientific issues.

David is a part of Motley Rice's team representing dozens of governmental entities, including states, counties, cities, towns, and townships in litigation arising from the nationwide opioid crisis. Among other work, he works closely with experts on written reports, depositions, and trial testimony, including epidemiologists who quantify abatement needs and economists who quantify harms and abatement costs. David is part of the trial team in the opioids MDL trial on behalf of the City of Huntington and Cabell County, W.Va.

David also represents investors in complex securities fraud litigation. In Motley Rice's case against NYSE, Nasdaq, and BATS, alleging that the stock exchanges enabled high-frequency traders' manipulation of the markets, David deposed the President of NYSE, wrote an order of proof, and drafts briefs and letters to court.

David worked with victims of September 11 terrorist attacks on documenting their harms at Ground Zero. He has also performed detailed contractual and liability analyses in Motley Rice's Proton Pump Inhibitor litigation against major pharmaceutical companies.

Prior to joining Motley Rice, David served as a vice president of underwriting at Burford Capital, where he evaluated the legal and economic merits of 50 potential investments in lawsuits, up to nine figures in value each, and monitored dozens of active litigation investments. He gained experience in evaluating the cost-benefits of litigation and structuring financing terms commensurate with legal risks.

Prior to Burford, David worked for 11 years as an associate and Of Counsel at Quinn Emanuel in New York, where he represented institutional investors as plaintiffs in litigation arising from losses on mortgage-backed securities and CDOs following the 2008 financial crisis. He recovered hundreds of millions of dollars* in dozens of favorable settlements for plaintiffs in residential mortgage-backed securities litigation, including settlements reached on his own for a client he originated.

While completing his law degree at the University of Virginia, David clerked for an international corporate law firm in New York and a plaintiffs' asbestos firm in Washington, D.C. During

TEAM BIOS:

law school David was selected as a Hardy Cross Dillard Fellow (a teaching assistant in Legal Research and Writing), worked with law professors as a journal editor, and published two journal articles.

Outside of work, David serves on the Board of Advisors of the Appalachian Mountain Club. Before law school, among other roles, David worked with at-risk youths for Outward Bound and bicycled across the country for charity.

Rebecca M. Katz

LICENSED IN: NY

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the Second Circuit; U.S. District Courts for the Southern, Eastern, and Western Districts of New York

EDUCATION:

J.D., Hofstra University School of Law, 1990

B.S., Hofstra University, 1987

As a lead attorney on Motley Rice's whistleblower litigation team, Rebecca Katz represents and protects individual whistleblowers who expose corporate misconduct. Her clients come from all levels of job responsibility in a wide range of industries and she helps them to investigate and report fraud to governmental enforcement agencies including the SEC, DOJ, IRS and CTFC. She has represented senior executives, mid-level managers and staff of multinational banking and financial services and public companies, including financial advisors, clinical researchers, quantitative analysts, engineers, commodities and securities traders.

Rebecca has been at the forefront of this field since the SEC Whistleblower Program was established under the Dodd-Frank Act in 2010 and is recognized in the field of whistleblower representation. She has represented numerous clients in navigating the intricacies of the SEC whistleblower process from filing the initial complaint through the final award process.

For nearly a decade prior to entering private practice, Rebecca served as senior counsel for the SEC's Enforcement Division. In addition to her whistleblower work, Rebecca has more than 20 years of experience litigating complex securities fraud cases, and was a partner and held senior leadership roles at two large New York plaintiffs' litigation firms.

Using her experience as a former SEC attorney and in private practice, Rebecca provides critical, objective legal counsel to those who need knowledge and support to ensure their confidentiality and protection in undertaking the complex and ever-changing whistleblower laws.

Rebecca is a frequent speaker at legal conferences nationwide and provides insight on numerous issues involving the SEC whistleblower program and securities litigation for national and local media outlets, including *The Wall Street Journal*, *The New York Times*, and *Law360*, among others. She is a published author and former faculty member at the Practising Law Institute's Securities Litigation & Enforcement Institute (both in

the United States and United Kingdom) and has also lectured at the Fordham University School of Law's Eugene P. and Delia S. Murphy Conference on Corporate Law – Corporations, Investors and the Securities Markets.

While completing her law degree from Hofstra University School of Law, Rebecca was a member of the *Hofstra Law Review*.

She is an active supporter of several community organizations, including Friends of Firefighters and Komen Race for a Cure.

PUBLISHED WORKS:

Rebecca M. Katz & James M. Weir, Plaintiffs' Perspective: The SEC's Final Rules for Whistleblowers Offer a Balanced Approach to an Important New Program, *Securities Litigation Report* (July/Aug. 2011)

Rebecca M. Katz & David B. Harrison, The Dodd-Frank Act: New Life for Whistleblowers and the SEC; *Securities Litigation Report* (Sept. 2010)

AWARDS AND ACCOLADES:

Best Lawyers®

2017–2022 Mass tort litigation / class actions – plaintiffs

Super Lawyers

2008–2010, 2013–2021 New York Metro Super Lawyers – Securities

Hofstra University, Maurice A. Deane School of Law

2019 Outstanding Woman in Law honoree

Benchmark Plaintiff

2014 Top 150 Women in Litigation list: New York – securities

2013–2014 New York "Litigation Star" securities

ASSOCIATIONS:

New York City Bar Association, Securities Litigation Committee

ASSOCIATES

Andrew P. Arnold

LICENSED IN: NY, SC

EDUCATION:

J.D., with honors, University of North Carolina School of Law, 2013

B.A., with highest honors, University of North Carolina at Chapel Hill, 2002

Andrew Arnold represents institutional investors and individuals in complex securities, corporate governance and shareholder litigation.

He concentrates his practice on investigating and developing securities fraud class actions, shareholder derivative lawsuits, merger and acquisition litigation, and consumer fraud. He joined Motley Rice co-founder Joe Rice in negotiations in the Volkswagen Diesel Emissions Fraud class action for consumers whose vehicles were allegedly designed to bypass regulations. The \$15 billion settlement for 2.0-liter vehicles is the largest consumer auto-related consumer class action in U.S. history, and among the fastest reached of its kind.

TEAM BIOS:

Prior to joining Motley Rice, Andrew practiced commercial litigation and investor-state dispute settlement in the Washington, D.C. office of a large international law firm. He was recognized on the 2014 Capital *Pro Bono* High Honor Roll for serving 100 *pro bono* hours in the D.C. area. While attending the University of North Carolina School of Law, Andrew was a member of the *North Carolina Law Review* and served as a judicial intern for the North Carolina Court of Appeals and as a research assistant for Professor Thomas Lee Hazen, a prominent securities regulation scholar.

Andrew also has an extensive background in software development, primarily in the healthcare industry, where he designed and developed software to ensure compliance with government regulations.

AWARDS AND ACCOLADES:

Best Lawyers®

2021-2022 Ones to Watch list: Litigation – Securities

Elizabeth A. Camputaro

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the Federal and Fourth Circuits; U.S. District Court for the District of South Carolina

EDUCATION:

J.D. magna cum laude, Charleston School of Law, 2008

B.A., Columbia College, 2004

Elizabeth Camputaro is part of the team representing county and municipal governments in litigation involving opioid manufacturers and distributors for their alleged deceptive marketing and fraudulent distribution of highly addictive opioids.

In addition, Elizabeth has several years of experience representing institutional investors in complex securities fraud and shareholder derivative matters, including serving on litigation teams in class action suits filed against Medtronic, Inc, State Street Corp., Sprint Nextel Corp., and Advanced Micro Devices.

Prior to joining Motley Rice, Elizabeth served as a judicial law clerk for the Honorable Deadra L. Jefferson, Ninth Judicial Circuit. While in law school, Elizabeth was a member of the Federal Courts Law Review, contributed more than 100 hours of *pro bono* service, and served as a judicial extern for the Honorable Thomas L. Hughston, Ninth Judicial Circuit.

Active in her community, Elizabeth previously served on the South Carolina Bar Diversity Committee, and has served as an Election Commissioner for Beaufort and Summerville municipalities, Beaufort County Council Library Board Trustee, and international missionary with Project Medishare and One World Health.

ASSOCIATIONS:

American Bar Association

South Carolina Bar Association

Charleston Bar Association

Ebony Williams Bobbitt

LICENSED IN: SC

EDUCATION:

J.D. magna cum laude, North Carolina Central University School of Law 2020

B.S., North Carolina Agricultural and Technical State University, 2012

Ebony Williams Bobbitt represents institutional investors and individuals in complex securities and consumer protection class actions that aspire to hold corporations accountable for alleged misconduct.

Ebony's casework includes litigating for U.S. tax return preparers who allege they were charged unlawful fees by the IRS to obtain their Preparer Tax Identification Numbers (PTIN) in *Adam Steele, et al. v. United States of America*, Case No. 1:14-cv-01523-RCL. She also represents a class of patients who allege Cigna Health and Life Insurance Co. fraudulently inflated copayments and coinsurance by overcharging for medical services and products, *Neufeld v. Cigna Health and Life Insurance Company et al.*, Case No. 3:17-cv-01693.

Ebony has a background in criminal justice and worked for several years as a legal assistant for the New Hanover District Attorney's Office and as a deputy clerk for the New Hanover County Board of Commissioners prior to pursuing her law degree. She gained additional legal experience while interning with the North Carolina Department of Justice during the summer of 2018 and is a former Motley Rice law clerk.

Jessica C. Colombo

LICENSED IN: CT, NY

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the Second Circuit, U.S. District Court for the District of Connecticut

EDUCATION:

J.D. with high honors, University of Connecticut School of Law, 2017

B.A. cum laude, State University of New York at New Paltz, 2014

Jessica Colombo works to deter misconduct and fraud by representing individuals and institutional investors in complex securities and consumer protection class actions. In addition, Jessica's practice includes representing whistleblowers in cases involving the False Claims Act, and she contributes to the firm's appellate practice. She is also a part of the firm's team that represents dozens of governmental entities, including states, cities, towns, counties and townships in litigation against several pharmaceutical drug manufacturers and distributors for the alleged deceptive marketing and distribution of highly addictive prescription opioids.

Prior to joining Motley Rice, Jessica served as a law clerk to the Honorable Bethany J. Alvord of the Connecticut Appellate Court. She gained additional experience in complex consumer

TEAM BIOS:

fraud and product liability litigation while serving as a Motley Rice law clerk in 2016. She also interned with the U.S. Attorney's Office for the District of Connecticut.

While completing her legal studies, Jessica served as Executive Editor of the *Connecticut Law Review*, a member of the Public Interest Law Group, and a volunteer with the International Refugee Assistance Project. She also represented criminal defendants in the University of Connecticut School of Law Criminal Trial Clinic. She received multiple CALI awards in Lawyering Process, Torts, Estate Plan/Tax Practice, and Trademark Law.

Jessica previously worked as a toll collector for the New York State Thruway Authority, where she was a member of the International Brotherhood of Teamsters, Local 72.

ASSOCIATIONS:

American Bar Association
Connecticut Bar Association

Annie E. Kouba

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

U.S. District Court for the District of South Carolina

EDUCATION:

J.D., University of North Carolina School of Law, 2016

M.S.W., University of North Carolina School of Social Work, 2016

B.A., *magna cum laude*, Lenoir-Rhyne University, 2012

Annie Kouba represents institutional investors in securities fraud and shareholder litigation as well as public clients and government entities. Annie also advocates for survivors of childhood sexual abuse who wish to seek justice through the civil court system.

She is a part of Motley Rice's team of attorneys that represents dozens of cities, towns, counties and townships in the *National Prescription Opiate* MDL against opioid manufacturers, distributors and pharmacies for alleged deceptive marketing, fraudulent distribution and other business practices that contributed to the opioid crisis. Additionally, she represents several municipalities in litigation against multiple large telecommunications companies for alleged under-billing and under-remittance of 911 fees those municipalities depend upon to fund their emergency systems.

As an advocate for survivors of childhood sexual abuse, Annie represents abused former Boy Scouts in their Boy Scouts of America bankruptcy claims. She also litigates under newly enacted "window" laws that extend the number of years available for childhood sexual abuse survivors to file claims by opening a statute of limitations for a finite period of time.

Prior to joining Motley Rice, Annie interned with the North Carolina Department of Justice in the Health and Human Services Division where she drafted criminal briefs for the N.C. Court of Appeals and N.C. Supreme Court, and assisted

the president of the American Association of Public Welfare Attorneys. She also interned with the EMILY's List Political Opportunity Program and has worked as a *voir dire* consultant.

Annie concentrated in Community, Management, and Policy Practice at the University of North Carolina's School of Social Work Master's program where she specialized in the intersection of public policy and the law. Through a practicum with the program, Annie interned with the Compass Center for Women and Families in the Financial Literacy Education Program, where she served as a certified counselor with The Benefit Bank.

While pursuing her studies at the University of North Carolina School of Law, Annie served as a published staff member on the *First Amendment Law Review* and as vice president of the Carolina Public Interest Law Organization. She also contributed more than 100 hours in the Pro Bono Program there, through which she prepared tax returns for low-income citizens and researched and provided social work policy and legal perspective related to minors' rights after sexual assault for a guidebook from the NC Coalition Against Sexual Assault.

Annie serves on the board of the Green Heart Project, a volunteer-assisted service-learning organization connecting children living in food deserts with school gardens, healthy produce, and mentors.

AWARDS AND ACCOLADES:

South Carolina Bar Leadership Academy
 Class of 2019

ASSOCIATIONS:

American Association for Justice, Political Action Committee Task Force
South Carolina Association for Justice

Alexis N. Lilly

LICENSED IN: SC

EDUCATION:

J.D. *cum laude*, American University Washington College of Law, 2020

B.A. *magna cum laude*, The Ohio State University, 2017

Alexis Lilly protects public entities, institutional investors and individuals through complex litigation targeting corporate negligence and misconduct.

Alexis is a part of the firm's team that represents dozens of governmental entities, including states, counties, cities, towns, and townships in litigation targeting the alleged deceptive marketing and over-distribution of highly addictive opioid drugs, a contended cause of the nationwide opioid crisis.

A former Motley Rice law clerk, Alexis was the Technical Editor of the *American University Business Law Review*, Vol. 9, and served as a student attorney for American University Washington College of Law's Civil Advocacy Clinic in Washington, D.C., while completing her legal studies. She also assisted faculty as a Dean's Fellow for the school's Legal Rhetoric Department, served as a judicial intern for U.S. District Judge Rudolph Contreras of the U.S. District Court for D.C., and gained valuable experience as a law clerk for the U.S. Attorney's Office, District of Arizona.

TEAM BIOS:

Bruno Rosenbaum

LICENSED IN: NY

EDUCATION:

LL.M., Columbia Law School, 2019

M.B.A., Assas Paris II, 2014

Master II, Assas Paris II, 2014

Master I, Sorbonne Paris I, 2010

Bruno Rosenbaum consults on complex securities fraud class actions, merger and acquisition cases and shareholder derivative suits on behalf of domestic and foreign institutional investors.

As Director of European Investor Relations for Motley Rice, Bruno assists the firm, clients and co-counsel in matters relating to international financial regulations and securities law to enhance corporate governance and protect shareholders against misconduct and fraud.

Prior to joining Motley Rice, Bruno was associated with international law firms in Paris and Luxembourg, where he practiced in the areas of mergers and acquisitions and private equity.

Bruno is admitted to the practice of law in Paris as Avocat à la Cour, and in Luxembourg as Avocat au Barreau (*Liste IV*). His post-graduate studies concentrated in business and corporate law.

Bruno is fluent in English, French and Portuguese and conversant in German/Luxembourgish, Spanish and Italian.

Lisa M. Saltzburg

LICENSED IN: SC, CO

ADMITTED TO PRACTICE BEFORE:

U.S. Court of Appeals for the Fourth, Fifth and Eleventh Circuits

U.S. District Court for the District of South Carolina

EDUCATION:

J.D., Stanford Law School, 2006

B.A. with high distinction, University of California, Berkeley, 2003

Lisa Saltzburg represents individuals, government entities and institutional clients in complex securities and consumer fraud actions, public client litigation, and a variety of other consumer and commercial matters. Lisa is an integral part of Motley Rice's team of attorneys that represents dozens of cities, towns, counties and townships in the *National Prescription Opiate* MDL against opioid manufacturers and distributors for alleged deceptive marketing, fraudulent distribution and other business practices that contributed to the opioid crisis.

She is part of the BP Oil Spill litigation team, and helped people and businesses in Gulf Coast communities file claims through the new claims programs established by the two settlements reached with BP. Lisa also serves on the trial team for the Florida *Engle* tobacco litigation.

Prior to joining Motley Rice, Lisa was an associate attorney for a nonprofit advocacy organization, where she worked through law and policy to protect the environmental interests

of the Southeast. She drafted briefs and other filings in South Carolina's federal and state courts and worked with administrative agencies to prepare for hearings and mediation sessions. Lisa also served for two years as a judicial clerk for the Honorable Karen J. Williams of the U.S. Court of Appeals for the Fourth Circuit, where she developed valuable legal research and writing skills and gained experience involving a wide range of issues arising in civil and criminal cases.

Lisa held multiple positions in environmental organizations during law school, handling a broad array of constitutional, jurisdictional and environmental issues. She also served as an editor of the *Stanford Law Review* and as an executive editor of the *Stanford Environmental Law Journal*. A member of numerous organizations and societies, including the Stanford Environmental Law Society, Lisa attended the National Institute for Trial Advocacy's week-long Trial Advocacy College at the University of Virginia.

AWARDS AND ACCOLADES:

South Carolina Super Lawyers® Rising Stars list

2016 Securities litigation, Class action/mass torts, Personal injury-products: plaintiff

Meredith B. Weatherby

LICENSED IN: SC, TX

ADMITTED TO PRACTICE BEFORE:

U.S. District Court for the Northern, Southern, Eastern and Western Districts of Texas

EDUCATION:

J.D., University of Texas School of Law, 2011

B.A., *with distinction*, University of North Carolina, Chapel Hill, 2008

Meredith Weatherby develops and litigates securities fraud class actions and shareholder derivative suits on behalf of institutional investors.

Meredith represents unions, public pensions and institutional investors in federal courts throughout the country. Her casework includes representing clients in a number of cases related to high frequency trading (HFT), including the groundbreaking securities fraud litigation against NASDAQ and the New York Stock Exchange that was recently revived upon appeal to the U.S. Court of Appeals for the Second Circuit. She is also involved in the securities class action against Twitter Inc. Previously, Meredith was a member of the teams representing investors in securities fraud class actions filed against Advanced Micro Devices, Barrick Gold and SAC Capital, among others.

Meredith also has experience litigating medical malpractice and negligence suits in state court.

Prior to joining Motley Rice, Meredith gained trial and settlement experience as an associate at a Dallas, Texas, law firm working in business and construction litigation. While attending the University of Texas School of Law, she clerked for an Austin firm, represented victims in court as a student attorney in the UT Law Domestic Violence Clinic and was a Staff Editor of the

TEAM BIOS:

Review of Litigation journal. During her undergraduate and law school career, Meredith studied abroad in Paris, France, Geneva, Switzerland and Puebla, Mexico.

AWARDS AND ACCOLADES:

Best Lawyers®

2021 -2022 Ones to Watch list: Litigation – Securities

ASSOCIATIONS:

Charleston County Bar Association

Erin Casey Williams

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE:

United States Court of Appeals for the Second Circuit; U.S. District Court for the Eastern District of Michigan, and District of South Carolina

EDUCATION:

J.D., University of Illinois College of Law, 2014

B.S. with honors, University of Illinois at Urbana-Champaign, 2011

Erin Casey Williams protects the interests of institutional investors and consumers through complex securities litigation.

Erin is a member of Motley Rice's litigation teams representing investors in securities fraud class action cases. She supports the firm's efforts in matters involving Qualcomm Incorporated and Investment Technology Group, Inc.

Erin assisted in the development of deposition strategies and completed discovery with the Motley Rice securities team before joining the firm in 2017. Her previous experience includes litigating claims involving medical malpractice, wrongful death, personal injury and complex family law matters at a Charleston, S.C., law firm. She also researched and drafted memoranda regarding construction defects, insurance defense, and tort liability for a national litigation support agency.

While pursuing her law degree, Erin interned for the Federal Defender Program in Chicago in addition to working as a judicial extern for the Honorable Michael T. Mason of the U.S. District Court for the Northern District of Illinois. She served as an associate editor of the *University of Illinois Law Review* and the Community Service Chair of the Women's Law Society.

ASSOCIATIONS:

American Bar Association

South Carolina Bar Association

South Carolina Association for Justice

South Carolina Women Lawyers Association

Charleston County Bar Association

STAFF ATTORNEYS

Rebecca E. Jacobs

LICENSED IN: SC

EDUCATION:

J.D. with honors, Charleston School of Law, 2014

B.A., Furman University, 2010

Rebecca Jacobs focuses her practice on managing discovery efforts and implementing e-discovery best practices in large-scale antitrust, whistleblower, securities, and consumer fraud class actions. She also develops and manages teams that perform research and conduct document discovery for the firm.

Rebecca's casework includes assisting in antitrust litigation against Keurig Green Mountain, Inc., alleging a monopoly of single-serve coffee brewers and cups compatible with those brewers. She is also actively involved in various class actions against health insurers for drug and equipment overcharges.

Rebecca has been working with Motley Rice since 2015, where she leverages advanced processing and review technologies to increase efficiencies in cases with complex e-discovery. Rebecca was a member of the team that represented institutional investors as lead counsel in *In re Barrick Gold Securities Litigation*, which reached a \$140 million settlement for shareholders.* She has also contributed to discovery in securities fraud litigation against St. Jude Medical, Inc. and Conn's Inc.

Rebecca worked as a legal assistant and paralegal in Charleston while pursuing a law degree. She has also completed numerous *pro bono* hours with programs including Volunteer Income Tax Assistance as well as Adult Guardianship Assistance and Monitoring.

ASSOCIATIONS:

South Carolina Women Lawyers Association

South Carolina Bar Association

Charleston County Bar Association

Kelly A. Quillin

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE: U.S. District Court for the District of South Carolina

EDUCATION:

J.D., The John Marshall Law School, 2014

B.S., Indiana University, 2010

Kelly Quillin seeks to hold businesses accountable and recover losses for individuals and institutional investors who are harmed by corporate wrongdoing and misconduct.

Kelly is a member of the litigation teams representing investors as lead counsel in securities and consumer fraud class actions filed against Twitter, Inc. and Qualcomm, Inc. She has also assisted in the litigations filed against St. Jude Medical, Inc., LIBOR, American Realty Capital, and 3D Systems Corp. She was also involved in the litigation against NASDAQ and NYSE, among other defendants, related to high frequency trading.

TEAM BIOS:

Acting as a liaison among counsel, attorney review teams, vendors and data management personnel, Kelly oversees teams that conduct discovery and research in order to further complex securities litigation, including implementing best practices regarding e-discovery strategies in large scale, complex, and document-intensive cases. She has experience in advanced analytic technologies and technology assisted review processes.

Prior to joining the firm, she clerked for the Cook County State's Attorney's Office in Chicago, assisting with legal filings, court appearances and research in the Felony Trial Division.

In 2012, while completing her legal studies in Chicago, Kelly served as a judicial extern for U.S. District Judge Jon E. DeGuilio for the Northern District of Indiana, where she drafted proposed opinions, orders and memoranda. While completing her undergraduate studies, she interned for the Southern District of Indiana Clerk's Office.

Kelly applies her legal knowledge to benefit the less fortunate by providing assistance and access to judicial services through the Charleston Pro Bono organization.

ASSOCIATIONS:

American Bar Association
 South Carolina Bar Association
 Charleston County Bar Association
 American Association for Justice

Laura C. Rublee

LICENSED IN: SC

ADMITTED TO PRACTICE BEFORE: U.S. Court of Appeals for the Fourth Circuit; U.S. District Court for the Eastern and Western Districts of Virginia, and the Western District of North Carolina

EDUCATION:

J.D., Marshall-Wythe School of Law, College of William & Mary, 1985

B.A. *with distinction*, University of Virginia, 1977

Laura Rublee litigates for consumers, unions, public pensions and other institutional investors as a part of Motley Rice's securities and consumer fraud practice. Laura advances complex class actions that shine a light on alleged financial violations and corporate misconduct that negatively impact investors and consumers.

Laura's litigation experience includes representing a class of patients who allege Cigna Health and Life Insurance Co. fraudulently inflated copayments and coinsurance by overcharging for medical services and products, *Neufeld v. Cigna Health and Life Insurance Company et al.* She also represents more than a million tax return preparers who allege the IRS charged unauthorized user fees for the issuance and renewal of preparer tax identification numbers, *Steele v. United States*. Laura served on additional litigation teams in class action suits filed against Medtronic, Inc.; Sprint Nextel Corp.; and Twitter, Inc.

Prior to joining Motley Rice, Laura worked for several years as an escrow officer in Texas where she assisted with real estate transactions. She has additional experience as a staff attorney and associate for defense firms in South Carolina and Virginia. She also has a background in biophysics, having worked as laboratory specialist for several years before pursuing a law degree.

ASSOCIATIONS:

South Carolina Bar Association

SECURITIES LITIGATION PROFESSIONAL STAFF

Ellie Kimmel

EDUCATION:

B.A., University of South Florida, 1993

Business Analyst Ellie Kimmel began working with Motley Rice attorneys in 2000. Prior to her work with the securities litigation team, she was a founding member of the firm's Central Research Unit and also supervised the firm's file management. She currently completes securities research and client portfolio analysis for the firm's securities cases.

Ellie has a diverse background that includes experience in education as well as the banking industry. She began her career in banking operations, where she served as an operations manager and business analyst in corporate banking support for 14 years. She then spent seven years teaching high school economics, Latin and history before joining Motley Rice.

Evelyn Richards

EDUCATION:

A.S. *cum laude*, Computer Technology, Trident Technical College, 1995

J.D., University of South Carolina School of Law, 1989

B.A., English Literature and Religion, University of Virginia, 1986

Evelyn Richards joined Motley Rice in 2007. As a law clerk for the Securities and Consumer Fraud practice group, she plays a key role in supporting the securities litigation team through editing, cite-checking and Shepardizing complaints, briefs, and other legal documents. She also trains support staff on how to use The Bluebook.

Evelyn has over 25 years of experience in the legal field. As an Assistant Solicitor for the Ninth Circuit Solicitor's Office, she prosecuted child abuse and neglect and criminal cases. She also worked as a programmer/analyst for a few years. Prior to joining Motley Rice, Evelyn worked as an administrator for a large telecom, corporate and litigation firm, supervising all office operations, including human resources and accounting procedures. She also served as office manager for a small worker's compensation law office, where she managed trust and operating accounts and provided information technology support.

Evelyn's diverse background in information technology, management, programming and analysis adds great depth to the resources provided to Motley Rice clients.

TEAM BIOS:

Joshua Welch

EDUCATION:

M.B.A., The Citadel, 2017

B.S. with honors, The College of Charleston, 2015

As a Financial Analyst with the securities litigation team, Joshua Welch is responsible for monitoring client portfolios, analyzing investor losses, and conducting research on companies facing allegations of securities fraud. He also assists in submitting claims for securities class action settlements.

Joshua holds a Master of Business Administration degree from The Citadel, where he worked as a graduate assistant. As an undergraduate, he double-majored in Accounting and Business Administration.



www.motleyrice.com
1 800.768.4026

28 BRIDGESIDE BLVD.
MT. PLEASANT, SC 29464
SC | RI | CT | NY | WV
DC | MO | NJ | PA

William H. Narwold (CT, DC, NY, SC) is the attorney responsible for this communication. Prior results do not guarantee a similar outcome. Motley Rice LLC, a South Carolina Limited Liability Company, is engaged in the New Jersey practice of law through Motley Rice New Jersey LLC. Esther Berezofsky attorney responsible for New Jersey practice.

PD: 12.14.2021



www.motleyrice.com
1 800.768.4026